{"data":[{"id":"b1b5a31e-8093-4188-9a17-5e2ef00a0d66","public_id":"7zR4dgUy","name":"Akero Therapeutics","canonical_name":"Akero Therapeutics","aliases":["Akero Therapeutics, Inc.","Akero","AKRO"],"one_liner":"Akero develops efruxifermin for MASH and other serious metabolic diseases marked by high unmet medical need.","description":"Akero is a clinical-stage company developing transformational treatments for serious metabolic diseases. Its pipeline is anchored by efruxifermin (EFX), a novel FGF21 analogue designed to treat MASH by harnessing the natural biology of FGF21. The company states that Novo Nordisk acquired Akero in 2025 to unlock the full potential of efruxifermin and reach more patients living with MASH.","website":"https://akerotx.com","canonical_website":"https://akerotx.com/","logo_url":"https://akerotx.com/wp-content/uploads/2025/12/akero-logo.webp","headquarters":"San Francisco, California, United States","hq_country_code":"US","founding_year":2017,"primary_approach":"FGF21 analogue, metabolic disease, MASH","primary_field_slug":"modulating","field_slugs":["modulating","repairing"],"primary_idea_root_slug":"modulating","idea_root_slugs":["modulating","repairing"],"primary_modality_slug":"biologic","modality_slugs":["biologic"],"classification_rationale":"Akero Therapeutics is a clinical-stage therapeutic biotech developing efruxifermin/AKR-001 for MASH/NASH and related metabolic liver disease. Across the supplied evidence, its lead program is consistently described as an FGF21 analogue or agonist that mimics the biological activity of FGF21 and aims to restore metabolic balance, which fits a primary classification of modulating biology through pathway signaling rather than editing, replacement, or reprogramming. The therapeutic modality is best classified as biologic because the asset is explicitly described as a protein therapeutic and fibroblast growth factor 21 analogue. There is weaker secondary evidence for repairing based on claims of reversing fibrosis, but the dominant mechanism described is signaling modulation.","classification_confidence":95,"funding_stage":"acquired","total_funding_usd":"1388500000","latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"acquired","operating_status_reason":"acquired","operating_status_rationale":"Derived from funding_stage=acquired (site-analyzer acquisition/dissolution evidence); operating-status detector had not run.","operating_status_confidence":60,"business_model":"drug_developer","business_model_rationale":"Multiple candidates consistently describe Akero Therapeutics as a clinical-stage biotechnology/biopharmaceutical company developing therapeutic candidates, especially efruxifermin/AKR-001, for MASH/NASH and other serious metabolic diseases. The evidence centers on clinical trials, regulatory milestones, and advancing drug candidates rather than diagnostics, services, delivery technology, or a general platform business.","business_model_confidence":98,"ip_market_structure":"The patent corridor appears to be defined by a newer Akero filing layered on top of an older, more established Amgen estate. Akero’s identifiable in-house asset is IL319173A, “Mutant FGF21 polypeptides,” filed from a 2022-09-12 priority and published on 2025-04-01, with a linked PCT family member, WO2024059507A1. That gives the organization a current stake in mutant FGF21 sequence space, but it looks late relative to the main corridor patents. The apparent blocking IP is Amgen’s US8034770B2 and US8835385B2, both directed to FGF21 polypeptides with two or more mutations, with the latter also explicitly covering uses thereof. US8034770B2 is marked active and expiring 2029-12-27, and US8835385B2 is also marked active. On freedom to operate, the posture looks constrained rather than clean. A later-filed Akero patent can protect Akero’s own mutant constructs, but it does not by itself remove infringement risk against earlier third-party rights. If Akero’s therapeutic candidate sits inside claim scope covering mutated FGF21 polypeptides or their therapeutic use, especially in the US, the Amgen patents are the patents that matter most. The evidence also suggests Amgen built this estate deliberately over time, with continuations and related descendants, which usually means claim coverage was expanded and reinforced around the core scaffold. Design-around is possible in principle, but it does not look trivial from this evidence. The corridor is centered on mutated FGF21 itself, not just one narrow product embodiment. A design-around would likely require showing that Akero’s molecule falls outside the specific mutation combinations, sequence definitions, or therapeutic-use claim boundaries in the Amgen patents, or relying on jurisdictions where those rights are weaker or absent. For a direct mutant FGF21 drug, that seems like a technically and legally narrow path rather than an easy one. The likely blockers look more strategically controlled than open. Amgen is the assignee on both core patents, and the presence of a mature, active family around mutant FGF21 suggests a guarded platform position. That does not rule out licensing, but the estate looks like the kind of IP that would be licensed selectively, not casually, especially for head-on FGF21 therapeutic competition.","is_public":true,"disqualified":true,"disqualified_reason":"Akero is a clinical-stage metabolic disease biotech developing efruxifermin for MASH and related liver disease. That is real drug development, but the program targets hepatometabolic disease, not the biology of aging itself, and there is no evidence here of an aging-specific platform, intervention, or measurement tool.","disqualified_at":"2026-07-01T16:28:34.611Z","research_status":"ready","is_editors_choice":false,"overall_score":56.61,"overall_score_computed_at":"2026-07-01 16:28:09.867266+00","pipeline_version":"0.24.1","proximity_score":"85.00","proximity_band":"near_readout","proximity_rationale":"Derived deterministically from 7 extracted project(s). Most-advanced status: phase 3. Band: near_readout. Modifiers: +5 depth (3 programs at phase_3). Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":2,"social_links":{"github":null,"twitter":"https://twitter.com/akerotx","youtube":null,"facebook":null,"instagram":null,"linkedin_company":"https://www.linkedin.com/company/akerotx/"},"careers_page_url":"https://akerotx.com/job-opportunities/","pipeline_page_url":"https://akerotx.com/pipeline/","external_registry_ids":{"sec":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-26T09:18:00.248Z\",\"rationale\":\"sec returned 0 candidates for \\\"Akero Therapeutics\\\".\",\"officers_matched\":[],\"candidate_count\":0}","opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-26T09:18:00.252Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"Akero Therapeutics\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-06-03 01:09:11.419501+00","updated_at":"2026-09-22 23:18:12.626188+00","scores":{"ambition":6.5,"publicity":5,"media_reach":4,"reliability":7.6,"falsifiability":9,"claim_integrity":2,"collaborativity":7,"context_validity":8,"pipeline_quality":7,"explanatory_power":7,"results_alignment":8,"scandal_integrity":8,"publication_quality":8,"premise_plausibility":8,"implementation_fidelity":9,"independent_replication":5},"public_records_count":183,"publications_count":19,"projects_count":7,"funding_rounds_count":8,"clinical_trials_count":6,"publication_status":"published_disqualified","public_url":"https://eternalsearch.net/companies/7zR4dgUy","api_url":"https://eternalsearch.net/api/v1/companies/7zR4dgUy"},{"id":"6cd4e173-db67-453c-a33b-c8428489d8a5","public_id":"lePPrIF5","name":"Amprion","canonical_name":"Amprion","aliases":["Ampriondx"],"one_liner":"Amprion provides a clinically available test detecting pathological alpha-synuclein for neurodegenerative disease diagnosis.","description":"Amprion develops and offers SAAmplify-ɑSYN, a clinically available validated test for detecting pathological alpha-synuclein in CSF. The site describes the test as providing biological clarity for diseases including Parkinson's, Lewy body dementia, and atypical Alzheimer's. Amprion positions the assay for clinicians, patients, researchers, and biopharma partners.","website":"https://ampriondx.com","canonical_website":"https://ampriondx.com/","logo_url":"https://upload.wikimedia.org/wikipedia/commons/thumb/2/2e/Amprion_2020_logo.svg/1280px-Amprion_2020_logo.svg.png","headquarters":"San Diego, California, United States; San Francisco, California, United States","hq_country_code":"US","founding_year":null,"primary_approach":"seed amplification assay, alpha-synuclein, CSF diagnostics","primary_field_slug":"diagnostics","field_slugs":["diagnostics","research_tools"],"primary_idea_root_slug":null,"idea_root_slugs":[],"primary_modality_slug":null,"modality_slugs":[],"classification_rationale":"Amprion is primarily a neurodegenerative-disease diagnostics company. Across the evidence, it is consistently described as developing and commercializing clinically available biomarker tests and seed amplification assays, especially for detecting pathological alpha-synuclein to aid diagnosis of Parkinson’s disease, Lewy body dementia, and related synucleinopathies. There is no direct evidence here of a therapeutic program or aging-intervention modality; the only secondary signal beyond diagnostics is limited research-tooling activity through collaborations and research licensing around its assay platform.","classification_confidence":98,"funding_stage":null,"total_funding_usd":"15000000","latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"operating","operating_status_reason":null,"operating_status_rationale":null,"operating_status_confidence":null,"business_model":"diagnostics","business_model_rationale":"The evidence consistently describes Amprion as developing, offering, and commercializing diagnostic biomarker tests for neurodegenerative disease. Its own site says, \"Amprion develops and offers SAAmplify-ɑSYN, a clinically available validated test for detecting pathological alpha-synuclein in CSF,\" and other supplied sources describe SYNTap as a laboratory-developed test that aids diagnosis of synucleinopathies. Although some sources mention a seed amplification assay platform and research licensing, the clearest primary commercial model is diagnostics.","business_model_confidence":96,"ip_market_structure":"On the evidence provided, the organization appears to have a meaningful proprietary position in misfolded-protein detection, especially around seeded amplification style assays for neurodegenerative biomarkers. The clearest granted U.S. asset is US11249092B2, covering detection of misfolded tau protein, filed by Amprion and later showing a confirmatory NIH license. The portfolio also appears to extend more broadly to misfolded-protein detection methods through US20160077112A1 and AU2015314783B2, although the U.S. application is marked abandoned, which weakens that particular U.S. claim set even if related foreign rights survived. The newer alpha-synuclein bead-based family, including EP4025702A4 and the related U.S. grant US11079396B2 referenced in that family data, suggests continued expansion into assay-format improvements and disease-specific targets. Because the prompt says blocking third-party corridor patents would follow the held patents, but none are actually included in the supplied evidence, no specific outside blocker can be identified from this record alone. That materially limits any hard freedom-to-operate conclusion. Based only on what is here, the organization’s posture looks stronger on offense than obviously constrained on defense: it has granted or pending rights in tau, alpha-synuclein, and broader misfolded-protein detection, but there is no cited third-party patent in the record showing a direct exclusion risk against its core assay approach. Design-around looks plausible in some areas and harder in others. Disease target, substrate choice, bead usage, incubation protocol, and assay readout are all possible engineering levers if a claim is narrow. But if granted claims are written at the level of repeated incubation of sample with folded monomer to detect soluble misfolded protein, then design-around becomes more difficult because the protected concept may sit close to the assay’s core operating principle rather than a peripheral implementation detail. Licensability is mixed. University-linked and NIH-linked assets usually can be licensed in principle, which suggests these rights are not inherently closed. At the same time, the fact pattern here indicates Amprion has built around exclusive or tightly controlled assay IP, so practically the corridor may be strategically defended even if formal licensing is possible. In short, the evidence supports a relatively strong proprietary moat for the organization, but it does not establish concrete third-party blocking risk without the missing corridor patents.","is_public":true,"disqualified":true,"disqualified_reason":"Amprion is a neurodegenerative diagnostics company. Its core product is a clinically available CSF alpha-synuclein assay for Parkinson's, Lewy body dementia, and related disease stratification, which measures pathology but does not develop an intervention that targets the biology of aging.","disqualified_at":"2026-07-01T17:44:17.898Z","research_status":"ready","is_editors_choice":false,"overall_score":52.61,"overall_score_computed_at":"2026-07-01 17:43:41.373143+00","pipeline_version":"0.24.1","proximity_score":"92.00","proximity_band":"near_readout","proximity_rationale":"Derived deterministically from 2 extracted project(s). Most-advanced status: approved. Band: near_readout. Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":2,"social_links":null,"careers_page_url":"https://ampriondx.com/about/careers","pipeline_page_url":null,"external_registry_ids":{"sec":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-26T09:51:25.582Z\",\"rationale\":\"sec returned 0 candidates for \\\"Amprion\\\".\",\"officers_matched\":[],\"candidate_count\":0}","opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-26T07:18:13.272Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"Amprion\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-06-03 01:09:11.482577+00","updated_at":"2026-09-22 23:20:13.506004+00","scores":{"ambition":5.8,"publicity":4.4,"media_reach":4,"reliability":7,"falsifiability":8.6,"claim_integrity":9.77,"collaborativity":7,"context_validity":8,"pipeline_quality":5,"explanatory_power":6.8,"results_alignment":8,"scandal_integrity":7,"publication_quality":7,"premise_plausibility":7.6,"implementation_fidelity":8,"independent_replication":6},"public_records_count":159,"publications_count":46,"projects_count":2,"funding_rounds_count":1,"clinical_trials_count":0,"publication_status":"published_disqualified","public_url":"https://eternalsearch.net/companies/lePPrIF5","api_url":"https://eternalsearch.net/api/v1/companies/lePPrIF5"},{"id":"e17512a8-8b06-440a-8e18-00264cdb3789","public_id":"gb9JB1Ul","name":"C2N Diagnostics","canonical_name":"C2N Diagnostics","aliases":["C2N","Precivity"],"one_liner":"C2N develops and commercializes blood-based diagnostics for Alzheimer’s disease and related neurodegeneration.","description":"C2N Diagnostics is a specialty diagnostics company providing laboratory services and products in brain health. Its high-resolution mass spectrometry-based biomarker products support clinical decision-making, clinical trials for neurodegeneration, and research into mechanisms of disease. Its Precivity blood tests are intended to help health care professionals assess amyloid plaques associated with Alzheimer’s disease in patients with cognitive impairment.","website":"https://c2n.com","canonical_website":"https://c2n.com/","logo_url":"https://s.yimg.com/ny/api/res/1.2/fVOJAdqC0XJaA4jayXeCBA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0/https://media.zenfs.com/en/business-wire.com/24ffbd73eab3085df6ad7a8be0ff26a0","headquarters":"St Louis, Missouri, United States","hq_country_code":"US","founding_year":null,"primary_approach":"blood biomarkers, LC-MS/MS, Alzheimer’s diagnostics","primary_field_slug":"diagnostics","field_slugs":["diagnostics"],"primary_idea_root_slug":null,"idea_root_slugs":[],"primary_modality_slug":null,"modality_slugs":[],"classification_rationale":"C2N Diagnostics is a specialty diagnostics company focused on blood-based testing for Alzheimer’s disease and related neurodegeneration. Across the supplied evidence, the company is consistently described through its Precivity blood tests, in-vitro diagnostic products, clinical mass spectrometry platform, and related diagnostic services used to aid diagnosis, screening, and clinical decision-making in brain health. The evidence does not ground any therapeutic aging mechanism or drug modality, so the company is best classified as diagnostics/testing rather than a therapeutics developer.","classification_confidence":98,"funding_stage":null,"total_funding_usd":"19225000","latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"operating","operating_status_reason":null,"operating_status_rationale":null,"operating_status_confidence":null,"business_model":"diagnostics","business_model_rationale":"The strongest evidence consistently describes C2N as a specialty diagnostics company and ties its commercial activity to blood-based tests for Alzheimer's disease and related neurodegeneration, including Precivity-branded tests and in-vitro diagnostic approvals. That supports classifying the company as diagnostics rather than drug development, delivery technology, or a general platform business.","business_model_confidence":98,"ip_market_structure":"On the evidence provided, the organization appears to have a meaningful but method-focused patent position of its own, and there is no actual third-party blocking patent evidence in the record excerpt to establish a crowded external corridor. The clearest internal assets are C2N Diagnostics’ biomolecule measurement family, especially EP2373988A1 / EP2373988A4 / granted EP2373988B1, which covers methods for measuring biomolecule concentrations and appears active in Europe with priority back to December 5, 2008. That looks like core assay-platform IP around labeled/unlabeled biomolecule quantitation. US20180364260A1 adds a later filing around extracting and measuring biomolecules in complex matrices without immunocapture, suggesting a second layer of protection around sample preparation and workflow efficiency. WO2016201434A2 on stable formulations of a humanized anti-tau antibody points to a therapeutic or reagent-side estate tied specifically to tau-directed biologics. Freedom to operate therefore looks better described as internally supported than externally cleared. Based only on this evidence, C2N seems to own important patents around biomolecule measurement methods and possibly tau-antibody formulation, which strengthens its operating position in those exact workflows. But because no field-corridor patents held by others are actually included here, there is no evidentiary basis to say external blocking risk is low; only that it is not demonstrated in this packet. In practice, the strongest likely exposure area would be if the organization’s products depend on particular tau antibodies, formulation regimes, or assay architectures not fully covered by its own families. Design-around feasibility appears moderate. Method claims around biomolecule quantitation and extraction are often designable around by changing labeling strategy, capture/no-capture workflow, solvent partitioning scheme, matrix handling, calibration approach, or assay modality. The anti-tau formulation asset is narrower by nature: formulation claims can sometimes be designed around through excipient systems, concentration ranges, stability conditions, or antibody sequence changes, but if a specific humanized anti-tau molecule is central, workarounds become harder. On licensability versus strategic closure, the evidence points more toward strategically important platform IP than purely defensive filing. The measurement family looks like technology a diagnostics company could license, but also the kind it might keep tightly controlled because it sits close to assay differentiation. The anti-tau formulation filing likewise looks more likely to be strategically closed if it protects a lead reagent or therapeutic program.","is_public":true,"disqualified":true,"disqualified_reason":"C2N Diagnostics is a neurodegeneration diagnostics company. Its core business is blood tests and lab services for Alzheimer's disease and related disorders, and the evidence here does not show a program aimed at the biology of aging itself or a platform built to measure biological aging rather than disease-specific pathology.","disqualified_at":"2026-07-02T04:59:26.667Z","research_status":"ready","is_editors_choice":false,"overall_score":48.58,"overall_score_computed_at":"2026-07-02 04:58:45.479923+00","pipeline_version":"0.24.1","proximity_score":"55.00","proximity_band":"translational","proximity_rationale":"Derived deterministically from 6 extracted project(s). Most-advanced status: phase 1. Band: translational. Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":3,"social_links":null,"careers_page_url":"https://c2n.com/careers","pipeline_page_url":null,"external_registry_ids":{"sec":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-26T18:39:00.345Z\",\"rationale\":\"sec returned 0 candidates for \\\"C2N Diagnostics\\\".\",\"officers_matched\":[],\"candidate_count\":0}","opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-26T18:39:00.349Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"C2N Diagnostics\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-06-03 01:09:11.754693+00","updated_at":"2026-09-22 23:22:40.366548+00","scores":{"ambition":5.5,"publicity":7,"media_reach":4,"reliability":7,"falsifiability":9,"claim_integrity":9.83,"collaborativity":9,"context_validity":7,"pipeline_quality":5,"explanatory_power":7,"results_alignment":7,"scandal_integrity":8,"publication_quality":7,"premise_plausibility":8,"implementation_fidelity":8,"independent_replication":6},"public_records_count":178,"publications_count":57,"projects_count":6,"funding_rounds_count":3,"clinical_trials_count":4,"publication_status":"published_disqualified","public_url":"https://eternalsearch.net/companies/gb9JB1Ul","api_url":"https://eternalsearch.net/api/v1/companies/gb9JB1Ul"},{"id":"0d519226-cc3a-4f63-8276-4b666602bf08","public_id":"Y9uAICmb","name":"Cambridge Epigenetix","canonical_name":"biomodal","aliases":[],"one_liner":"biomodal provides multiomics technologies that resolve genetic and epigenetic DNA information from a single low-input sample.","description":"biomodal creates technologies that bring changing biology into focus by integrating multiple modes of biology from a single sample in a single experiment. Its duet multiomics solution evoC distinguishes 5-methylcytosine and 5-hydroxymethylcytosine alongside the four canonical DNA bases from low-input DNA samples. The site highlights applications in cancer research, neurodegenerative disease, ageing, precision medicine, liquid biopsy, and non-invasive prenatal testing.","website":"https://cambridge-epigenetix.com","canonical_website":"https://cambridge-epigenetix.com/","logo_url":"https://s.yimg.com/ny/api/res/1.2/v59ytkxtFoP.pbJUzln8Dw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD0zMDE-/https://media.zenfs.com/en/globenewswire.com/9b08f1a364bbb81113721ddc2363866c","headquarters":"Cambridge, United Kingdom","hq_country_code":"GB","founding_year":null,"primary_approach":"6-base genome, multiomics, epigenetic sequencing","primary_field_slug":"research_tools","field_slugs":["research_tools","diagnostics","software_data"],"primary_idea_root_slug":null,"idea_root_slugs":[],"primary_modality_slug":null,"modality_slugs":[],"classification_rationale":"biomodal, formerly Cambridge Epigenetix, is primarily a life-science research tools and services company focused on epigenetics, multiomics, and DNA sequencing technology. Across company and third-party sources, it is described as developing epigenetics tools, multiomic products, sequencing workflows, and custom solutions for researchers; there is also meaningful evidence of diagnostics activity, especially cancer-detection programs and studies based on its methylation-enabled sequencing platform, but the dominant pattern is platform and product provision rather than therapeutics.","classification_confidence":94,"funding_stage":null,"total_funding_usd":"88000000","latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"operating","operating_status_reason":null,"operating_status_rationale":null,"operating_status_confidence":null,"business_model":"platform","business_model_rationale":"The strongest and most consistent evidence describes biomodal as an enabling technology company commercializing multiomics and sequencing products rather than a therapeutic developer. Sources describe it as an \"omics-based life sciences technology and analytics company\" delivering customers a \"new duet multiomics solution,\" and as a company offering \"Technology Products\" and \"Custom solutions\" to explore multiple modes of biology from a single sample. While some evidence references cancer detection applications, that appears to be an application area of its sequencing platform rather than its primary business model.","business_model_confidence":94,"ip_market_structure":"On the evidence provided, the clearest IP holders in this corridor are the organization itself, through the Cambridge Epigenetix to biomodal chain of title. The patents that appear to matter most are US10428381B2, an active US patent expiring July 2, 2033 on methods for detecting nucleotide modification, and US9822394B2, the granted counterpart of US20160251700A1, active to February 24, 2035 on nucleic acid sample preparation. Together, those two assets appear to cover a meaningful portion of the practical workflow: upstream library/sample-prep steps and downstream detection of modified bases, especially around cytosine/5hmC-type chemistry. CA3187549A1, still pending, looks like a newer and potentially broader attempt to extend protection around compositions and methods for nucleic acid analysis, with a 2020 priority date. The Brazilian filing appears to be a foreign-family member of the nucleotide-modification detection estate. Because no third-party field-corridor patents are actually included in the supplied evidence, there is no concrete basis here to name an external blocker or say which outside patent currently constrains freedom to operate. So, strictly from this record, the organization’s posture looks stronger on offense than its exposure is knowable on defense: it appears to own relevant core patents, but the evidence set is incomplete for a true FTO conclusion. The right reading is not “clear FTO,” but “internally protected, externally unproven.” Design-around feasibility looks mixed. Sample-preparation claims are often more engineerable around by changing adapter structure, ligation strategy, end chemistry, or workflow order, so that part of the corridor may be moderately navigable. The nucleotide-modification detection estate looks harder to avoid if the commercial method depends on the same modified-base readout logic, bisulfite-related chemistry, or closely adjacent 5hmC/cytosine discrimination scheme; in that case, design-around may require a genuinely different detection modality rather than a minor protocol tweak. As to licensing posture, there is no direct evidence of licensability or strategic openness from third parties because no third-party patents are supplied. The company’s own filings instead suggest a deliberate effort to build a strategically closed moat around a sequencing/epigenetics stack rather than a narrow, easily bypassed patent position.","is_public":true,"disqualified":true,"disqualified_reason":"This is not a longevity company. biomodal builds a general multiomics and epigenetic sequencing platform, and the concrete programs shown here are cancer liquid-biopsy biomarker studies, not therapies or tools built specifically to measure or alter aging biology in living patients.","disqualified_at":"2026-07-01T12:44:02.345Z","research_status":"ready","is_editors_choice":false,"overall_score":45.5,"overall_score_computed_at":"2026-07-01 12:42:50.937981+00","pipeline_version":"0.24.1","proximity_score":"15.00","proximity_band":"far","proximity_rationale":"Derived deterministically from 3 extracted project(s). Most-advanced status: undisclosed. Band: far. Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":3,"social_links":null,"careers_page_url":"https://biomodal.com/careers/","pipeline_page_url":null,"external_registry_ids":{"opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-26T05:47:00.975Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"biomodal\\\".\",\"officers_matched\":[],\"candidate_count\":0}","companies_house":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-26T05:47:00.969Z\",\"rationale\":\"companies_house returned 0 candidates for \\\"biomodal\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-06-03 01:09:11.768187+00","updated_at":"2026-09-22 23:24:15.061244+00","scores":{"ambition":6.33,"publicity":4,"media_reach":4,"reliability":6,"falsifiability":9,"claim_integrity":10,"collaborativity":7,"context_validity":7,"pipeline_quality":5,"explanatory_power":7,"results_alignment":8,"scandal_integrity":8,"publication_quality":7,"premise_plausibility":8,"implementation_fidelity":8,"independent_replication":3},"public_records_count":178,"publications_count":4,"projects_count":3,"funding_rounds_count":1,"clinical_trials_count":0,"publication_status":"published_disqualified","public_url":"https://eternalsearch.net/companies/Y9uAICmb","api_url":"https://eternalsearch.net/api/v1/companies/Y9uAICmb"},{"id":"e67c48f6-56a3-480b-b66e-aa558f467755","public_id":"7KflaKWD","name":"Neurona Therapeutics","canonical_name":"Neurona Therapeutics","aliases":["Neurona","Neurona Therapeutics Inc."],"one_liner":"Neurona develops allogeneic neural cell therapies to repair dysfunctional neural circuits in chronic nervous system disorders.","description":"Neurona Therapeutics is a privately held, clinical-stage biotherapeutics company focused on allogeneic neural cell therapies for chronic nervous system diseases. Its platform manufactures fully differentiated neuronal, glial, and gene-edited cell therapy candidates for targeted delivery into the nervous system. The lead candidate, NRTX-1001, is an inhibitory GABAergic interneuron therapy being evaluated for drug-resistant mesial temporal lobe epilepsy.","website":"https://neuronatherapeutics.com","canonical_website":"https://neuronatherapeutics.com/","logo_url":"https://image.pitchbook.com/6LjYfV5ywoalVN1HJNOEwyXP1wo1779468869116_200x200","headquarters":"San Francisco","hq_country_code":"US","founding_year":2015,"primary_approach":"allogeneic neural cell therapy, GABAergic interneurons, regenerative medicine","primary_field_slug":"replacement","field_slugs":["replacement","editing","repairing","measurement"],"primary_idea_root_slug":"replacing","idea_root_slugs":["replacing","editing","repairing","translating"],"primary_modality_slug":"cell_therapy","modality_slugs":["cell_therapy","gene_editing","gene_therapy","biologic"],"classification_rationale":"Neurona Therapeutics is a clinical-stage biotech developing allogeneic, regenerative neural cell therapies for chronic neurological disorders, especially epilepsy. The strongest evidence supports a replacing mechanism and a primary cell_therapy modality because the company repeatedly describes neuron and glial cell transplantation or off-the-shelf neural cell therapeutics intended to restore dysfunctional neural circuits. Secondary evidence supports editing and gene-focused modalities because the platform also references gene-edited neural cell therapy candidates and gene-therapy-related programs.","classification_confidence":95,"funding_stage":"series_c_plus","total_funding_usd":"305265285","latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"operating","operating_status_reason":null,"operating_status_rationale":null,"operating_status_confidence":null,"business_model":"drug_developer","business_model_rationale":"Neurona Therapeutics is described as a clinical-stage biotherapeutics company advancing named therapeutic candidates, including NRTX-1001 in clinical testing, which indicates a primary focus on developing therapeutic products rather than selling diagnostics, services, or software.","business_model_confidence":96,"ip_market_structure":"On the evidence provided, the organization appears to sit in a comparatively strong patent position rather than facing a clearly documented external blockade. The core assets are the Neurona Therapeutics filings on “Neural precursor cell populations and uses thereof” in the US and Canada, built off a 2015-10-08 priority date, and the earlier European family on in vitro production of medial ganglionic eminence precursor cells, with a 2013-03-14 priority and an active granted EP right through an anticipated 2034 expiration. Those families matter because they appear to cover both the cell populations themselves and the methods for producing and using precursor cells that migrate and differentiate into inhibitory interneurons, which looks close to the therapeutic center of gravity. The freedom-to-operate posture therefore looks favorable inside this specific evidence set, but with an important limitation: no third-party field-corridor patents are actually included here. That means there is no direct evidence in this record of blocking IP held by competitors, universities, or platform suppliers outside the organization’s apparent control. If this is the full record, the main conclusion is that the organization has meaningful offensive and defensive coverage in its intended lane, especially around MGE-like / interneuron precursor manufacturing and use. If the EP family is controlled by license rather than direct ownership, then continued FTO depends on the durability and scope of that license, because that earlier granted right looks foundational. Design-around feasibility appears mixed. It would likely be hard to design around if a product depends on substantially the same precursor identity, manufacturing route, migratory behavior, and differentiation into inhibitory interneurons, because the claims seem aimed at exactly those features. Design-around becomes more plausible only by moving to materially different cell sources, differentiation protocols, marker-defined populations, or therapeutic use cases. Nothing in this evidence suggests the key blockers are strategically closed by hostile third parties. The opposite is more likely: the most important rights appear to be held or controlled by the organization itself, or at least aligned with it. The real caveat is evidentiary, not legal: without the omitted field-corridor patents held by others, this supports a strong internal moat but not a complete third-party FTO clearance.","is_public":true,"disqualified":true,"disqualified_reason":"Neurona Therapeutics is a neurology cell therapy biotech, not a longevity company. It develops allogeneic neural cell therapies for chronic nervous system disorders, with NRTX-1001 aimed at drug-resistant mesial temporal lobe epilepsy; that is disease-focused regenerative medicine, not a program built to measure, slow, reverse, or otherwise target the biology of aging itself.","disqualified_at":"2026-07-04T02:05:14.643Z","research_status":"ready","is_editors_choice":false,"overall_score":45.13,"overall_score_computed_at":"2026-07-04 02:05:05.610595+00","pipeline_version":"0.24.1","proximity_score":"60.00","proximity_band":"translational","proximity_rationale":"Derived deterministically from 6 extracted project(s). Most-advanced status: phase 1. Band: translational. Modifiers: +5 depth (2 programs at phase_1). Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":5,"social_links":{"github":null,"twitter":null,"youtube":null,"facebook":null,"instagram":null,"linkedin_company":"https://www.linkedin.com/company/neurona-therapeutics/"},"careers_page_url":"https://www.neuronatherapeutics.com/careers/","pipeline_page_url":"https://www.neuronatherapeutics.com/pipeline/","external_registry_ids":{"sec":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-27T08:45:00.369Z\",\"rationale\":\"sec returned 0 candidates for \\\"Neurona Therapeutics\\\".\",\"officers_matched\":[],\"candidate_count\":0}","opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-27T07:24:00.251Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"Neurona Therapeutics\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-06-03 01:09:12.939157+00","updated_at":"2026-09-22 23:26:21.314747+00","scores":{"ambition":8,"publicity":4,"media_reach":4,"reliability":7,"falsifiability":8.8,"claim_integrity":9.23,"collaborativity":7,"context_validity":6,"pipeline_quality":6,"explanatory_power":7,"results_alignment":7,"scandal_integrity":8,"publication_quality":8,"premise_plausibility":8,"implementation_fidelity":8,"independent_replication":5},"public_records_count":136,"publications_count":21,"projects_count":6,"funding_rounds_count":8,"clinical_trials_count":2,"publication_status":"published_disqualified","public_url":"https://eternalsearch.net/companies/7KflaKWD","api_url":"https://eternalsearch.net/api/v1/companies/7KflaKWD"},{"id":"5afde731-818e-4b86-a79d-69c2dc8afd1c","public_id":"qwvd527y","name":"Caraway Therapeutics","canonical_name":"Merck","aliases":["Merck & Co.","Merck & Co., Inc."],"one_liner":"Merck develops important medicines and vaccines and maintains a diverse pipeline to drive meaningful impact for patients.","description":"Merck states that for more than 130 years it has brought hope through the development of important medicines and vaccines. The site highlights one of the most diverse pipelines in the company's history and says Merck follows the science where it can make the greatest difference. Research areas shown include oncology, vaccines, infectious diseases, cardiometabolic and respiratory diseases, immunology, neuroscience, and ophthalmology.","website":"https://carawaytx.com","canonical_website":"https://carawaytx.com/","logo_url":"https://image.pitchbook.com/vLR5aAtJb4vlz3pYpXw7bG6G0NO1775232511029_200x200","headquarters":"United States","hq_country_code":"US","founding_year":null,"primary_approach":"medicines, vaccines, clinical trials","primary_field_slug":"modulating","field_slugs":["modulating","discovery","clearing"],"primary_idea_root_slug":"modulating","idea_root_slugs":["modulating","discovering","clearing"],"primary_modality_slug":"biologic","modality_slugs":["biologic","small_molecule","immunotherapy"],"classification_rationale":"The merged candidates characterize Merck primarily as a large therapeutic biopharma company with a broad R&D pipeline spanning antibody/biologic programs, small-molecule drugs, and immunotherapy-oriented oncology assets, with some evidence of computational drug-discovery capability. The strongest Merck-specific evidence comes from its pipeline and product records, which point most clearly to modulating biology through conventional pharmaceutical intervention rather than to a non-therapeutic offering business.","classification_confidence":72,"funding_stage":"public","total_funding_usd":null,"latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"operating","operating_status_reason":null,"operating_status_rationale":null,"operating_status_confidence":null,"business_model":"drug_developer","business_model_rationale":"Multiple candidates consistently describe Merck as developing medicines and vaccines, maintaining a diverse pipeline, supporting Phase III trials, and preparing products for commercialization. The strongest direct evidence comes from Merck's official pipeline materials: \"Merck develops important medicines and vaccines and maintains a diverse pipeline to drive meaningful impact for patients.\" That fits a primary business model of therapeutic product development rather than platform, diagnostics, delivery technology, or services.","business_model_confidence":97,"ip_market_structure":"On the evidence provided, the organization’s meaningful live IP position appears to center on Caraway Therapeutics’ TRPML modulator filings, especially WO2024168104A3 and EP4661864A2. Those are the patents that matter for the current corridor because they are directed to TRPML modulators, compositions, and methods of use, which suggests protection at the compound and therapeutic-use level rather than merely formulation detail. The PCT publication WO2024168104A3 is marked “ceased,” so it is better read as an international filing event and disclosure point than as an enforceable right by itself. The more important asset for current exclusivity is the pending European application EP4661864A2, which indicates the company is still trying to secure territory-specific claims around this chemistry. The freedom-to-operate picture is hard to call severely blocked from this record because no third-party field-corridor patents are actually included in the evidence set. That means there is no concrete basis here to identify a named outside blocker, a dominant competing assignee, or a specific hostile claim set that would fence the company out of TRPML modulation. So, based only on what is shown, the organization looks better described as building its own corridor than operating under a clearly demonstrated third-party overhang. The older US5853759A effervescent alendronate patent is explicitly expired and therefore not a present blocker. US7326708B2 appears to be an older DPP-IV salt patent and, from the text provided, does not look central to the TRPML corridor. Design-around feasibility appears moderate. If the company’s eventual claims are broad Markush chemistry and method-of-use claims around TRPML modulation, competitors may need to move to distinct chemotypes, different salt or formulation strategies, or different biological entry points within the lysosomal/autophagy pathway. If the granted claims end up narrower, design-around becomes easier because others could avoid the claimed scaffold while still targeting TRPML biology. On licensability versus strategic closure, the only active corridor shown is the company’s own. That usually points to a strategically closed posture around core compounds rather than an obviously licensable, standards-like blocking estate. But there is not enough third-party evidence here to say the surrounding field is closed by others; the record instead suggests the main IP gravity is with the company’s own pending TRPML filings.","is_public":true,"disqualified":true,"disqualified_reason":"This is a large pharmaceutical company with broad drug and vaccine programs in oncology, infectious disease, cardiometabolic disease, immunology, neuroscience, and ophthalmology. Nothing in the evidence shows an aging-biology program, a therapy aimed at mechanisms of aging, or a platform built specifically to measure or modify aging, so the longevity label does not hold.","disqualified_at":"2026-07-02T00:15:40.202Z","research_status":"ready","is_editors_choice":false,"overall_score":44.86,"overall_score_computed_at":"2026-07-02 00:15:10.419352+00","pipeline_version":"0.24.1","proximity_score":"100.00","proximity_band":"near_readout","proximity_rationale":"Derived deterministically from 11 extracted project(s). Most-advanced status: approved. Band: near_readout. Modifiers: +5 depth (2 programs at approved); +5 modality breadth (3 modalities at max band). Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":1,"social_links":null,"careers_page_url":null,"pipeline_page_url":"https://www.merck.com/research/product-pipeline/","external_registry_ids":{"sec":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-26T12:53:00.309Z\",\"rationale\":\"sec returned 0 candidates for \\\"Merck\\\".\",\"officers_matched\":[],\"candidate_count\":0}","opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-26T12:53:00.313Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"Merck\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-06-03 01:09:11.802661+00","updated_at":"2026-07-20 03:07:56.629024+00","scores":{"ambition":5.4,"publicity":4,"media_reach":7,"reliability":7,"falsifiability":8.5,"claim_integrity":2,"collaborativity":7,"context_validity":6,"pipeline_quality":10,"explanatory_power":5.2,"results_alignment":7,"scandal_integrity":8,"publication_quality":7,"premise_plausibility":7.2,"implementation_fidelity":7,"independent_replication":6},"public_records_count":297,"publications_count":155,"projects_count":11,"funding_rounds_count":0,"clinical_trials_count":0,"publication_status":"published_disqualified","public_url":"https://eternalsearch.net/companies/qwvd527y","api_url":"https://eternalsearch.net/api/v1/companies/qwvd527y"},{"id":"ba630b6b-d32a-4e63-bd60-f05ca73127aa","public_id":"pSJKtEQr","name":"Blue Rock Therapeutics (owned by Bayer)","canonical_name":"BlueRock Therapeutics","aliases":["BlueRock Therapeutics LP","BlueRock"],"one_liner":"BlueRock is a clinical-stage cell therapy company investigating replacement of cells damaged or lost to disease.","description":"BlueRock Therapeutics is a clinical-stage cell therapy company investigating medicines that replace cells damaged or lost to disease. Its programs include neurology and ophthalmology, with visible references to bemdaneprocel for Parkinson's disease and OpCT-001. The site describes its goal as transforming treatment of degenerative diseases through cellular medicine.","website":"https://bluerocktx.com","canonical_website":"https://bluerocktx.com/","logo_url":"https://www.bluerocktx.com/wp-content/uploads/2023/12/BlueRock-Logo-Dark-Blue-Final.jpg","headquarters":"Boston, Massachusetts, United States; New York City, New York, United States; Toronto, Canada","hq_country_code":"US","founding_year":null,"primary_approach":"cell therapy, cellular medicine","primary_field_slug":"replacement","field_slugs":["replacement"],"primary_idea_root_slug":"replacing","idea_root_slugs":["replacing"],"primary_modality_slug":"cell_therapy","modality_slugs":["cell_therapy","gene_therapy"],"classification_rationale":"BlueRock Therapeutics is a clinical-stage regenerative-medicine company centered on iPSC-derived cell therapies that replace cells lost or damaged by disease. Across multiple sources, the strongest and most repeated evidence describes BlueRock as a cell therapy company developing engineered cellular medicines for disorders such as Parkinson’s disease and photoreceptor degeneration, which maps primarily to the replacing idea root and the cell_therapy modality. Some evidence also indicates a broader cell+gene platform, supporting secondary inclusion of gene_therapy.","classification_confidence":95,"funding_stage":null,"total_funding_usd":null,"latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"operating","operating_status_reason":null,"operating_status_rationale":null,"operating_status_confidence":null,"business_model":"drug_developer","business_model_rationale":"The strongest evidence consistently describes BlueRock Therapeutics as a clinical-stage cell therapy company developing medicines and advancing named therapeutic programs and clinical trials. References to a cell+gene or iPSC platform are framed as internal technology used to create cellular medicines, not as a standalone product or service business. On balance, the primary business model is therapeutic development.","business_model_confidence":94,"ip_market_structure":"On the evidence provided, the organization appears to be BlueRock Therapeutics LP, and the only clearly material IP holders in the corridor are BlueRock itself and, potentially, University Health Network in the cardiomyocyte composition family. The strongest BlueRock-controlled assets shown are the pending iPSC manufacturing family, `US20220306991A1` and its continuation, the granted delivery-device patent `US11666710B2`, and the genomic-integration filing `CA3256155A1`. The cardiomyocyte composition family, `WO2020227232A3`, is important because it sits close to the core therapeutic product, but the record suggests shared provenance: it was filed by University Health Network and BlueRock, and Google’s assignee data points to UHN, albeit with accuracy caveats. That makes this family the most likely source of a real corridor constraint within the supplied evidence. Freedom to operate therefore looks reasonably strong in the areas BlueRock directly controls, especially for device implementation and internal cell-processing methods. The posture is less clean around cardiomyocyte compositions because ownership and control appear less exclusively BlueRock-held. If BlueRock already has contractual rights through its relationship with UHN, that risk may be operationally contained, but on the face of this evidence the composition claims are the place where dependence on another institution is most plausible. Just as important, no third-party field-corridor patents are actually supplied here, so there is no direct evidence of an external blocking wall beyond that UHN-linked family. That means the FTO picture is favorable but incomplete rather than unequivocally clear. Design-around feasibility varies by layer. The delivery-device patent is probably the easiest to work around by changing needle, plunger, threading, passage, or administration architecture. The iPSC and cardiomyocyte assets are harder to avoid if their claims cover specific enriched populations, differentiation outputs, or process conditions central to product identity; those are usually closer to the therapeutic core. The safe-integration-site filing also looks more design-aroundable if alternative loci or non-integrating engineering methods are available. As to licensing posture, BlueRock-held patents are internal enablers, not blockers. The likely blocker, if any, is the UHN-linked cardiomyocyte family, and that type of academic-origin asset generally looks more licensable than strategically closed. Nothing in the supplied evidence shows a hostile or structurally closed third-party patent thicket.","is_public":true,"disqualified":false,"disqualified_reason":null,"disqualified_at":null,"research_status":"ready","is_editors_choice":false,"overall_score":44.83,"overall_score_computed_at":"2026-07-01 04:28:11.060929+00","pipeline_version":"0.24.1","proximity_score":"80.00","proximity_band":"near_readout","proximity_rationale":"Derived deterministically from 5 extracted project(s). Most-advanced status: phase 3. Band: near_readout. Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":2,"social_links":null,"careers_page_url":null,"pipeline_page_url":"https://www.bluerocktx.com/the-science/pipeline/","external_registry_ids":{"sec":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-26T04:27:00.235Z\",\"rationale\":\"sec returned 0 candidates for \\\"BlueRock Therapeutics\\\".\",\"officers_matched\":[],\"candidate_count\":0}","opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-26T01:45:00.528Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"BlueRock Therapeutics\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-06-03 01:09:11.693668+00","updated_at":"2026-07-20 04:02:34.801227+00","scores":{"ambition":7.08,"publicity":4,"media_reach":5,"reliability":7,"falsifiability":8.5,"claim_integrity":10,"collaborativity":8,"context_validity":8,"pipeline_quality":8,"explanatory_power":6.08,"results_alignment":7,"scandal_integrity":8,"publication_quality":6,"premise_plausibility":7.92,"implementation_fidelity":8,"independent_replication":4},"public_records_count":173,"publications_count":13,"projects_count":5,"funding_rounds_count":0,"clinical_trials_count":5,"publication_status":"published","public_url":"https://eternalsearch.net/companies/pSJKtEQr","api_url":"https://eternalsearch.net/api/v1/companies/pSJKtEQr"},{"id":"6b419203-a9f2-4e53-b9b7-a4b00986d942","public_id":"bb3Viu75","name":"Pentara","canonical_name":"Pentara","aliases":["Pentara Corporation"],"one_liner":"Pentara provides biostatistics, clinical programming, data management, fraud detection, medical writing, and regulatory support for clinical trials.","description":"Pentara Brain Stride appears to be a neurodegeneration-focused clinical-trials analytics and services effort rather than a therapeutic program: Pentara presents it as biostatistics, data management, fraud/anomaly detection, regulatory support, and study-design support for clinical trials, with claimed relevance to Alzheimer’s and related disorders. The evidence supports a real operating team and publication activity, but it is still mostly self-authored company material with no project-specific outcome data in the excerpt, so the strongest claim is that this is research infrastructure for brain-health trials, not validated brain-health impact.","website":"https://pentara.com/","canonical_website":"https://pentara.com/","logo_url":"https://www.pentara.com/images/Action%20Shots/hero.JPG","headquarters":null,"hq_country_code":"US","founding_year":2001,"primary_approach":"clinical biostatistics, study design, integrity analytics","primary_field_slug":"measurement","field_slugs":["measurement","research_tools","software_data"],"primary_idea_root_slug":"operating-trials","idea_root_slugs":["operating-trials","measuring"],"primary_modality_slug":null,"modality_slugs":[],"classification_rationale":"Pentara appears to be a non-therapeutic clinical research, trial-analytics, and data-management company serving pharma and biotech rather than a developer of longevity therapeutics. The evidence consistently points to operating clinical trials through services such as biostatistics, study design, clinical programming, data management, fraud and data-integrity detection, medical writing, and regulatory support, with some measurement-adjacent work on biomarkers and MRI surrogate endpoints in Alzheimer's and other neurodegenerative diseases.","classification_confidence":95,"funding_stage":"bootstrapped","total_funding_usd":null,"latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"operating","operating_status_reason":null,"operating_status_rationale":null,"operating_status_confidence":null,"business_model":"services","business_model_rationale":"The evidence describes Pentara primarily as a contract services provider for clinical trials rather than a therapeutic developer, diagnostics company, or standalone technology platform. Its own materials center on study design, clinical programming, data management, biostatistics, fraud detection, medical writing, and regulatory support for medical research and industry clients.","business_model_confidence":95,"ip_market_structure":"On this record, the blocking IP appears to sit almost entirely with established rare-disease and lipid-therapy incumbents rather than with the organization itself. The clearest corridor patents are Alexion’s `WO2017058822A1` and its national counterparts, which target dosage-regimen identification for TNSALP enzyme-replacement therapy in hypophosphatasia, and BioMarin’s `WO2007067570A1`, which is broader treatment-method IP in the disease-therapy space. Separately, Sanofi/Regeneron appear to control a substantial PCSK9 treatment corridor through `EA037526B1` and the related family reflected in `JP2016538248A` and `WO2015054619A2`, covering use of a PCSK9 inhibitor for treating hyperlipidemia. Those PCSK9 filings matter because they look like classic method-of-use protection around a commercially central therapeutic mechanism, not a narrow manufacturing detail. The organization’s freedom-to-operate posture therefore looks weak to constrained if its product concept depends directly on TNSALP enzyme replacement for hypophosphatasia or on PCSK9 inhibition for lipid disorders. The evidence provided does not show any held patents by the organization that would create bargaining leverage or carve out a proprietary lane, so the posture is defensive only to the extent the organization can argue it is outside the claimed indication, regimen, molecule class, or patient population. If the organization is pursuing adjacent biology rather than those exact modalities, the corridor is less threatening, but the patent owners named here are strong enough that a directly overlapping program would face meaningful infringement risk. Design-around feasibility looks mixed. It is more feasible where claims are regimen-specific, indication-specific, or tied to a defined inhibitor class, because alternatives could include different targets, different modalities, distinct patient subsets, or non-overlapping dosing strategies. It looks less feasible if the commercial thesis depends on the same core mechanism in the same disease setting, especially for PCSK9 inhibition and TNSALP replacement, where the patents appear to protect the heart of the therapeutic use rather than an incidental implementation detail. These blockers look more strategically closed than naturally licensable. Alexion, BioMarin, and Sanofi/Regeneron are all operating companies with obvious strategic reasons to preserve exclusivity around flagship therapeutic franchises. Licensing is not impossible, but based on the evidence alone, these look like assets held to protect product markets first and to monetize through broad third-party access only selectively.","is_public":true,"disqualified":true,"disqualified_reason":"Pentara is a clinical-trials services company. It does biostatistics, data management, fraud detection, medical writing, and study-design support for Alzheimer's and other neurodegenerative trials, but the evidence does not show a therapeutic program, an aging-biology intervention, or a platform built specifically to measure or modify aging itself.","disqualified_at":"2026-06-24T14:18:46.282Z","research_status":"ready","is_editors_choice":false,"overall_score":44.74,"overall_score_computed_at":"2026-06-24 14:17:51.727925+00","pipeline_version":"0.24.1","proximity_score":"90.00","proximity_band":"near_readout","proximity_rationale":"Derived deterministically from 26 extracted project(s). Most-advanced status: phase 3. Band: near_readout. Modifiers: +5 depth (3 programs at phase_3); +5 modality breadth (2 modalities at max band). Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":2,"social_links":null,"careers_page_url":"https://pentara.com/careers","pipeline_page_url":null,"external_registry_ids":{"sec":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-22T05:18:57.129Z\",\"rationale\":\"sec returned 0 candidates for \\\"Pentara\\\".\",\"officers_matched\":[],\"candidate_count\":0}","opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-22T05:12:00.598Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"Pentara\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-05-23 03:00:00.937285+00","updated_at":"2026-07-20 08:44:06.451731+00","scores":{"ambition":5.06,"publicity":4,"media_reach":3,"reliability":7,"falsifiability":8.36,"claim_integrity":9.84,"collaborativity":8,"context_validity":8,"fact_check_score":3.57,"pipeline_quality":2,"explanatory_power":6.45,"results_alignment":7,"scandal_integrity":8,"publication_quality":7,"premise_plausibility":7.87,"implementation_fidelity":8,"independent_replication":4},"public_records_count":71,"publications_count":67,"projects_count":26,"funding_rounds_count":0,"clinical_trials_count":0,"publication_status":"published_disqualified","public_url":"https://eternalsearch.net/companies/bb3Viu75","api_url":"https://eternalsearch.net/api/v1/companies/bb3Viu75"},{"id":"e2a2a167-37b1-4a0c-8863-3afdd2eb7315","public_id":"ahhahAQ5","name":"Medipost","canonical_name":"Medipost","aliases":["MEDIPOST","MEDIPOST Co., Ltd.","MEDIPOST Inc.","MEDIPOST K.K."],"one_liner":"MEDIPOST develops stem cell therapeutics, regenerative medicine products, cord blood banking services, CDMO services, and nutritional supplements.","description":"MEDIPOST says its mission is to help patients with incurable diseases and unmet medical needs through stem cells and regenerative medicine. The company commercialized CARTISTEM, described as the world's first regulatory-approved allogeneic human umbilical cord blood-derived mesenchymal stem cell product for knee osteoarthritis, launched in Korea in 2012. Its business also includes CELLTREE cord blood banking, CDMO services, and MOVITA nutritional supplements.","website":"https://en.medi-post.co.kr","canonical_website":"https://en.medi-post.co.kr/","logo_url":"https://en.medi-post.co.kr/wp-content/uploads/2025/04/main-banner-mobile-eng2.jpg","headquarters":"South Korea; Boston, Massachusetts, United States","hq_country_code":"KR","founding_year":2000,"primary_approach":"umbilical cord blood-derived MSCs, regenerative medicine, stem cell therapeutics","primary_field_slug":"replacement","field_slugs":["replacement","repairing","biobanking","consumer_products","research_tools"],"primary_idea_root_slug":"replacing","idea_root_slugs":["replacing","repairing"],"primary_modality_slug":"cell_therapy","modality_slugs":["cell_therapy","tissue_engineered","gene_therapy","biologic"],"classification_rationale":"Medipost is primarily a stem-cell therapeutics company focused on regenerative medicine, with strongest evidence around CARTISTEM and other umbilical cord blood-derived mesenchymal stem cell programs. That supports classifying its main idea root as replacing and its main modality as cell therapy, with a secondary repairing signal because its products target cartilage defects, osteoarthritis, and cartilage regeneration. The company also appears to have adjacent non-therapeutic businesses including cord blood banking, consumer supplements, and some research/manufacturing automation activity, but the dominant company profile in the evidence is commercial and clinical stem-cell therapy.","classification_confidence":95,"funding_stage":"public","total_funding_usd":null,"latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"operating","operating_status_reason":null,"operating_status_rationale":null,"operating_status_confidence":null,"business_model":"multi","business_model_rationale":"MEDIPOST has multiple material business lines. The company develops stem cell therapeutics such as CARTISTEM, PNEUMOSTEM, SMUP-IA-01, and SMUP-IV-01, and it also presents CDMO services, CELLTREE cord blood banking, and MOVITA nutritional supplements on its company site. That supports a multi classification rather than a single-model drug developer or services company.","business_model_confidence":95,"ip_market_structure":"I’m pulling the repo-level operating context first so the assessment stays aligned with this project’s rules, then I’ll draft the patent corridor narrative strictly from the evidence you provided. `CLAUDE.md` wasn’t in the current sub-home, so I’m locating the canonical copy the repo instructions point to before I write the assessment. On the evidence provided, the strongest identifiable IP holder in this corridor is the organization itself, Medipost, rather than a clearly documented third-party blocker. The most important asset appears to be `CA2884000C`, an active Canadian patent on a method for culturing mesenchymal stem cells, granted in 2021 with anticipated expiry in 2033. The record also indicates a broader family with corresponding US, EP, and JP filings, which suggests this culture-method estate is the core proprietary position. Two older China filings reinforce historical depth but not current exclusion power in the same way: `CN1281739C` covered isolation/expansion of cord-blood-derived mesenchymal stem/progenitor cells but is expired as of 2023, and `CN102281883A` appears to be a published application around neurologic uses of mesenchymal stem cells or conditioned media, with no grant status shown in the supplied text. The hair-growth filing `US20160000699A1` is specifically weak as a blocker because the evidence labels it abandoned. For freedom to operate, the organization’s posture looks mixed but generally better on foundational know-how than on enforceable exclusivity. It appears to have owned meaningful process IP around MSC culture and some application-focused inventions, but the supplied evidence does not show active third-party “field-corridor” patents that would clearly block commercialization. That absence matters: based only on this record, there is no demonstrated outside patent wall around the corridor. At the same time, the company’s own moat is not airtight, because one application is abandoned and one foundational China patent has already expired. Design-around looks reasonably feasible unless a live counterpart of the culture-method family has claims broad enough to cover standard MSC expansion conditions. Process claims of this kind are often designed around by changing source material, media composition, stimulation conditions, expansion protocol, or using cell-free derivatives rather than the exact claimed culture method. The hair-growth program especially appears more open given the abandoned US application. As to licensing posture, the only clearly evidenced live blocker-quality asset is the organization’s own active culture patent family, which by nature looks licensable if the owner chooses. The record does not show strategically closed third-party incumbents; more importantly, it does not identify any such third-party blockers at all.","is_public":true,"disqualified":false,"disqualified_reason":null,"disqualified_at":null,"research_status":"ready","is_editors_choice":false,"overall_score":44.37,"overall_score_computed_at":"2026-06-29 02:29:12.59078+00","pipeline_version":"0.24.1","proximity_score":"100.00","proximity_band":"near_readout","proximity_rationale":"Derived deterministically from 10 extracted project(s). Most-advanced status: approved. Band: near_readout. Modifiers: +5 depth (4 programs at approved); +5 modality breadth (3 modalities at max band). Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":1,"social_links":null,"careers_page_url":null,"pipeline_page_url":"https://en.medi-post.co.kr/development/","external_registry_ids":{"opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-25T02:54:00.094Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"Medipost\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-06-03 01:09:12.747423+00","updated_at":"2026-09-22 23:35:46.897158+00","scores":{"ambition":6.5,"publicity":4,"media_reach":4,"reliability":7,"falsifiability":8.25,"claim_integrity":2,"collaborativity":7,"context_validity":6,"pipeline_quality":8,"explanatory_power":6,"results_alignment":7,"scandal_integrity":8,"publication_quality":7,"premise_plausibility":7,"implementation_fidelity":8,"independent_replication":5},"public_records_count":144,"publications_count":99,"projects_count":10,"funding_rounds_count":4,"clinical_trials_count":20,"publication_status":"published","public_url":"https://eternalsearch.net/companies/ahhahAQ5","api_url":"https://eternalsearch.net/api/v1/companies/ahhahAQ5"},{"id":"1fddeb3e-ebb3-46c4-8425-974c0b90b97e","public_id":"UpiLcNQS","name":"Treefrog Therapeutics","canonical_name":"TreeFrog Therapeutics","aliases":["TreeFrog"],"one_liner":"TreeFrog Therapeutics develops iPS-derived regenerative cell therapies using its proprietary C-Stem biomimetic technology platform.","description":"TreeFrog Therapeutics is a Research & Development biotech advancing a pipeline of regenerative medicine cell therapies. Its lead program is in Parkinson’s Disease and is described as on track for a first-in-human trial by 2026. The company’s proprietary C-Stem technology is a biomimetic platform integrating GMP-compliant encapsulation to support large-scale cell production.","website":"https://treefrog.fr","canonical_website":"https://treefrog.fr/","logo_url":"https://treefrog.fr/wp-content/uploads/2021/06/2021-team.jpg","headquarters":"France","hq_country_code":"FR","founding_year":null,"primary_approach":"iPS-derived cell therapies, C-Stem, 3D microtissue","primary_field_slug":"replacement","field_slugs":["replacement","repairing"],"primary_idea_root_slug":"replacing","idea_root_slugs":["replacing","repairing"],"primary_modality_slug":"cell_therapy","modality_slugs":["cell_therapy"],"classification_rationale":"TreeFrog Therapeutics is a regenerative-medicine biotech focused on developing and manufacturing iPSC-derived cell therapies, using its proprietary C-Stem platform to scale production of allogeneic and disease-targeted cell therapy programs such as Parkinson’s and liver disease. The company is best classified under replacing because its therapies aim to supply new functional cells or microtissues rather than modulate signaling or measure aging, and its core therapeutic modality is clearly cell therapy.","classification_confidence":96,"funding_stage":null,"total_funding_usd":"75000000","latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"operating","operating_status_reason":null,"operating_status_rationale":null,"operating_status_confidence":null,"business_model":"multi","business_model_rationale":"The strongest evidence consistently shows two primary models: TreeFrog advances its own therapeutic pipeline and also develops/deploys its C-Stem production platform. Multiple sources describe both \"a pipeline of stem cell-derived cell therapies\" and proprietary C-Stem technology or platform deployment, so \"multi\" is better supported than either drug developer or platform alone.","business_model_confidence":94,"ip_market_structure":"On the supplied record, the organization appears to have a relatively strong internal IP position around cell-encapsulation and 3D microtissue manufacturing, and there is no concrete third-party blocking patent evidence in the packet. The key patents that matter are the earlier microcompartment family, led by `WO2018096277A1` and related national filings such as `CL2019001378A1`, which appears to establish the base platform for “cellular microcompartments” and preparation methods. That earlier family is notable because the listed assignees are public research institutions rather than Treefrog Therapeutics, suggesting foundational rights may sit with or originate from CNRS/University of Bordeaux/Institut d’Optique and may have been licensed, assigned, or otherwise made available to the company. Treefrog’s later filings, especially `AU2022273180A1`, appear to build a second layer of protection around microcompartments containing amplified cells with maintained genomic integrity, which is commercially important for scalable cell-therapy manufacturing. `WO2023214055A1` then narrows into a product/application corridor for specific 3D liver microtissues and therapeutic use in liver failure. From a freedom-to-operate perspective, the evidence points to a better posture than a company operating without platform patents, because the organization appears to control or at least benefit from both broad process/platform claims and newer application-specific claims. The main FTO caution is not visible third-party blockers, but chain-of-title and scope: if the foundational 2018 microcompartment family is not fully owned by the company, its operating freedom may depend on continued access to rights from the original institutional assignees. Design-around looks possible in principle but not obviously easy if a competitor wants to stay in the same technical lane. A third party might try to avoid these claims by changing the encapsulation architecture, hydrogel/layer structure, cell-loading method, genomic quality-control workflow, or by moving into non-liver indications. But if the commercial goal is scalable, protected 3D stem-cell-derived microtissue production with preserved cell quality, the later Treefrog filings likely make clean workarounds narrower and more expensive. As to licensability versus strategic closure, the foundational academic-origin family looks more likely to be licensable in general market terms, while Treefrog’s newer filings look more strategically closed because they appear targeted at the company’s manufacturing and therapeutic product corridor. On this evidence alone, the corridor looks more defensible than blocked.","is_public":true,"disqualified":false,"disqualified_reason":null,"disqualified_at":null,"research_status":"ready","is_editors_choice":false,"overall_score":44.04,"overall_score_computed_at":"2026-07-04 16:18:25.173698+00","pipeline_version":"0.24.1","proximity_score":"40.00","proximity_band":"early_mechanism","proximity_rationale":"Derived deterministically from 5 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Modifiers: +5 depth (2 programs at preclinical). Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":3,"social_links":null,"careers_page_url":"https://treefrog.fr/become-a-froggy/","pipeline_page_url":"https://treefrog.fr/cell-therapy-pipeline-ips-derived-cell-therapies-allogeneic-stem-cell-therapies/","external_registry_ids":{"opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-27T12:24:55.560Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"TreeFrog Therapeutics\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-06-03 01:09:13.670883+00","updated_at":"2026-09-22 23:37:58.093033+00","scores":{"ambition":7.25,"publicity":5,"media_reach":4,"reliability":7,"falsifiability":9,"claim_integrity":10,"collaborativity":8,"context_validity":6,"pipeline_quality":5,"explanatory_power":7,"results_alignment":8,"scandal_integrity":8,"publication_quality":7,"premise_plausibility":8,"implementation_fidelity":8,"independent_replication":3},"public_records_count":157,"publications_count":5,"projects_count":5,"funding_rounds_count":1,"clinical_trials_count":0,"publication_status":"published","public_url":"https://eternalsearch.net/companies/UpiLcNQS","api_url":"https://eternalsearch.net/api/v1/companies/UpiLcNQS"},{"id":"fa8133c5-88af-4f37-a272-48c90060a85d","public_id":"ISryp0XY","name":"GlycanAge","canonical_name":"GlycanAge","aliases":["Glycanage"],"one_liner":"GlycanAge provides biological age testing based on glycans, chronic inflammation, and immune health.","description":"GlycanAge offers an advanced biological age test designed to act as a warning system for disease development by measuring chronic inflammation and immune health. The site describes glycans as the immune system’s molecular record and says they can translate lifestyle, stress, and interventions into measurable outcomes. GlycanAge serves personal users, healthcare providers, and researchers.","website":"https://glycanage.com","canonical_website":"https://glycanage.com/","logo_url":"https://glycanage.com/linkedinpost.png","headquarters":"Newcastle, United Kingdom","hq_country_code":"GB","founding_year":null,"primary_approach":"glycans, inflammaging, biological age","primary_field_slug":"diagnostics","field_slugs":["diagnostics","research_tools","clinical_care"],"primary_idea_root_slug":null,"idea_root_slugs":[],"primary_modality_slug":null,"modality_slugs":[],"classification_rationale":"GlycanAge is a non-therapeutic biological age testing company centered on glycan-based measurement of immune health, chronic inflammation, and biological age. The evidence consistently describes a blood-based GlycanAge test sold for personal use and through healthcare providers, with an additional researcher-facing offering that supports studies using glycan analysis. The materials support classification as diagnostics first, with a secondary research-tools component and some provider-integration activity, but do not support any therapeutic intervention modality or aging-mechanism idea root.","classification_confidence":98,"funding_stage":null,"total_funding_usd":null,"latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"operating","operating_status_reason":null,"operating_status_rationale":null,"operating_status_confidence":null,"business_model":"diagnostics","business_model_rationale":"The supplied evidence consistently describes GlycanAge as a biological age test company offering glycan-based testing for personal users, healthcare providers, and researchers. That fits a diagnostics company more closely than a drug developer, platform, or delivery technology business.","business_model_confidence":93,"ip_market_structure":"On the evidence provided, the organization appears to have one meaningful owned asset, `US9910046B2`, now associated with Glycanage Ltd, covering analysis of N-glycans attached to IgG from human blood plasma and use of that analysis for assessing physiological state. That gives it a defendable position around a specific plasma IgG glycan workflow, but it does not by itself clear the broader analytical stack. The most visible third-party corridor patent is `EP2533039B1`, held by Max Planck Gesellschaft, which appears to claim automated high-throughput identification of carbohydrates and carbohydrate-mixture composition patterns, including glycosylation patterns of antibodies and other biologics. That matters because it sits close to workflow automation, pattern identification, and systemization rather than the narrow clinical use case alone. `EP2306199A1`, on reductive amination and carbohydrate analysis using 2-picoline borane, also looks relevant if the organization’s assay depends on that derivatization chemistry. `CN112505328B`, held by Wuhan Genecreate, looks narrower and more geographic: an active China patent on an isotope-labeling kit and labeling method, relevant if the company uses that specific labeling approach or sells into China. The resulting freedom-to-operate posture looks mixed but not blocked outright. In its narrowest lane, the company has some protection for an IgG N-glycan plasma analysis method. The main FTO risk is not the biological insight itself, but dependence on third-party sample-prep chemistry, labeling kits, and high-throughput analytical systems. On this evidence, Europe looks more constraining than the US because `EP2533039B1` is active and comparatively broad in subject matter; China has a more specific kit-method risk via `CN112505328B`. Design-around looks reasonably feasible. The corridor patents seem to cluster around particular analytical implementations rather than the full commercial objective. That usually leaves room to change derivatization chemistry, labeling strategy, throughput architecture, software patterning approach, instrument modality, or market geography. The hardest patent to route around appears to be `EP2533039B1` if the product relies on automated high-throughput carbohydrate-pattern identification in Europe. The likely blockers also look more licensable than strategically closed. Max Planck is a classic institutional patent holder, which often signals a licensing posture rather than pure exclusion. Wuhan Genecreate’s kit patent also reads like commercially licensable supplier IP. The least clear item is `EP2306199A1`, because the excerpt does not identify the assignee or claim scope well enough to judge whether it is open for licensing or held defensively.","is_public":false,"disqualified":false,"disqualified_reason":null,"disqualified_at":null,"research_status":"ready","is_editors_choice":false,"overall_score":43.3,"overall_score_computed_at":"2026-07-02 20:06:59.065722+00","pipeline_version":"0.24.1","proximity_score":"23.00","proximity_band":"far","proximity_rationale":"Derived deterministically from 8 extracted project(s). Most-advanced status: exploratory. Band: far. Modifiers: +5 depth (6 programs at exploratory). Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":3,"social_links":null,"careers_page_url":null,"pipeline_page_url":null,"external_registry_ids":{"opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-14T01:39:21.132Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"GlycanAge\\\".\",\"officers_matched\":[],\"candidate_count\":0}","companies_house":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-14T02:03:19.383Z\",\"rationale\":\"companies_house returned 0 candidates for \\\"GlycanAge\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-06-03 01:09:12.295914+00","updated_at":"2026-07-20 02:48:03.699651+00","scores":{"ambition":5.76,"publicity":4,"media_reach":4,"reliability":7,"falsifiability":7.92,"claim_integrity":10,"collaborativity":7,"context_validity":6,"pipeline_quality":4,"explanatory_power":5.95,"results_alignment":7,"scandal_integrity":8,"publication_quality":7,"premise_plausibility":7.39,"implementation_fidelity":8,"independent_replication":5},"public_records_count":60,"publications_count":9,"projects_count":8,"funding_rounds_count":0,"clinical_trials_count":0,"publication_status":"evaluated_not_published","public_url":null,"api_url":"https://eternalsearch.net/api/v1/companies/ISryp0XY"},{"id":"9a3d7802-63d8-481c-88d9-cf11b0831d6f","public_id":"CjV17lvc","name":"SNPM / CHU de Nice","canonical_name":"CHU de Nice","aliases":["CHU","Nice University Hospital"],"one_liner":"CHU de Nice provides hospital care, clinical research, training, and patient services in Nice.","description":"CHU de Nice is presented as a university hospital with patient and visitor services, professional and student resources, research activities, and institutional information. The site lists research-related areas including clinical research, public health, biological resources, cell and gene therapy, partnerships, publications, and clinical trials.","website":"https://chu-nice.fr","canonical_website":"https://chu-nice.fr/","logo_url":"https://systeme-nerveux-peripherique-muscle.chu-nice.fr/wp-content/uploads/chu.svg","headquarters":"Nice","hq_country_code":"FR","founding_year":null,"primary_approach":"clinical care, clinical research","primary_field_slug":"clinical_care","field_slugs":["clinical_care","research_tools"],"primary_idea_root_slug":null,"idea_root_slugs":[],"primary_modality_slug":null,"modality_slugs":[],"classification_rationale":"CHU de Nice is a university hospital providing patient care, including emergency care, consultations, hospitalization, and clinical services, alongside clinical research and support for investigators and clinical trials. The supplied evidence does not establish an institution-wide therapeutic-development platform or aging-focused mechanism.","classification_confidence":97,"funding_stage":null,"total_funding_usd":null,"latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"operating","operating_status_reason":null,"operating_status_rationale":null,"operating_status_confidence":null,"business_model":null,"business_model_rationale":null,"business_model_confidence":null,"ip_market_structure":null,"is_public":false,"disqualified":false,"disqualified_reason":null,"disqualified_at":null,"research_status":"failed_at_people_finding","is_editors_choice":false,"overall_score":42.67,"overall_score_computed_at":"2026-06-05 17:45:47.467717+00","pipeline_version":"0.22.3","proximity_score":"35.00","proximity_band":"early_mechanism","proximity_rationale":"Derived deterministically from 6 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":35,"social_links":{"github":null,"twitter":"https://x.com/CHUdeNice","youtube":"https://youtube.com/c/CHUNiceofficiel","facebook":"https://www.facebook.com/centrehospitalieruniversitaireNice/","instagram":null,"linkedin_company":"https://www.linkedin.com/company/centre-hospitalier-universitaire-de-nice/posts/?feedView=all"},"careers_page_url":"https://chu-nice.nous-recrutons.fr/","pipeline_page_url":null,"external_registry_ids":{"opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-02T12:48:04.218Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"CHU de Nice\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-05-21 22:31:23.16207+00","updated_at":"2026-09-22 23:45:25.28239+00","scores":{"ambition":5.28,"publicity":4,"media_reach":4,"reliability":6,"falsifiability":8.44,"claim_integrity":10,"collaborativity":7,"context_validity":6,"pipeline_quality":5,"explanatory_power":6.56,"results_alignment":7,"scandal_integrity":2,"publication_quality":8,"premise_plausibility":7.83,"implementation_fidelity":7,"independent_replication":4},"public_records_count":73,"publications_count":58,"projects_count":6,"funding_rounds_count":0,"clinical_trials_count":0,"publication_status":"under_evaluation","public_url":null,"api_url":"https://eternalsearch.net/api/v1/companies/CjV17lvc"},{"id":"4504c6e5-3b8a-441b-8301-8c20dc81ed62","public_id":"8m5W8qvZ","name":"Glyscend","canonical_name":"Glyscend","aliases":["Glyscend, Inc.","Glyscend Therapeutics"],"one_liner":"Glyscend develops oral gut-targeted polymer therapies that mimic bariatric surgery physiology for type 2 diabetes, obesity, and metabolic disease.","description":"Glyscend is developing a novel class of oral, gut-targeted polymer therapies for type 2 diabetes, obesity, and metabolic disease. Its dynamic barrier approach seeks to provide benefits associated with gastric bypass surgery and duodenal exclusion devices without invasive surgery or procedures. The company describes its drugs as polymer therapeutic platform-based candidates that non-invasively mimic the physiology of bariatric surgery.","website":"https://glyscend.com","canonical_website":"https://glyscend.com/","logo_url":"https://glyscend.com/wp-content/uploads/2020/06/glyscend-logo-color-tagline.png","headquarters":"Boston, Massachusetts, United States","hq_country_code":"US","founding_year":null,"primary_approach":"gut-targeted polymers, dynamic barrier, metabolic surgery mimicry","primary_field_slug":"modulating","field_slugs":["modulating","training"],"primary_idea_root_slug":"modulating","idea_root_slugs":["modulating","training"],"primary_modality_slug":"device_hardware","modality_slugs":["device_hardware","small_molecule"],"classification_rationale":"Glyscend is a clinical-stage biopharmaceutical company developing oral, gut-targeted polymer therapies for type 2 diabetes, obesity, and related metabolic disease. Across the evidence, its approach is framed as mimicking aspects of bariatric surgery or duodenal exclusion without invasive procedures, including an orally ingestible intestinal coating or gut-restricted polymer therapeutic that alters proximal-gut signaling and metabolic regulation. That supports classifying the company primarily under modulating, while the therapeutic tool is best captured by a proposed polymer-therapeutic modality; existing modality evidence in the candidate set also supports retaining weaker device_hardware and small_molecule mappings.","classification_confidence":72,"funding_stage":null,"total_funding_usd":"21225000","latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"operating","operating_status_reason":null,"operating_status_rationale":null,"operating_status_confidence":null,"business_model":"drug_developer","business_model_rationale":"Across the evidence, Glyscend is consistently described as a clinical-stage biopharmaceutical/biotechnology company developing oral therapies and named drug candidates for metabolic disease. The strongest current evidence says it is \"developing oral, first-in-class therapies for type 2 diabetes and obesity,\" and multiple sources describe GLY-200 as a lead oral polymeric drug candidate in clinical development. Although some sources mention a polymer or MCP platform, that platform is presented as the basis for Glyscend's own therapeutic pipeline rather than as a standalone product or service business.","business_model_confidence":96,"ip_market_structure":"The organization’s apparent patent position is anchored by two directly relevant internal assets and one likely partner-origin clinical-method asset, but the strength of that corridor is mixed. The most on-point held filing is US20210403625A1, assigned to Glyscend Inc., covering boronic acid polymers and methods of use for metabolic disease, including oral or digestive-tract administration and residence-time concepts. That looks like the core platform patent for a polymer-based metabolic intervention. EP3331499A4, assigned to Johns Hopkins University and still pending, appears to cover compositions and methods for treating metabolic disorders; based on the inventor overlap, it likely supports the same therapeutic program, but its ownership suggests dependence on a license or other rights from Johns Hopkins rather than clean in-house control. By contrast, US20100184938A1 on polyurethane polymers is assigned to Lubrizol Advanced Materials and is abandoned; even if treated here as “held,” it does not read like a strong enforceable moat for the present metabolic-use corridor. On freedom to operate, the evidence suggests a moderate but not clean posture. The organization appears to have meaningful claim coverage around boronic-acid polymer compositions and metabolic use, but that protection is weakened by abandonment of the U.S. boronic-acid application and by the fact that a key European therapeutic-method case sits with Johns Hopkins and remains pending rather than clearly issued. The only identified third-party corridor patent, WO2024138076A1 on selective anti-myostatin antibodies, does not obviously overlap the polymer/metabolic-disorder platform described in the held filings. On this record alone, it looks peripheral rather than a direct blocker. Design-around feasibility appears fairly good for others unless the eventual claims are narrow and well supported around specific repeat units, GI residence behavior, or disease-use combinations. Conversely, for the organization itself, design-around risk from third parties also looks manageable because the cited outside patent is in a different modality. The likeliest practical constraint is not a hostile external blockade but chain-of-title and licensing dependence: Johns Hopkins looks licensable in the ordinary biotech sense, whereas Lubrizol’s abandoned polyurethane case offers little strategic exclusion value. Overall, the corridor looks more licensable and collaborative than strategically closed, with the main issue being consolidation and durability of rights rather than a hard external FTO wall.","is_public":true,"disqualified":true,"disqualified_reason":"This is a metabolic-disease biotech, not a longevity company. Glyscend develops gut-targeted polymer drugs such as GLY-200 for type 2 diabetes, obesity, and related metabolic endpoints by mimicking bariatric-surgery physiology; nothing in the evidence shows a program aimed at aging biology or an intervention built to measure or modify aging itself.","disqualified_at":"2026-06-30T10:18:02.488Z","research_status":"ready","is_editors_choice":false,"overall_score":42.39,"overall_score_computed_at":"2026-06-30 10:16:22.030888+00","pipeline_version":"0.24.1","proximity_score":"70.00","proximity_band":"translational","proximity_rationale":"Derived deterministically from 5 extracted project(s). Most-advanced status: phase 2. Band: translational. Modifiers: +5 depth (2 programs at phase_2). Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":1,"social_links":null,"careers_page_url":null,"pipeline_page_url":null,"external_registry_ids":{"sec":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-14T06:09:00.303Z\",\"rationale\":\"sec returned 0 candidates for \\\"Glyscend\\\".\",\"officers_matched\":[],\"candidate_count\":0}","opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-14T06:06:00.385Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"Glyscend\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-06-03 01:09:12.299057+00","updated_at":"2026-09-22 23:49:00.375951+00","scores":{"ambition":6.81,"publicity":4,"media_reach":4,"reliability":7,"falsifiability":8.09,"claim_integrity":10,"collaborativity":7,"context_validity":6,"pipeline_quality":5,"explanatory_power":6.13,"results_alignment":8,"scandal_integrity":8,"publication_quality":7,"premise_plausibility":7.34,"implementation_fidelity":8,"independent_replication":3},"public_records_count":37,"publications_count":3,"projects_count":5,"funding_rounds_count":4,"clinical_trials_count":0,"publication_status":"published_disqualified","public_url":"https://eternalsearch.net/companies/8m5W8qvZ","api_url":"https://eternalsearch.net/api/v1/companies/8m5W8qvZ"},{"id":"688d5502-227f-4832-8bf9-3b0621ea6be6","public_id":"5GR2aFOg","name":"Mitochondrial All-Stars","canonical_name":"Mighty Therapeutics","aliases":["Stealth BioTherapeutics Inc.","Stealth BioTherapeutics"],"one_liner":"Mighty Therapeutics advances therapies that target mitochondrial dysfunction.","description":"Stealth BioTherapeutics is an innovative biopharmaceutical company developing therapies for mitochondrial dysfunction associated with genetic mitochondrial diseases and many common age-related diseases. Its lead product, elamipretide, targets the inner mitochondrial membrane by binding reversibly to cardiolipin and is marketed in the U.S. as FORZINITY for Barth syndrome. The company is also investigating elamipretide, Bevemipretide, SBT-255, and SBT-580 series compounds across ophthalmic, neuromuscular, neurological, and cardiac indications.","website":"https://stealthbt.com","canonical_website":"https://stealthbt.com/","logo_url":null,"headquarters":"123 Highland Ave, Suite 201, Needham, MA 02494","hq_country_code":"US","founding_year":null,"primary_approach":"mitochondrial cardiolipin binders, mitochondrial dysfunction, small molecules and peptides","primary_field_slug":"modulating","field_slugs":["modulating"],"primary_idea_root_slug":"modulating","idea_root_slugs":["modulating"],"primary_modality_slug":"biologic","modality_slugs":["biologic"],"classification_rationale":"Mighty Therapeutics, formerly Stealth BioTherapeutics, develops mitochondrial-medicine therapies for genetic mitochondrial diseases and age-related conditions. Its lead peptide, elamipretide, targets cardiolipin in the inner mitochondrial membrane to restore electron transport, improve cellular energy production, and reduce oxidative stress, representing modulation of mitochondrial function.","classification_confidence":91,"funding_stage":null,"total_funding_usd":null,"latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"unknown","operating_status_reason":null,"operating_status_rationale":"This evidence proves Stealth BioTherapeutics existed and was operating in January 2015. It does not prove current operations in 2026, and it also does not show an acquisition, dissolution, bankruptcy, or shutdown. Thin evidence stays thin.","operating_status_confidence":28,"business_model":null,"business_model_rationale":null,"business_model_confidence":null,"ip_market_structure":null,"is_public":false,"disqualified":false,"disqualified_reason":null,"disqualified_at":null,"research_status":"failed_at_people_finding","is_editors_choice":false,"overall_score":42.1,"overall_score_computed_at":"2026-06-02 14:28:33.156836+00","pipeline_version":"0.22.1","proximity_score":"92.00","proximity_band":"near_readout","proximity_rationale":"Derived deterministically from 4 extracted project(s). Most-advanced status: approved. Band: near_readout. Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":12,"social_links":null,"careers_page_url":"https://stealthbt.com/our-company/#careers","pipeline_page_url":"https://stealthbt.com/science-pipeline/#pipeline","external_registry_ids":{"sec":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-05-31T17:18:20.038Z\",\"rationale\":\"sec returned 0 candidates for \\\"Stealth BioTherapeutics\\\".\",\"officers_matched\":[],\"candidate_count\":0}","opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-05-31T17:15:02.464Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"Stealth BioTherapeutics\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-05-21 22:31:23.16207+00","updated_at":"2026-09-23 00:37:22.63408+00","scores":{"ambition":6.96,"publicity":7,"media_reach":1,"reliability":6,"falsifiability":8.15,"claim_integrity":10,"collaborativity":6,"context_validity":7,"pipeline_quality":7,"explanatory_power":6.12,"results_alignment":6,"scandal_integrity":8,"publication_quality":7,"premise_plausibility":7.65,"implementation_fidelity":8,"independent_replication":4},"public_records_count":3,"publications_count":14,"projects_count":4,"funding_rounds_count":0,"clinical_trials_count":0,"publication_status":"under_evaluation","public_url":null,"api_url":"https://eternalsearch.net/api/v1/companies/5GR2aFOg"},{"id":"3aab20cc-3ae0-4c09-b91e-526ccb4940a4","public_id":"hV3htD0E","name":"TAmiRNA","canonical_name":"TAmiRNA","aliases":["TAmiRNA GmbH"],"one_liner":"TAmiRNA develops RNA biomarker discovery, validation, diagnostics, and analysis services for precision medicine and age-associated diseases.","description":"TAmiRNA supports researchers and clinicians in RNA biomarker discovery, validation, and development. The company specializes in cell-free RNAs, including microRNAs, mRNAs, and long non-coding RNAs, and integrates RNA signatures with AI-driven analysis. Its R&D and contract research focus includes liver disease, senescence, cardiovascular disease, oncology, and bone and joint disorders.","website":"https://tamirna.com","canonical_website":"https://tamirna.com/","logo_url":"https://image.pitchbook.com/sNb7bvp4ywnjIUeEP2zNS3PFx4f1605382812528_200x200","headquarters":"Vienna, Austria","hq_country_code":"AT","founding_year":null,"primary_approach":"RNA biomarkers, microRNA diagnostics, extracellular vesicles","primary_field_slug":"modulating","field_slugs":["modulating","measurement","diagnostics","research_tools"],"primary_idea_root_slug":"modulating","idea_root_slugs":["modulating","measuring"],"primary_modality_slug":"rna_therapeutic","modality_slugs":["rna_therapeutic","extracellular_vesicle"],"classification_rationale":"TAmiRNA is best characterized as an RNA biomarker, diagnostics, and research-services company focused on age-associated disease, with strong evidence for marketed and service offerings in miRNA-based diagnostics, sequencing, RT-qPCR, exosome/EV services, and biomarker analysis. Historical company materials also describe RNA therapeutics development and exosomal miRNA research, supporting inclusion of an RNA-therapeutic modality and a modulating aging-mechanism classification, while its diagnostics business clearly supports a measuring component. Overall, the current evidence is strongest for diagnostics and research tools, with therapeutic positioning better supported by older archived materials than by recent commercial pages.","classification_confidence":90,"funding_stage":null,"total_funding_usd":null,"latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"operating","operating_status_reason":null,"operating_status_rationale":null,"operating_status_confidence":null,"business_model":"multi","business_model_rationale":"The strongest current evidence shows both diagnostics and services as active offerings: TAmiRNA's website lists a \"hepatomiR® IVD kit\" and \"miRNA disease panels,\" alongside \"RNA services,\" \"small RNA sequencing services,\" \"RNA sequencing services,\" and \"RT-qPCR services.\" Historical company descriptions also state it was founded to develop microRNAs \"as tools for diagnosis and treatment of age-associated disorders\" and to create \"diagnostic tests or therapeutic drugs.\" Diagnostics and services are clearly supported as primary current models, with historical evidence of therapeutic development intent, so `multi` is the best fit.","business_model_confidence":93,"ip_market_structure":"On the evidence provided, the organization’s owned patent position appears narrow and focused: both `DK3814533T3` and `SG11202101798QA` are the same family, originating from the 2018-09-20 priority application and directed to “micro-RNA signatures for the prediction of liver dysfunction,” with Tamirna GmbH and Univ Wien Med as the assignees/original applicants. That gives the organization at least some proprietary coverage around using specific miRNA signature sets for liver dysfunction prediction, but only in the jurisdictions shown here, Denmark and Singapore. This is not broad platform control on its face; it is a disease-area and biomarker-signature position. The main corridor patents held by others suggest the greatest blocking risk is not directly liver dysfunction, but adjacent liquid-biopsy and cell-free RNA diagnostic territory. `WO2023147445A2`, associated with Oregon Health and Science University, matters because it claims cell-free RNA biomarkers for detecting cancer or cancer predisposition. `WO2023056300A1`, associated with Pillar Biosciences, matters because it covers personalized cancer liquid biopsies using primers from a primer bank. If the organization stays within liver dysfunction prediction using miRNA signatures, those cancer-focused filings do not read like obvious direct blockers from the limited text provided. If, however, the company’s platform expands into broader cell-free RNA diagnostics, oncology screening, or personalized liquid-biopsy workflows, those third-party rights could become meaningful corridor constraints. The freedom-to-operate posture therefore looks moderate but conditional. For a liver-dysfunction product built around the owned miRNA-signature family, FTO appears better than it would be in oncology, because the identified third-party patents are cancer-centered rather than liver-centered. The weakness is that the organization’s own rights do not appear broad enough to clear the wider field; they protect a lane, not the whole road. Design-around looks feasible based on this evidence. The most obvious routes are to avoid cancer applications, avoid personalized primer-bank architectures, and differentiate on biomarker class, assay format, sample-prep pipeline, or signature composition. In other words, there seems to be room to remain in liver dysfunction and avoid the tighter oncology/liquid-biopsy corridor. As to licensing posture, Oregon Health and Science University looks more plausibly licensable because universities often out-license diagnostic IP, while Pillar Biosciences may be more strategically closed if the patent supports a core commercial liquid-biopsy product architecture. That said, this is only an inference from assignee type and patent framing; the evidence does not show actual licensing behavior.","is_public":true,"disqualified":true,"disqualified_reason":"TAmiRNA is an RNA biomarker and diagnostics company, plus a contract research provider. The evidence points to microRNA discovery, validation, analysis services, and disease biomarker programs across liver disease, cardiovascular disease, oncology, bone, and diabetes; a few senescence-related projects do not turn a general diagnostics platform into a company that develops interventions against aging biology.","disqualified_at":"2026-06-29T20:57:32.742Z","research_status":"ready","is_editors_choice":false,"overall_score":41.56,"overall_score_computed_at":"2026-06-29 20:57:15.151096+00","pipeline_version":"0.24.1","proximity_score":"40.00","proximity_band":"early_mechanism","proximity_rationale":"Derived deterministically from 6 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Modifiers: +5 depth (4 programs at preclinical). Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":5,"social_links":null,"careers_page_url":"https://www.tamirna.com/about/#joboffers","pipeline_page_url":"https://www.tamirna.com/rd/#pipeline","external_registry_ids":{"opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-25T10:00:00.445Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"TAmiRNA\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-06-03 01:09:13.575714+00","updated_at":"2026-07-20 06:17:17.041036+00","scores":{"ambition":6,"publicity":3,"media_reach":3,"reliability":7,"falsifiability":8.17,"claim_integrity":9.57,"collaborativity":7,"context_validity":6,"pipeline_quality":4,"explanatory_power":5.67,"results_alignment":7,"scandal_integrity":8,"publication_quality":7,"premise_plausibility":7.17,"implementation_fidelity":8,"independent_replication":5},"public_records_count":130,"publications_count":106,"projects_count":6,"funding_rounds_count":0,"clinical_trials_count":0,"publication_status":"published_disqualified","public_url":"https://eternalsearch.net/companies/hV3htD0E","api_url":"https://eternalsearch.net/api/v1/companies/hV3htD0E"},{"id":"34355756-582b-46c5-ab7b-be4c631758b9","public_id":"P8Xl7pIg","name":"Chondrial Therapeutics","canonical_name":"Larimar Therapeutics","aliases":["Larimar","Larimar Therapeutics, Inc."],"one_liner":"Clinical-stage biotech developing intracellular protein replacement therapies for complex rare diseases, initially Friedreich's ataxia.","description":"Larimar Therapeutics is based in the Philadelphia area and is developing treatments for complex rare diseases, with an initial focus on Friedreich's ataxia. Its proprietary protein replacement therapy platform is intended to deliver missing proteins inside cells. Its lead candidate, nomlabofusp, previously known as CTI-1601, is being evaluated in a Phase 2 clinical program for Friedreich's ataxia.","website":"https://chondrialtherapeutics.com","canonical_website":"https://chondrialtherapeutics.com/","logo_url":"https://images.crunchbase.com/image/upload/c_pad,f_auto,q_auto:eco,dpr_1/rt2sfceixhkqq3xzu4ho?ik-sanitizeSvg=true","headquarters":"Bala Cynwyd, Pennsylvania, United States","hq_country_code":"US","founding_year":null,"primary_approach":"protein replacement therapy, intracellular delivery, fusion proteins","primary_field_slug":"delivery","field_slugs":["delivery","replacement","repairing"],"primary_idea_root_slug":"delivering","idea_root_slugs":["delivering","replacing","repairing"],"primary_modality_slug":"biologic","modality_slugs":["biologic"],"classification_rationale":"Larimar Therapeutics is a clinical-stage biotech developing nomlabofusp and related intracellular protein replacement therapies for Friedreich's ataxia and other rare mitochondrial diseases. The merged evidence consistently describes the company as using a proprietary protein replacement platform built around a fusion protein/cell-penetrant approach that delivers frataxin inside cells and into mitochondria, which supports `biologic` as the modality. Within the idea-root taxonomy, `delivering` is the best primary fit because the company explicitly emphasizes intracellular delivery of missing proteins, while `replacing` is also supported because the therapy is framed as protein replacement.","classification_confidence":91,"funding_stage":"public","total_funding_usd":"60000000","latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"operating","operating_status_reason":null,"operating_status_rationale":null,"operating_status_confidence":null,"business_model":"drug_developer","business_model_rationale":"Across the strongest evidence, Larimar is consistently described as a clinical-stage biotechnology company developing treatments for rare diseases and advancing named therapeutic candidates such as nomlabofusp/CTI-1601 through Phase 1, Phase 2, Phase 3, and BLA preparation. While predecessor materials mention a protein replacement platform, the merged company's primary activity is therapeutic product development and regulatory advancement, so `drug_developer` is the best fit.","business_model_confidence":97,"ip_market_structure":"On the evidence provided, the organization’s own IP position appears to center on Zafgen-originated, now Larimar-associated rights around MetAP-2 inhibitors and related formulations/use cases, rather than on a clearly populated third-party blocking corridor. The most concrete assets are US9260419B2, covering a polymorphic salt of a MetAP-2 inhibitor and methods of making/using it, and US8367721B2, covering methods of treating overweight or obese subjects using MetAP-2-related chemistry. AU2013259760A1 appears to extend the formulation/polymorph theme internationally. WO2019118612A1, by contrast, looks weaker as a corridor asset because the record says “Ceased,” suggesting that particular targeting-compounds family may no longer be active leverage. The freedom-to-operate posture therefore looks mixed but not obviously boxed in by the record here. On one hand, the company does appear to have owned meaningful patent coverage in formulation and therapeutic-use space, which would have helped carve out proprietary ground around specific MetAP-2 assets. On the other hand, two of the key US families shown, US9260419B2 and US8367721B2, are marked “Expired - Fee Related.” That materially weakens exclusivity and suggests that, at least for those specific claims, the company may no longer be able to rely on them either offensively or defensively. Just as importantly, because no third-party field-corridor patents are actually included in the evidence set, there is no direct basis here to identify an external blocker with confidence. Design-around feasibility looks fairly plausible from this record. Form/polymorph claims are often narrower than core composition claims, so alternative salts, polymorphs, formulations, or manufacturing routes may be available if a live claim set exists elsewhere. Therapeutic-method claims tied to obesity treatment also tend to leave room for different indications, regimens, or molecules, assuming they are not captured by broader composition coverage. The ceased WO family reinforces the impression that at least some portions of the estate may be porous rather than dominant. As to licensability versus strategic closure, the evidence does not show a strong, closed third-party wall. What it shows instead is an aging and partially lapsed internal estate. That usually points to a corridor that is more negotiable and design-aroundable than strategically sealed, but the main caveat is that this conclusion is limited by the absence of the promised third-party blocking patents in the evidence provided.","is_public":true,"disqualified":true,"disqualified_reason":"Larimar Therapeutics is a real clinical-stage biotech, but it is not a longevity company. Its program is intracellular protein replacement for Friedreich's ataxia, a specific rare genetic disease, and nothing in the evidence shows a program aimed at aging biology, age-related degeneration broadly, or a mechanism of aging itself.","disqualified_at":"2026-07-03T03:25:56.134Z","research_status":"ready","is_editors_choice":false,"overall_score":41.22,"overall_score_computed_at":"2026-07-03 03:25:43.197792+00","pipeline_version":"0.24.1","proximity_score":"65.00","proximity_band":"translational","proximity_rationale":"Derived deterministically from 4 extracted project(s). Most-advanced status: phase 2. Band: translational. Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":2,"social_links":null,"careers_page_url":"https://larimartx.com/about-larimar/careers/","pipeline_page_url":"https://larimartx.com/our-programs/pipeline/","external_registry_ids":{"sec":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-26T17:48:01.826Z\",\"rationale\":\"sec returned 0 candidates for \\\"Larimar Therapeutics\\\".\",\"officers_matched\":[],\"candidate_count\":0}","opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-26T17:48:01.829Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"Larimar Therapeutics\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-06-03 01:09:11.910362+00","updated_at":"2026-09-22 23:58:49.776129+00","scores":{"ambition":7,"publicity":4,"media_reach":3,"reliability":7,"falsifiability":9,"claim_integrity":9.33,"collaborativity":7,"context_validity":6,"pipeline_quality":6,"explanatory_power":7,"results_alignment":7,"scandal_integrity":8,"publication_quality":7,"premise_plausibility":7.75,"implementation_fidelity":8,"independent_replication":4},"public_records_count":210,"publications_count":14,"projects_count":4,"funding_rounds_count":4,"clinical_trials_count":8,"publication_status":"published_disqualified","public_url":"https://eternalsearch.net/companies/P8Xl7pIg","api_url":"https://eternalsearch.net/api/v1/companies/P8Xl7pIg"},{"id":"c00c1966-bcfc-4d21-b0f6-69a79ede8b9e","public_id":"yRNhhKg2","name":"Omeicos Therapeutics","canonical_name":"Omeicos Therapeutics","aliases":["OMEICOS","OMEICOS Therapeutics GmbH","OMEICOS Therapeutics, Inc."],"one_liner":"OMEICOS develops first-in-class small molecules for cardiovascular, inflammatory and mitochondrial diseases by targeting cell-protective omega-3 pathways.","description":"Omeicos Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class small molecules that target cell-protective pathways. Its lead compound OMT-28 is an orally available synthetic analog of the omega-3 fatty acid metabolite 17,18-EEQ and has been evaluated in Phase 2 studies. The company focuses on mitochondrial dysfunction, inflammatory and cardiovascular diseases, with additional exploratory work in ophthalmology.","website":"https://omeicos.com","canonical_website":"https://omeicos.com/","logo_url":"https://image.pitchbook.com/ysifEI4UERSzBAOw4Nnutqx6CAH1705916118101_200x200","headquarters":"Cambridge, Massachusetts, United States","hq_country_code":"DE","founding_year":2013,"primary_approach":"omega-3 epoxyeicosanoid analogs, mitochondrial protection, anti-inflammatory small molecules","primary_field_slug":"modulating","field_slugs":["modulating"],"primary_idea_root_slug":"modulating","idea_root_slugs":["modulating"],"primary_modality_slug":"small_molecule","modality_slugs":["small_molecule"],"classification_rationale":"Omeicos Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class small-molecule therapeutics, including omega-3 metabolite analog programs such as OMT-28, for cardiovascular, inflammatory, and mitochondrial diseases. The evidence consistently describes its approach as small-molecule drug development and frames the mechanism as targeting or activating endogenous cell-protective, cardio-protective, and omega-3-related signaling pathways, which supports classifying the company under the modulating idea root rather than editing, replacing, or reprogramming.","classification_confidence":93,"funding_stage":"series_c_plus","total_funding_usd":"32000000","latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"operating","operating_status_reason":null,"operating_status_rationale":null,"operating_status_confidence":null,"business_model":"drug_developer","business_model_rationale":"Across the candidates, OMEICOS is consistently described as a clinical-stage biopharmaceutical company developing first-in-class small molecule therapeutics and advancing named drug candidate OMT-28 through Phase 1, Phase 2a, and Phase 2 studies. That evidence supports a primary model of therapeutic drug development rather than platform, diagnostics, delivery technology, services, or software.","business_model_confidence":97,"ip_market_structure":"The organization’s visible IP position is built around a fairly specific family covering “metabolically robust analogs of CYP-eicosanoids” for cardiac disease, with WO2017013265A1 as the apparent core filing and granted counterparts at least in Australia (AU2016296923B2, active) and Hong Kong (HK1246771B). Those are the patents that matter most for offensive protection because they appear to claim stabilized CYP-eicosanoid analogs plus therapeutic use in cardiac disease, and they name Omeicos Therapeutics together with academic co-owners or co-filers such as the University of Texas System and Max Delbrueck Centrum. That gives the organization a real corridor around a defined chemistry-and-use space, but it is not a broad platform estate on the face of this evidence. The main freedom-to-operate question comes from the older epoxyeicosatrienoic-acid analogue patent family reflected in NI201300102A. Although it is labeled here as company-held evidence, the text identifies Mcw Res Found Inc as original assignee and shows a 2011 priority date, materially earlier than the 2015/2016 Omeicos family. That earlier family looks like the strongest potential blocking layer because it appears foundational to EET/CYP-eicosanoid analogs generally, whereas the Omeicos family looks narrower and later, focused on metabolically robust analogs for cardiac disease. So the organization’s FTO appears stronger for its specific later embodiments than for the full underlying analog class; there is at least some risk that core compound concepts or methods sit upstream. Design-around looks feasible but not trivial. If third-party rights center on broad EET analogue scaffolds or general preparation/use methods, the organization may still be able to work around by claiming and practicing narrower metabolically stabilized structures, distinct substitution patterns, formulation choices, or indication-specific positioning in cardiac disease. But if the earlier family has broad composition claims, design-around would narrow commercial flexibility and likely push the company toward license or ownership-chain clarity. On licensability, the Omeicos-linked patents look licensable because they are already shared across institutional assignees, which usually points to a transaction-friendly posture rather than a strategically closed one. The older Mcw-origin family also looks more like classic university-origin IP than a closed strategic blockade, so it is more likely a licensable upstream right than an exclusionary wall, assuming claims remain live and relevant in target jurisdictions.","is_public":true,"disqualified":true,"disqualified_reason":"Omeicos is a clinical-stage biopharma company developing small molecules for cardiovascular, inflammatory, and mitochondrial diseases. That is real drug development, but the evidence here points to disease-focused cardiometabolic and mitochondrial pharmacology, not a program aimed at the biology of aging itself.","disqualified_at":"2026-07-05T17:20:24.520Z","research_status":"ready","is_editors_choice":false,"overall_score":41.22,"overall_score_computed_at":"2026-07-05 17:20:16.693598+00","pipeline_version":"0.24.1","proximity_score":"70.00","proximity_band":"translational","proximity_rationale":"Derived deterministically from 8 extracted project(s). Most-advanced status: phase 2. Band: translational. Modifiers: +5 depth (2 programs at phase_2). Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":4,"social_links":null,"careers_page_url":"https://omeicos.com/careers/","pipeline_page_url":"https://omeicos.com/pipeline/","external_registry_ids":{"opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-28T04:39:00.071Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"Omeicos Therapeutics\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-06-03 01:09:13.047014+00","updated_at":"2026-09-23 00:16:16.011318+00","scores":{"ambition":6.67,"publicity":4,"media_reach":4,"reliability":7,"falsifiability":8.5,"claim_integrity":9.38,"collaborativity":7,"context_validity":6,"pipeline_quality":7,"explanatory_power":6.67,"results_alignment":7,"scandal_integrity":8,"publication_quality":7,"premise_plausibility":7.83,"implementation_fidelity":8,"independent_replication":4},"public_records_count":91,"publications_count":26,"projects_count":8,"funding_rounds_count":13,"clinical_trials_count":3,"publication_status":"published_disqualified","public_url":"https://eternalsearch.net/companies/yRNhhKg2","api_url":"https://eternalsearch.net/api/v1/companies/yRNhhKg2"},{"id":"1f260378-a4c1-45ea-b324-50c14ae21467","public_id":"FMVgvsb8","name":"Adaptyv Biosystems","canonical_name":"Adaptyv Biosystems","aliases":["Adaptyv Bio","Adaptyv"],"one_liner":"Adaptyv provides a cloud lab platform for ordering, managing, and analyzing protein validation experiments.","description":"Adaptyv Biosystems offers a cloud lab for protein designers to upload protein sequences and receive experimental data in under three weeks. Its platform supports binding, expression, and thermostability workflows with experiment management, result analysis, API access, and transparent per-protein pricing.","website":"https://adaptyvbio.com","canonical_website":"https://adaptyvbio.com/","logo_url":"https://www.eu-startups.com/wp-content/uploads/2021/12/Adaptyv-Biosystems.png","headquarters":"Switzerland","hq_country_code":"US","founding_year":null,"primary_approach":"protein validation, automated lab, protein engineering","primary_field_slug":"research_tools","field_slugs":["research_tools","software_data"],"primary_idea_root_slug":null,"idea_root_slugs":[],"primary_modality_slug":null,"modality_slugs":[],"classification_rationale":"Adaptyv Biosystems appears to be a non-therapeutic protein-engineering infrastructure company. The evidence consistently describes it as a cloud lab, protein foundry, and automated lab platform for designing, synthesizing, and experimentally testing proteins such as antibodies and enzymes, with workflow software, API access, and data/analysis capabilities. That supports classifying it primarily as Research Tools & Services, with a secondary Software & Data component, and does not support assigning an aging idea root or therapeutic modality from the supplied evidence.","classification_confidence":95,"funding_stage":null,"total_funding_usd":null,"latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"operating","operating_status_reason":null,"operating_status_rationale":null,"operating_status_confidence":null,"business_model":"platform","business_model_rationale":"The strongest evidence consistently describes Adaptyv as enabling research infrastructure rather than a proprietary therapeutic pipeline: a \"cloud lab platform\" for protein validation experiments, a \"next-gen protein foundry,\" and \"fully automated labs for protein engineering.\" While some sources mention designing custom proteins or drug-discovery-adjacent applications, the dominant model is platform/infrastructure for protein design, synthesis, screening, and experimental validation.","business_model_confidence":93,"ip_market_structure":"On the evidence provided, the apparent historical blocking IP sits primarily with Syva Co and its successors/assignees, not with the organization being assessed. The most important corridor patents are US4508892A and its Canadian counterpart CA1121345A, both directed to competitive protein binding assays that reduce non-specific interference, and EP0063852B1, directed to energy-absorbing particle quenching in light-emitting competitive protein binding assays. US4508892A is now associated with Siemens Healthcare Diagnostics GmbH through assignment history from Syva/Behring, while CA1121345A and EP0063852B1 also trace back to Syva. US4399228A appears relevant to the same assay corridor, but the evidence excerpt is too thin to weigh it as heavily as the others. The organization’s freedom-to-operate posture looks relatively favorable on the present record because the corridor patents shown are marked expired. That matters more than the historical breadth of the claims: these patents appear to have covered core assay-format concepts around competitive binding, conjugates, fluorescence/quenching, and interference suppression, but if expired they no longer present direct exclusion risk in the jurisdictions shown. The more important caution is practical rather than legal: this is still a technically crowded and well-developed assay space, so the organization may face know-how competition and possible later-filed improvement patents outside the evidence set, but those are not part of this analysis. Design-around feasibility also appears reasonably strong. Even if these patents were still live, the claim themes suggest multiple architecture choices: different detection chemistries, non-quenching readouts, alternative supports/conjugation schemes, or assay formats that avoid the specific interference-control or particle-quenching mechanisms described here. Because the cited patents seem to cover recognizable legacy immunoassay design patterns rather than an unavoidable platform choke point, the corridor does not look structurally closed. As for licensability versus strategic closure, the evidence points to a corridor that was historically commercial and licensable rather than strategically sealed off. Syva and successor diagnostics companies look like conventional assay IP owners, not actors using these assets to permanently foreclose the field. Given the expired status, though, the practical conclusion is that licensing pressure from these particular patents should be low to nonexistent.","is_public":true,"disqualified":true,"disqualified_reason":"Adaptyv Biosystems is a protein-engineering infrastructure company. It sells a cloud lab for binding, expression, thermostability, and sequence-function experiments, plus supporting tools like parSEQ and ProteinFlow; the evidence does not show an aging-biology program, a longevity therapeutic, or a platform built specifically to measure or intervene on aging.","disqualified_at":"2026-07-13T18:02:50.110Z","research_status":"ready","is_editors_choice":false,"overall_score":41.18,"overall_score_computed_at":"2026-07-13 18:02:09.929184+00","pipeline_version":"0.24.1","proximity_score":"15.00","proximity_band":"far","proximity_rationale":"Derived deterministically from 4 extracted project(s). Most-advanced status: undisclosed. Band: far. Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":2,"social_links":null,"careers_page_url":"https://adaptyvbio.com/careers","pipeline_page_url":null,"external_registry_ids":{"sec":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-26T09:21:00.228Z\",\"rationale\":\"sec returned 0 candidates for \\\"Adaptyv Biosystems\\\".\",\"officers_matched\":[],\"candidate_count\":0}","opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-26T05:53:00.304Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"Adaptyv Biosystems\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-06-03 01:09:11.343381+00","updated_at":"2026-09-23 00:02:11.410565+00","scores":{"ambition":5,"publicity":5,"media_reach":4,"reliability":7,"falsifiability":8,"claim_integrity":10,"collaborativity":5,"context_validity":8,"pipeline_quality":3,"explanatory_power":6.25,"results_alignment":7,"scandal_integrity":8,"publication_quality":6,"premise_plausibility":8,"implementation_fidelity":8,"independent_replication":3},"public_records_count":195,"publications_count":3,"projects_count":4,"funding_rounds_count":4,"clinical_trials_count":0,"publication_status":"published_disqualified","public_url":"https://eternalsearch.net/companies/FMVgvsb8","api_url":"https://eternalsearch.net/api/v1/companies/FMVgvsb8"},{"id":"fea434e2-5499-48eb-90c4-2db79950c54c","public_id":"hs5FuNcl","name":"Luca Science","canonical_name":"LUCA Science","aliases":["LUCA Science Inc."],"one_liner":"Pre-clinical biotechnology company developing functional mitochondria as therapeutic agents to treat damaged tissues and organs.","description":"LUCA Science is a pre-clinical stage biotechnology company focused on developing functional mitochondria as therapeutic agents. The company says it has developed a proprietary method to isolate functional mitochondria and combines this with drug delivery and formulation technology so mitochondria can be stored and delivered as biopharmaceutical agents. Its site highlights potential applications in damaged tissues and organs and inherited mitochondrial diseases.","website":"https://luca-science.com","canonical_website":"https://luca-science.com/","logo_url":"https://image.pitchbook.com/WrdawZpUom2AiNetWzI5nR0y8gA1654529766960_200x200","headquarters":"Tokyo, Japan","hq_country_code":"JP","founding_year":null,"primary_approach":"mitochondria transfer, drug delivery, formulation","primary_field_slug":"replacement","field_slugs":["replacement","delivery","repairing"],"primary_idea_root_slug":"replacing","idea_root_slugs":["replacing","delivering","repairing"],"primary_modality_slug":"organelle_transplantation","modality_slugs":["organelle_transplantation","biologic","cell_therapy"],"classification_rationale":"LUCA Science is a pre-clinical biotechnology company developing functional mitochondria as therapeutic agents for damaged tissues, organs, and mitochondrial-related disease. The strongest fit is a replacing mechanism because the therapy centers on supplying functional mitochondria themselves, which maps most directly to organelle transplantation or mitochondrial augmentation. The evidence also supports a secondary delivering component because the company emphasizes formulation, storage, and drug-delivery technology for administering its mitochondrial products as biopharmaceutical agents.","classification_confidence":94,"funding_stage":null,"total_funding_usd":"9800000","latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"operating","operating_status_reason":null,"operating_status_rationale":null,"operating_status_confidence":null,"business_model":"drug_developer","business_model_rationale":"The strongest and most consistent evidence describes LUCA Science as a pre-clinical biotechnology company developing functional mitochondria as therapeutic agents and biopharmaceuticals. While some sources also describe its work as an emerging platform and mention proprietary isolation, delivery, and formulation technology, those capabilities are presented as enabling its therapeutic products rather than as a standalone platform business.","business_model_confidence":93,"ip_market_structure":"On the supplied evidence, the organization appears to be Luca Science Inc, and the strongest identifiable IP position is around mitochondrial delivery and manipulation rather than a crowded corridor defined by named third-party blockers. The most consequential asset is US11814640B2, an active US patent expiring in 2038, covering a recombinant expression vector and a lipid membrane structure encapsulating that vector. That looks like the company’s clearest enforceable claim set for mitochondrial-targeted nucleic-acid delivery. WO2021015298A1 adds process-oriented coverage around obtaining mitochondria from cells and the resulting mitochondria, but the record shown says “ceased,” so its practical blocking value is less certain unless supported by live national-phase rights not detailed here. EP3763393A1, directed to nucleic acids for expressing protein in mitochondria and lipid membrane structures, is explicitly marked withdrawn, so it does not presently strengthen European exclusivity on the evidence provided. EP4551939A1 indicates continuing filing activity around “organelle complexes,” but the excerpt is too thin to judge scope or status. Because no third-party field-corridor patents are actually included in the evidence block, no specific outside blocker can be identified from this record alone. That materially limits any claim that the company faces a defined hostile patent thicket. On the evidence given, the freedom-to-operate posture looks mixed but not clearly trapped: Luca appears to own at least one substantial granted US asset in its core platform area, while some parallel foreign or adjacent filings are withdrawn, ceased, or too undeveloped here to confirm. That suggests offensive leverage in the US, but a less complete moat internationally. Design-around feasibility appears moderate. If a competitor can avoid the claimed combination of recombinant vector plus lipid membrane encapsulation, or use different mitochondrial loading, targeting, or organelle-complex architectures, there may be room to work around the company’s claims. Likewise, if Luca must operate outside the exact boundaries of its own granted claims, the incomplete European/PCT picture leaves some exposure. As for blockers being licensable or strategically closed, the evidence does not show any third-party owners at all, so there is no basis here to call the corridor closed. The more defensible conclusion is that Luca’s biggest issue is not obvious external blocking IP in this record, but uneven patent durability across jurisdictions.","is_public":true,"disqualified":false,"disqualified_reason":null,"disqualified_at":null,"research_status":"ready","is_editors_choice":false,"overall_score":40.69,"overall_score_computed_at":"2026-07-03 12:04:14.599902+00","pipeline_version":"0.24.1","proximity_score":"40.00","proximity_band":"early_mechanism","proximity_rationale":"Derived deterministically from 5 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Modifiers: +5 depth (4 programs at preclinical). Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":1,"social_links":null,"careers_page_url":null,"pipeline_page_url":null,"external_registry_ids":{"opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-27T03:02:00.426Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"LUCA Science\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-06-03 01:09:12.68955+00","updated_at":"2026-09-23 00:04:19.525614+00","scores":{"ambition":7.6,"publicity":4,"media_reach":4,"reliability":7,"falsifiability":8.6,"claim_integrity":10,"collaborativity":7,"context_validity":6,"pipeline_quality":4,"explanatory_power":6.4,"results_alignment":8,"scandal_integrity":8,"publication_quality":6,"premise_plausibility":7.4,"implementation_fidelity":8,"independent_replication":3},"public_records_count":124,"publications_count":6,"projects_count":5,"funding_rounds_count":1,"clinical_trials_count":0,"publication_status":"published","public_url":"https://eternalsearch.net/companies/hs5FuNcl","api_url":"https://eternalsearch.net/api/v1/companies/hs5FuNcl"},{"id":"67d5338c-e45b-4299-89be-ad14f09c67d9","public_id":"ygSxhKxr","name":"Magnitude Biosciences","canonical_name":"Magnitude Biosciences","aliases":["Magnitude Biosciences Ltd"],"one_liner":"Magnitude Biosciences provides customised C. elegans studies and whole-organism high-throughput screening for research areas including ageing, neurodegeneration, toxicity, and gut health.","description":"Magnitude Biosciences offers contract lab services using customised C. elegans studies to generate reproducible research data. Its VivoScan platform is described as a high-throughput screening platform for whole-organism screening at scale. The site lists service areas including ageing and longevity, neurodegeneration, muscle health, gut health, cognition, disease modelling, weight management, and toxicity.","website":"https://magnitudebiosciences.com","canonical_website":"https://magnitudebiosciences.com/","logo_url":"https://image.pitchbook.com/W2CociMfeR5vxgE5mkEAGTxYwZG1685604666876_200x200","headquarters":"United Kingdom","hq_country_code":"GB","founding_year":null,"primary_approach":"C. elegans, whole-organism HTS, automated imaging","primary_field_slug":"research_tools","field_slugs":["research_tools"],"primary_idea_root_slug":null,"idea_root_slugs":[],"primary_modality_slug":null,"modality_slugs":[],"classification_rationale":"Magnitude Biosciences is a research tools and services company, not a therapeutic developer. Across the candidate evidence, it is consistently described as a specialist CRO offering customised C. elegans studies, automated assay technology, compound and intervention screening, transgenics, and other contract lab services for ageing, neurodegeneration, microbiome, and toxicity research. The strongest evidence supports classifying it under research tools and services rather than assigning a biological idea root or therapeutic modality of its own.","classification_confidence":97,"funding_stage":null,"total_funding_usd":null,"latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"operating","operating_status_reason":null,"operating_status_rationale":null,"operating_status_confidence":null,"business_model":"services","business_model_rationale":"The strongest evidence describes Magnitude Biosciences as a contract research provider rather than a company primarily developing its own therapeutics or selling a standalone platform product. Official and archived materials say it is \"a specialist CRO\" and that it \"offers contract lab services using customised C. elegans studies to generate reproducible research data.\" Although the company highlights VivoScan and WormGazer technology, the supplied evidence presents these as enabling tools within its fee-for-service research offering.","business_model_confidence":93,"ip_market_structure":"The organization appears to have one relevant in-house asset: Magnitude Biosciences’ worm-tracking patent family, published as `US20210358134A1` and granted as `US11756214B2`, covering a method/apparatus for tracking nematode worms through image-based pixel/block analysis. On the face of this evidence, that is the strongest proprietary position in the corridor because it is active, granted, and directly tied to automated phenotyping of worms rather than generic screening infrastructure. The assignment history suggests the rights now sit with The University of Durham, so the organization’s practical control depends on its relationship to that assignee, but the family itself is a real exclusionary asset through about 2040. The main external corridor patents look broader and more heterogeneous. `US8993486B2` from Lankenau/Chemical Genomics Center matters most as a live granted patent on ultra-high-throughput screening for synergistic drug interactions, including screening with and without a sensitizing agent to identify combination effects. `WO2001032844A1` points to older microtiter-plate-based high-throughput screening infrastructure; without grant/status details here, it reads more like background platform IP than a clear present blocker. `US20210024974A1` from Rutgers is less threatening because the application is explicitly abandoned, so it does not currently support a blocking position on its own. Freedom to operate therefore looks moderate rather than cleanly open or shut. If the organization stays close to worm tracking, image analysis, and nematode-specific phenotyping, its own granted patent gives it a reasonably defensible lane. FTO tightens if its product or workflow expands into broad high-throughput drug-combination screening, especially synergy/synthetic-lethality style assays, where the Lankenau patent could be asserted depending on claim scope and implementation details. The evidence does not show a direct third-party patent on “worm tracking” itself that would obviously dominate Magnitude’s family. Design-around looks fairly feasible. The abandoned Rutgers case can largely be ignored. The older microtiter-screening art is often avoidable by changing assay format, plate architecture, workflow, or readout pipeline. Even the Lankenau blocker likely can be worked around by avoiding claimed combination-screen logic, sensitizing-agent protocols, and specific triage/analysis schemes, while positioning the offering as organism tracking or phenotypic measurement rather than combination-drug discovery. As to licensability, the likely blocker set looks more licensable than strategically closed. University and research-institute owners typically license when there is a credible commercial use case. Nothing in this evidence suggests a vertically integrated operating company using these patents to hard-close the field. The strongest caution is simply that a granted screening-method patent held by a research institution is often enforceable enoug","is_public":true,"disqualified":false,"disqualified_reason":null,"disqualified_at":null,"research_status":"ready","is_editors_choice":false,"overall_score":40.29,"overall_score_computed_at":"2026-07-03 16:35:29.58386+00","pipeline_version":"0.24.1","proximity_score":"40.00","proximity_band":"early_mechanism","proximity_rationale":"Derived deterministically from 6 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Modifiers: +5 depth (4 programs at preclinical). Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":4,"social_links":{"github":null,"twitter":null,"youtube":null,"facebook":null,"instagram":null,"linkedin_company":"https://linkedin.com/company/magnitudebiosciences/"},"careers_page_url":"https://magnitudebiosciences.com/jobs/","pipeline_page_url":null,"external_registry_ids":{"opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-27T00:56:00.477Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"Magnitude Biosciences\\\".\",\"officers_matched\":[],\"candidate_count\":0}","companies_house":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-27T00:56:00.473Z\",\"rationale\":\"companies_house returned 0 candidates for \\\"Magnitude Biosciences\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-06-03 01:09:12.718703+00","updated_at":"2026-07-20 02:11:20.214496+00","scores":{"ambition":5.5,"publicity":4,"media_reach":4,"reliability":7,"falsifiability":8.75,"claim_integrity":10,"collaborativity":7,"context_validity":5,"pipeline_quality":3,"explanatory_power":6.5,"results_alignment":7,"scandal_integrity":8,"publication_quality":7,"premise_plausibility":7.5,"implementation_fidelity":8,"independent_replication":4},"public_records_count":167,"publications_count":7,"projects_count":6,"funding_rounds_count":0,"clinical_trials_count":0,"publication_status":"published","public_url":"https://eternalsearch.net/companies/ygSxhKxr","api_url":"https://eternalsearch.net/api/v1/companies/ygSxhKxr"},{"id":"e7567352-b806-4c25-bc01-949b95e2c969","public_id":"jnNgD9yl","name":"Isomorphic Labs","canonical_name":"Isomorphic Labs","aliases":["Iso","ISO"],"one_liner":"Isomorphic Labs uses machine learning and AI drug design models to transform and accelerate drug discovery.","description":"Isomorphic Labs is advancing human health by building on and beyond the AlphaFold system. Its interdisciplinary team of drug discovery experts and machine learning specialists has built predictive and generative AI models to accelerate scientific discovery. The company aims to model complex biological phenomena, design novel molecules, anticipate drug performance, and develop medicines for devastating diseases.","website":"https://www.isomorphiclabs.com/?utm_source=chatgpt.com","canonical_website":"https://www.isomorphiclabs.com/?utm_source=chatgpt.com","logo_url":"https://techcrunch.com/wp-content/uploads/2021/11/isomorphic-labs.png","headquarters":"London, UK (in the King’s Cross neighbourhood), Lausanne, Switzerland (in Le Flon district) and Cambridge, MA (in Kendall Square)","hq_country_code":"GB","founding_year":2021,"primary_approach":"AI drug discovery, machine learning, digital biology","primary_field_slug":"discovery","field_slugs":["discovery"],"primary_idea_root_slug":"discovering","idea_root_slugs":["discovering"],"primary_modality_slug":"small_molecule","modality_slugs":["small_molecule","biologic"],"classification_rationale":"Isomorphic Labs is primarily an AI-enabled drug discovery company. Across the evidence, it consistently describes itself as using frontier AI, machine learning, AlphaFold-derived systems, and its IsoDDE platform to accelerate drug discovery and design therapeutic candidates. The clearest method classification is therefore discovering, while the strongest modality evidence points to small molecules through explicit partnered small-molecule discovery programs; biologics also appear as a supported modality on its platform, but less specifically evidenced as the primary output.","classification_confidence":94,"funding_stage":"series_b","total_funding_usd":"2700000000","latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"operating","operating_status_reason":null,"operating_status_rationale":null,"operating_status_confidence":null,"business_model":"multi","business_model_rationale":"The strongest evidence supports both a platform and a drug developer model. Isomorphic Labs describes itself as an \"AI-first drug design and development company\" and says its \"unified AI drug design engine, IsoDDE, works across multiple therapeutic areas and drug modalities,\" which supports a platform/infrastructure component. It also states that it aims to develop medicines, and third-party reporting says funding will help \"progress its drug candidate pipeline\" and accelerate programs \"towards the clinic,\" which supports active therapeutic development. Because both enabling technology and internal/partnered drug programs are core to the company, the best fit is multi.","business_model_confidence":94,"ip_market_structure":null,"is_public":true,"disqualified":true,"disqualified_reason":"This is an AI drug-discovery company, not a longevity company. Isomorphic Labs builds general-purpose drug design models and says its internal programs focus on oncology and immunology; nothing in the evidence shows an aging-biology program, an intervention aimed at the biology of aging, or tools built specifically to measure aging.","disqualified_at":"2026-06-23T23:23:16.610Z","research_status":"ready","is_editors_choice":false,"overall_score":40.15,"overall_score_computed_at":"2026-06-23 23:22:37.539078+00","pipeline_version":"0.24.1","proximity_score":"40.00","proximity_band":"early_mechanism","proximity_rationale":"Derived deterministically from 11 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Modifiers: +5 depth (3 programs at preclinical). Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":3,"social_links":{"github":null,"twitter":"https://x.com/IsomorphicLabs","youtube":null,"facebook":null,"instagram":null,"linkedin_company":"https://www.linkedin.com/company/isomorphic-labs/"},"careers_page_url":"https://www.isomorphiclabs.com/careers","pipeline_page_url":"https://www.isomorphiclabs.com/our-tech","external_registry_ids":{"opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-23T13:57:03.372Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"Isomorphic Labs\\\".\",\"officers_matched\":[],\"candidate_count\":0}","companies_house":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-23T13:57:03.367Z\",\"rationale\":\"companies_house returned 0 candidates for \\\"Isomorphic Labs\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-05-23 01:33:38.961594+00","updated_at":"2026-09-23 00:08:30.645252+00","scores":{"ambition":7.33,"publicity":7,"media_reach":8,"reliability":7,"falsifiability":8.11,"claim_integrity":9.82,"collaborativity":7,"context_validity":6,"pipeline_quality":4,"explanatory_power":5.44,"results_alignment":6,"scandal_integrity":8,"publication_quality":8,"premise_plausibility":7.44,"implementation_fidelity":7,"independent_replication":4},"public_records_count":87,"publications_count":67,"projects_count":11,"funding_rounds_count":2,"clinical_trials_count":0,"publication_status":"published_disqualified","public_url":"https://eternalsearch.net/companies/jnNgD9yl","api_url":"https://eternalsearch.net/api/v1/companies/jnNgD9yl"},{"id":"f36878a6-9f51-4683-b4ac-887cca1d41ab","public_id":"TnmcJ7bN","name":"Mitotech","canonical_name":"Mitotech","aliases":["Mitotech Ltd","MITO.tech"],"one_liner":"Mitotech develops orally bioavailable small molecules to protect mitochondria from oxidative stress and enhance energy expenditure.","description":"Mitotech focuses on protecting mitochondria from oxidative stress and enhancing energy expenditure. The company is developing orally bioavailable small molecules that could restore mitochondrial function and offer therapeutic options for rare mitochondrial, metabolic, autoimmune, cardiovascular, and neurodegenerative diseases.","website":"https://mitotechpharma.com","canonical_website":"https://mitotechpharma.com/","logo_url":"https://pbs.twimg.com/profile_images/864917832735145984/tpI_kOFT.jpg","headquarters":"Russia, Luxembourg","hq_country_code":"GB","founding_year":null,"primary_approach":"mitochondrial protection, oxidative stress, small molecules","primary_field_slug":"modulating","field_slugs":["modulating","repairing"],"primary_idea_root_slug":"modulating","idea_root_slugs":["modulating","repairing"],"primary_modality_slug":"small_molecule","modality_slugs":["small_molecule"],"classification_rationale":"Mitotech is a clinical-stage biotechnology company developing mitochondria-targeted pharmaceuticals, especially SkQ-class compounds such as SkQ1/Visomitin. The evidence consistently supports a small-molecule therapeutic modality, with the primary longevity-relevant mechanism best classified as modulating because its drugs are described as protecting mitochondria from oxidative stress, inhibiting cardiolipin peroxidation, and acting through inhibitor/antioxidant pharmacology rather than editing, replacing, or reprogramming biology. There is secondary support for repairing because some company language explicitly refers to restoring mitochondrial function.","classification_confidence":88,"funding_stage":null,"total_funding_usd":null,"latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"operating","operating_status_reason":null,"operating_status_rationale":null,"operating_status_confidence":null,"business_model":"drug_developer","business_model_rationale":"Across sources, Mitotech is consistently described as a clinical-stage biotechnology company developing drug candidates and running clinical programs. The strongest evidence says Mitotech Ltd. is \"focused on mitochondria-based therapies\" with an \"investigational compound SkQ1,\" while Mitotech S.A. announced initiation of a Phase II clinical trial of SkQ1. This fits a therapeutic drug developer rather than a platform, diagnostics, delivery technology, or services company.","business_model_confidence":95,"ip_market_structure":"On the supplied record, the core IP appears to sit primarily with the organization itself, not with an identified outside blocker. The most important live rights are Mitotech Ltd’s recent crystal-form filings around its antioxidant compound: granted US12077553B1, published September 3, 2024, and the related PCT application WO2025099491A1, published May 15, 2025. Those matter because crystal-form patents can be commercially significant even when the underlying active is known: they can control manufacturable, stable, or regulatorily preferred solid forms. The older Mitotech-family filings, including WO2015063553A3 on mitochondrially targeted thymoquinones/toluquinones and US9328130B2 on mitochondrial delivery/treatment methods, suggest a broader legacy estate around mitochondria-targeted antioxidant chemistry and therapeutic use, although WO2015063553A3 itself is marked ceased. Freedom to operate therefore looks relatively favorable on the evidence provided, but with an important caveat: no third-party field-corridor patents are actually included in the record excerpt. That means the visible constraint is mostly internal ownership concentration rather than a demonstrated hostile thicket held by others. If the organization is Mitotech or operating under its rights, the posture is stronger because the key recent composition/formulation claims appear in-house. If it is a third party, US12077553B1 is the clearest near-term blocker because it is active, recent, and likely aimed at a specific crystalline form of the antioxidant compound rather than a broad research concept. Design-around feasibility is probably moderate. Crystal-form claims are often narrower than compound-per-se claims, so a rival may be able to work around them by using a different polymorph, salt, solvate, amorphous form, process route, formulation, or non-infringing manufacturing window, assuming the therapeutic molecule itself is not otherwise covered by broader live claims. But if the commercially viable form is the patented one, practical design-around becomes harder even if legally possible. As to licensability, the pattern here looks more like strategically maintained proprietary platform IP than abandoned corridor space. The active US grant plus the follow-on PCT filing indicate deliberate estate building, which usually points to a licensable asset only on negotiated strategic terms rather than an open field. The supplied evidence does not show entrenched third-party incumbents, so the main question is access to Mitotech-controlled rights, not a fragmented blocking landscape.","is_public":true,"disqualified":false,"disqualified_reason":null,"disqualified_at":null,"research_status":"ready","is_editors_choice":false,"overall_score":39.86,"overall_score_computed_at":"2026-07-13 18:59:12.135905+00","pipeline_version":"0.24.1","proximity_score":"92.00","proximity_band":"near_readout","proximity_rationale":"Derived deterministically from 1 extracted project(s). Most-advanced status: approved. Band: near_readout. Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":2,"social_links":null,"careers_page_url":null,"pipeline_page_url":null,"external_registry_ids":{"opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-25T02:55:26.554Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"Mitotech\\\".\",\"officers_matched\":[],\"candidate_count\":0}","companies_house":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-25T03:59:00.083Z\",\"rationale\":\"companies_house returned 0 candidates for \\\"Mitotech\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-06-03 01:09:12.809984+00","updated_at":"2026-07-20 00:32:02.663687+00","scores":{"ambition":5.56,"publicity":4,"media_reach":4,"reliability":7,"falsifiability":8.11,"claim_integrity":10,"collaborativity":5,"context_validity":6,"pipeline_quality":5,"explanatory_power":5.67,"results_alignment":7,"scandal_integrity":8,"publication_quality":7,"premise_plausibility":7,"implementation_fidelity":7,"independent_replication":4},"public_records_count":140,"publications_count":3,"projects_count":1,"funding_rounds_count":0,"clinical_trials_count":3,"publication_status":"published","public_url":"https://eternalsearch.net/companies/TnmcJ7bN","api_url":"https://eternalsearch.net/api/v1/companies/TnmcJ7bN"},{"id":"34e123af-09d7-4eef-bb6d-4a39ad78ff91","public_id":"1gVSG1Z7","name":"Nuritas","canonical_name":"Nuritas","aliases":["Nuritas Ltd"],"one_liner":"Nuritas discovers and clinically validates natural peptides using its proprietary AI platform for health and ingredient applications.","description":"Nuritas uses its proprietary AI platform, the Nuritas Magnifier, to identify, unlock, and clinically validate smart peptides from nature. The company offers ready-to-use, clinically proven peptide ingredients including PeptiStrong, PeptiSleep, and PeptiYouth, and also supports custom peptide discovery partnerships. Its site describes a Dublin-based team of scientists, AI specialists, and industry experts working in a state-of-the-art research facility.","website":"https://nuritas.com","canonical_website":"https://nuritas.com/","logo_url":"https://www.nuritas.com/wp-content/themes/Nuritas/assets/images/newheader.svg?x39564","headquarters":"Dublin, Ireland","hq_country_code":"IE","founding_year":null,"primary_approach":"AI peptide discovery, clinically validated ingredients, natural peptides","primary_field_slug":"discovery","field_slugs":["discovery","modulating","consumer_products","research_tools","software_data"],"primary_idea_root_slug":"discovering","idea_root_slugs":["discovering","modulating"],"primary_modality_slug":"biologic","modality_slugs":["biologic"],"classification_rationale":"Nuritas is best characterized as an AI-enabled peptide discovery company that uses its proprietary platform to identify and validate bioactive or therapeutic peptides, while commercially emphasizing peptide ingredients such as PeptiStrong, PeptiSleep, and PeptiYouth. The strongest method classification is discovering, with weaker secondary support for modulating because the peptides are described as acting on targets or pathways of interest. Where a therapeutic modality is referenced, peptides fit best under biologic, but the company’s visible commercial footprint in the supplied evidence is more strongly in consumer peptide ingredients, alongside research/discovery partnerships and an AI-driven software/data platform.","classification_confidence":88,"funding_stage":null,"total_funding_usd":"3400000","latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"operating","operating_status_reason":null,"operating_status_rationale":null,"operating_status_confidence":null,"business_model":"multi","business_model_rationale":"The evidence supports multiple primary models. Nuritas operates a proprietary peptide-discovery platform (\"its proprietary AI platform, the Nuritas Magnifier\"), commercializes productized peptide ingredients (\"offers ready-to-use, clinically proven peptide ingredients including PeptiStrong, PeptiSleep, and PeptiYouth\"), and provides partnership-based discovery work (\"supports custom peptide discovery partnerships\"). Some sources also frame its work as therapeutic peptide discovery, but the strongest combined evidence supports platform plus product and services activity rather than a pure drug developer classification.","business_model_confidence":93,"ip_market_structure":"On the evidence provided, the only clearly identified patent holder is Nuritas Ltd itself. The most relevant assets appear to be WO2017009484A1, covering anti-inflammatory peptides and related topical/combination uses; US20170183386A1, covering peptides for wound treatment, cell growth, dressings, and culture media; EP3862014A1, covering peptides targeting PANX1-associated diseases; and ES3057136T3, which appears to be a territorial right on a specific peptide composition, `WKDEAGKPLVK`. Those patents suggest Nuritas has tried to build an IP position around specific peptide sequences, therapeutic uses, and formulation/use contexts, especially inflammation, wound healing, and target-specific peptide therapeutics. The freedom-to-operate posture is harder to call favorable from this evidence alone because the field-corridor, third-party blocking patents are not actually included here. That means there is no direct evidence of who else holds relevant exclusionary rights. What can be said is that Nuritas’s own position looks mixed rather than dominant: WO2017009484A1 is listed as ceased, US20170183386A1 as abandoned, and EP3862014A1 as withdrawn. That materially weakens the deterrent value of those applications unless parallel family members matured elsewhere. ES3057136T3 looks more substantial because it is a territorial granted-style publication, but on its face it seems narrower, tied to a named peptide composition rather than a broad platform fence. So Nuritas may have some protectable sequence-specific space, but the evidence does not show a broad, durable moat. Design-around looks reasonably feasible. The claim pattern reflected here is peptide-centric and sequence-centric, with therapeutic-use overlays. In practice, that usually leaves room to alter sequence, length, substitutions, indication, delivery format, or target mechanism, unless a granted claim family is both broad and well maintained. The PANX1 application, if not live in key jurisdictions, is especially less likely to block competitors directly. As to licensability versus strategic closure, the record does not show third-party blockers at all, so no specific outside holder can be tagged as licensable or closed. For Nuritas’s own estate, the posture looks more commercial than exclusionary-platform in nature: sequence/use filings are often licensable if they remain alive and jurisdictionally relevant, but the visible lapse/abandonment/withdrawal history suggests limited leverage unless stronger continuations or foreign grants exist outside this evidence.","is_public":true,"disqualified":true,"disqualified_reason":"Nuritas is an AI peptide discovery and ingredient company that sells clinically tested natural peptide ingredients for nutrition and health products. The longevity framing does not hold because the evidence points to functional ingredients for muscle, sleep, metabolic health, and wellbeing, not a therapeutic program or research effort aimed at the biology of aging itself.","disqualified_at":"2026-06-29T07:54:15.007Z","research_status":"ready","is_editors_choice":false,"overall_score":39.46,"overall_score_computed_at":"2026-06-29 07:53:43.434754+00","pipeline_version":"0.24.1","proximity_score":"20.00","proximity_band":"far","proximity_rationale":"Derived deterministically from 9 extracted project(s). Most-advanced status: undisclosed. Band: far. Modifiers: +5 depth (2 programs at undisclosed). Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":6,"social_links":{"github":null,"twitter":null,"youtube":null,"facebook":null,"instagram":"https://www.instagram.com/nuritasresearch/","linkedin_company":null},"careers_page_url":null,"pipeline_page_url":null,"external_registry_ids":{"opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-25T05:39:00.066Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"Nuritas\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-06-03 01:09:13.022868+00","updated_at":"2026-09-23 00:12:19.503258+00","scores":{"ambition":4.6,"publicity":4,"media_reach":4,"reliability":6,"falsifiability":8,"claim_integrity":9.55,"collaborativity":7,"context_validity":6,"pipeline_quality":6,"explanatory_power":5,"results_alignment":7,"scandal_integrity":8,"publication_quality":7,"premise_plausibility":6.6,"implementation_fidelity":7,"independent_replication":5},"public_records_count":192,"publications_count":13,"projects_count":9,"funding_rounds_count":5,"clinical_trials_count":10,"publication_status":"published_disqualified","public_url":"https://eternalsearch.net/companies/1gVSG1Z7","api_url":"https://eternalsearch.net/api/v1/companies/1gVSG1Z7"},{"id":"2f7f61a4-b659-4fbf-b317-9f0871019ace","public_id":"Hct0hiK3","name":"Pentraxin Therapeutics","canonical_name":"Pentraxin Therapeutics","aliases":["Pentraxin Therapeutics Ltd","Pentraxin"],"one_liner":"Pentraxin Therapeutics holds Mark Pepys's intellectual property for SAP, amyloidosis, Alzheimer's disease, CRP inhibition, and DNA vaccination programs.","description":"Pentraxin Therapeutics Ltd is described as a University College London spin-out company founded in 2001 by Professor Sir Mark Pepys FRS. The company holds intellectual property and proprietary knowledge created by Sir Mark and his research group. Its R&D programs focus on systemic amyloidosis and serum amyloid P component, SAP targeting in Alzheimer's disease, C-reactive protein inhibition, and SAP depletion for DNA vaccination.","website":"https://pentraxin.wordpress.com","canonical_website":"https://pentraxin.wordpress.com/","logo_url":"https://pentraxin.files.wordpress.com/2011/03/cropped-final.jpg","headquarters":"London, United Kingdom","hq_country_code":"GB","founding_year":2001,"primary_approach":"SAP depletion, amyloid immunotherapy, CRP inhibition","primary_field_slug":"clearing","field_slugs":["clearing","modulating"],"primary_idea_root_slug":"clearing","idea_root_slugs":["clearing","modulating"],"primary_modality_slug":"small_molecule","modality_slugs":["small_molecule","biologic"],"classification_rationale":"Pentraxin Therapeutics is a drug developer focused on serum amyloid P component and related amyloid diseases, with programs for systemic amyloidosis, Alzheimer’s disease, and C-reactive protein inhibition. The strongest fit is clearing because its pipeline explicitly includes SAP depletion and amyloid clearance, while modulating is a secondary fit because it also targets pathogenic C-reactive protein signaling. Its cited programs support both small-molecule and biologic modalities, including small-molecule CRP/SAP-directed agents and an antibody-based anti-SAP immunotherapy approach.","classification_confidence":90,"funding_stage":null,"total_funding_usd":null,"latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"operating","operating_status_reason":null,"operating_status_rationale":null,"operating_status_confidence":null,"business_model":"drug_developer","business_model_rationale":"Multiple sources describe Pentraxin Therapeutics Ltd as a UCL spin-out that \"designs new treatments\" for systemic amyloidosis, amyloid-related diseases including Alzheimer's disease and type II diabetes, and C-reactive-protein-mediated cardiovascular and inflammatory diseases. That supports a primary model of therapeutic R&D rather than diagnostics, services, or a general platform.","business_model_confidence":95,"ip_market_structure":"On the evidence provided, the organization appears to be Pentraxin Therapeutics Ltd, and the relevant IP picture is unusually favorable because all patents shown are company-held and no actual third-party field-corridor patents are included in the excerpt. The core company-owned assets appear to cover two main areas: SAP depletion/clearance biology and SAP-targeted small molecules or combinations. `ES2284895T3` concerns a therapeutic agent for eliminating unwanted plasma protein populations and is assigned to Pentraxin, but it is already expired. `GB0601818D0` is also company-held and ceased, so it does not appear to create present exclusionary value. `US7659299B2` is more meaningful because it claims compounds inhibiting SAP binding for osteoarthritis and, based on the evidence, remains in force until November 22, 2026 unless that status changes earlier; this is the strongest currently live asset shown. `US7910106B2` indicates Pentraxin also pursued combination protection around SAP-depleting agents plus anti-SAP antibodies, suggesting an effort to fence in combination regimens as well as single-agent use. For freedom to operate, the record here supports a relatively open posture rather than a constrained one. Because the supposed “blocking IP held by others” is not actually present in the evidence provided, there is no concrete third-party blocker that can be identified from this record. That means the main live constraints are internal to Pentraxin’s own estate, not external encumbrances. The practical implication is that Pentraxin likely had or has room to operate in its own SAP-directed programs, but the strength of exclusivity today looks narrower than it once did because some earlier family members have expired or ceased. Design-around feasibility looks moderate to high. The visible claims seem focused on specific SAP-depleting approaches, SAP-binding inhibitors for osteoarthritis, and certain combinations with anti-SAP antibodies. A third party might have room to avoid these by changing indication, molecular class, binding mechanism, sequencing, or therapeutic format, especially once `US7659299B2` expires. Based on the evidence alone, the blockers also look more licensable than strategically closed in the market-wide sense, because they are held by a single therapeutic company rather than dispersed across multiple entrenched owners. The bigger limitation here is not hostility of the corridor, but that the evidence does not actually show the third-party corridor.","is_public":true,"disqualified":true,"disqualified_reason":"Pentraxin Therapeutics is a conventional therapeutics company built around serum amyloid P component, amyloidosis, Alzheimer's disease, CRP inhibition, and DNA vaccination. That is real drug development, but the evidence points to disease-specific immunology and amyloid programs, not research or interventions aimed at the biology of aging itself.","disqualified_at":"2026-07-04T02:47:51.541Z","research_status":"ready","is_editors_choice":false,"overall_score":39.38,"overall_score_computed_at":"2026-07-04 02:47:20.993612+00","pipeline_version":"0.24.1","proximity_score":"20.00","proximity_band":"far","proximity_rationale":"Derived deterministically from 4 extracted project(s). Most-advanced status: undisclosed. Band: far. Modifiers: +5 depth (3 programs at undisclosed). Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":1,"social_links":null,"careers_page_url":null,"pipeline_page_url":"https://pentraxin.wordpress.com/rd-programs/","external_registry_ids":{"opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-27T07:56:00.105Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"Pentraxin Therapeutics\\\".\",\"officers_matched\":[],\"candidate_count\":0}","companies_house":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-27T07:56:00.101Z\",\"rationale\":\"companies_house returned 0 candidates for \\\"Pentraxin Therapeutics\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-06-03 01:09:13.164263+00","updated_at":"2026-07-20 01:47:21.330195+00","scores":{"ambition":6.5,"publicity":4,"media_reach":3,"reliability":6,"falsifiability":8.5,"claim_integrity":1,"collaborativity":4,"context_validity":6,"pipeline_quality":4,"explanatory_power":5.25,"results_alignment":6,"scandal_integrity":8,"publication_quality":8,"premise_plausibility":6.75,"implementation_fidelity":7,"independent_replication":4},"public_records_count":104,"publications_count":9,"projects_count":4,"funding_rounds_count":2,"clinical_trials_count":0,"publication_status":"published_disqualified","public_url":"https://eternalsearch.net/companies/Hct0hiK3","api_url":"https://eternalsearch.net/api/v1/companies/Hct0hiK3"},{"id":"b38cd5a9-442c-42f6-96af-54c4ff60a474","public_id":"1nDIsi3A","name":"Integrated Biosciences","canonical_name":"Integrated Biosciences","aliases":[],"one_liner":"Integrated Biosciences uses optogenetics, chemistry, and AI for small molecule therapeutic discovery in age-related diseases.","description":"Integrated Biosciences is advancing a pipeline of novel small molecule therapeutics for age-related diseases. Its platform combines synthetic biology, chemistry, and AI to probe disease biology and explore chemical space. The company states its science is built on pioneering work from scientific co-founder Prof. Jim Collins at MIT.","website":"https://integratedbiosciences.com","canonical_website":"https://integratedbiosciences.com/","logo_url":"https://image.pitchbook.com/tMb8hq7uQmhCm5AlmYZpZ8L5nQI1777959327790_200x200","headquarters":"Redwood City, California, United States","hq_country_code":"US","founding_year":null,"primary_approach":"optogenetics, chemistry, AI","primary_field_slug":"discovery","field_slugs":["discovery","modulating","clearing","measurement"],"primary_idea_root_slug":"discovering","idea_root_slugs":["discovering","modulating","clearing","measuring"],"primary_modality_slug":"small_molecule","modality_slugs":["small_molecule","optogenetic_therapy"],"classification_rationale":"Integrated Biosciences is a therapeutics company developing small-molecule drugs for age-related diseases and related biology, with a strong AI-enabled discovery-platform identity built around optogenetics, chemistry, synthetic biology, and machine learning. Across the evidence, the clearest company-level classification is discovering, while its therapeutic programs also show support for modulating biology through small-molecule targeting of stress responses and for clearing via senolytic compound discovery. The dominant modality is small_molecule; optogenetics appears primarily as part of the discovery platform rather than the main therapeutic product form.","classification_confidence":94,"funding_stage":null,"total_funding_usd":"17000000","latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"operating","operating_status_reason":null,"operating_status_rationale":null,"operating_status_confidence":null,"business_model":"multi","business_model_rationale":"The evidence supports both a drug developer and platform model. The company states, \"We are building a pipeline of innovative small molecule therapies,\" and elsewhere, \"We are advancing a pipeline of novel small molecule therapeutics,\" which directly supports therapeutic product development. It also describes \"Our Integrated Platform\" and says its platform combines synthetic biology, chemistry, and AI to probe disease biology and explore chemical space, which supports a discovery-enabling platform business. Because both are central in the supplied evidence, the best fit is multi.","business_model_confidence":95,"ip_market_structure":"Based on the evidence provided, the organization’s strongest apparent proprietary position is `EP4687893A1`, a pending European application assigned to Integrated Biosciences covering compounds and their uses, with repeated references to senescence, skin, and topical/oral delivery. That looks like a forward-looking composition-of-matter/use filing around a specific compound series, which is usually the most valuable kind of biotech/pharma IP if it ultimately issues. By contrast, the other “held” item, `US20190269675A1`, does not read as a strong in-house asset for this organization: it is an abandoned US application, and the assignee trail points to Buck, Unity, and Mayo rather than clearly to the organization itself. Even if strategically relevant, it does not materially strengthen exclusivity. The main apparent corridor risk comes from the third-party small-molecule therapeutic families, especially `WO2008057604A2` and the related `AU2014274599A1`. On the face of the excerpts, those families look broad and foundational: they claim small-molecule therapeutics, analogues/derivatives, compositions, and methods of use, with explicit discussion of topical, parenteral, inhaled, and other formulations. If the organization’s lead assets sit near those same chemotypes or formulation space, these patents are the most plausible blockers. That said, one important qualifier is that `WO2008057604A2` is marked “ceased,” which weakens its present blocking force unless active national descendants remain in force. So the corridor is real, but the evidence does not show a clean, unavoidable wall. Freedom to operate therefore looks mixed rather than clean. The organization appears to have an emerging proprietary lane around its own newer compound series, but not yet a clearly issued exclusionary estate from the evidence shown. At the same time, the third-party corridor may still constrain chemistry, formulations, or use claims if the company’s compounds are close enough to the older therapeutic families. The practical FTO posture is better if the organization’s compounds are structurally distinct and claimed as new matter; worse if they are optimized derivatives of known scaffold families. Design-around appears feasible. The most obvious routes are to move to differentiated chemotypes, narrower senescence-linked mechanisms, distinct delivery formats, or indication-specific positioning outside the older broad therapeutic composition claims. The apparent blockers also look more licensable than strategically closed, because the cited third-party owners are academic institutions rather than an obvious operating competitor. If those families are still active where it matters, they look like licensing candidates rather than permanently inaccessible choke points.","is_public":true,"disqualified":false,"disqualified_reason":null,"disqualified_at":null,"research_status":"ready","is_editors_choice":false,"overall_score":38.92,"overall_score_computed_at":"2026-06-29 09:55:56.586012+00","pipeline_version":"0.24.1","proximity_score":"35.00","proximity_band":"early_mechanism","proximity_rationale":"Derived deterministically from 6 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":6,"social_links":{"github":null,"twitter":null,"youtube":null,"facebook":null,"instagram":null,"linkedin_company":"https://www.linkedin.com/company/integrated-biosciences-inc"},"careers_page_url":"https://integratedbiosciences.com/contact","pipeline_page_url":null,"external_registry_ids":{"sec":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-25T06:48:00.842Z\",\"rationale\":\"sec returned 0 candidates for \\\"Integrated Biosciences\\\".\",\"officers_matched\":[],\"candidate_count\":0}","opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-25T05:39:00.242Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"Integrated Biosciences\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-06-03 01:09:12.495876+00","updated_at":"2026-09-23 00:19:53.167696+00","scores":{"ambition":7.25,"publicity":5,"media_reach":4,"reliability":5,"falsifiability":8.5,"claim_integrity":8.97,"collaborativity":7,"context_validity":6,"pipeline_quality":4,"explanatory_power":6.25,"results_alignment":7,"scandal_integrity":8,"publication_quality":8,"premise_plausibility":7.5,"implementation_fidelity":8,"independent_replication":3},"public_records_count":172,"publications_count":36,"projects_count":6,"funding_rounds_count":1,"clinical_trials_count":0,"publication_status":"published","public_url":"https://eternalsearch.net/companies/1nDIsi3A","api_url":"https://eternalsearch.net/api/v1/companies/1nDIsi3A"},{"id":"c61d7fdb-d342-4ac8-ac70-056c6e31564f","public_id":"zhU2cyCV","name":"Gallant","canonical_name":"Gallant","aliases":[],"one_liner":"Gallant develops ready-to-use regenerative stem cell therapies for pets that target disease at its source.","description":"Gallant is building ready-to-use regenerative therapies for veterinary medicine. Its stem cell therapies are designed to reduce inflammation, restore tissue function, and support long-term recovery in pets. The company lists multiple therapies in development following the FDA’s structured review and approval process.","website":"https://gallant.com","canonical_website":"https://gallant.com/","logo_url":"https://www.gallant.com/wp-content/uploads/2025/09/GallantU-1-scaled.png","headquarters":"San Diego, California, United States","hq_country_code":"US","founding_year":null,"primary_approach":"regenerative medicine, stem cell therapies, veterinary therapeutics","primary_field_slug":"replacement","field_slugs":["replacement","repairing","biobanking"],"primary_idea_root_slug":"replacing","idea_root_slugs":["replacing","repairing"],"primary_modality_slug":"cell_therapy","modality_slugs":["cell_therapy"],"classification_rationale":"Gallant is a veterinary regenerative-medicine company focused primarily on off-the-shelf stem cell therapies for pets, including allogeneic stem cell programs for conditions such as feline chronic gingivostomatitis and osteoarthritis. That maps most strongly to the replacing idea root and the cell_therapy modality. The evidence also shows Gallant operates a stem cell banking offering for dogs, so biobanking should be retained as an offering field alongside its core therapeutic activity.","classification_confidence":94,"funding_stage":null,"total_funding_usd":"15000000","latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"operating","operating_status_reason":null,"operating_status_rationale":null,"operating_status_confidence":null,"business_model":"multi","business_model_rationale":"The strongest evidence supports both therapeutic product development and a commercial stem-cell-banking offering. Gallant says it \"develops ready-to-use regenerative stem cell therapies for pets,\" and press coverage describes pivotal studies, pilot data, and FDA pathway progress for feline and canine indications, which fits drug development. Separate evidence says Gallant \"Launches Stem Cell Banking for Dogs Nationwide,\" which indicates an additional service/commercial offering. Together, the best fit is multi rather than only drug_developer.","business_model_confidence":89,"ip_market_structure":"On the evidence provided, the only clearly relevant, currently live-looking patent asset tied to this organization is US20240352425A1, assigned to Gallant Pet Inc., covering methods to optimize reproductive-tissue-derived cell yield and viability for clinical applications. That application appears to be the organization’s core proprietary position around tissue processing parameters, including enzymatic digestion and mechanical agitation conditions. The other listed “company held” items do not strengthen the corridor in any obvious way: WO2020114913A1 is a Velcro fastener application and not this organization’s biomedical IP; WO1987006515A1 is an old abrasive jet machining patent that is ceased and technologically unrelated; WO2014100158A1 appears to concern mannose derivatives for bacterial infections, but the excerpt is too incomplete to assess ownership or relevance. That mix suggests the evidence set may contain noise, and the real held estate visible here is narrow. Because no actual field-corridor patents held by others are included in the supplied evidence, there is no concrete basis here to identify specific blocking third-party owners or name particular blocking patents. So the freedom-to-operate posture looks provisionally better on offense than on defense: the organization appears to have at least one pending application staking out a process niche, but the record supplied does not show whether outsiders control adjacent cell-isolation, reproductive-tissue sourcing, enzyme cocktails, agitation devices, or clinical manufacturing workflows. In other words, this evidence supports a modest proprietary claim set, not a demonstrated clean FTO lane. Design-around feasibility looks fairly high if the organization is relying mainly on a process patent like US20240352425A1. Method claims around yield/viability optimization are often circumvented by changing tissue source definitions, digestion chemistry, incubation timing, agitation mode, device geometry, or downstream handling while still pursuing the same commercial objective. Conversely, if competitors hold broader composition, device, or manufacturing claims in the same area, those would be harder to avoid, but none are shown here. Licensing posture is also uncertain from this record. The relevant Gallant Pet application looks like ordinary venture-backed proprietary biotech IP, which is often licensable in principle but usually retained strategically unless there is platform or geographic partnering value. Since the provided evidence does not identify concrete third-party blockers, there is no factual basis to call the corridor either open for routine licensing or strategically closed by incumbents.","is_public":true,"disqualified":true,"disqualified_reason":"Gallant is a veterinary regenerative-medicine company, not a longevity company. It develops stem cell therapies for specific pet diseases such as feline gingivostomatitis, osteoarthritis, chronic kidney disease, and canine dermatitis, but the evidence does not show programs aimed at the biology of aging itself or tools built to measure or intervene on aging mechanisms.","disqualified_at":"2026-06-30T14:36:02.544Z","research_status":"ready","is_editors_choice":false,"overall_score":38.88,"overall_score_computed_at":"2026-06-30 14:35:42.634177+00","pipeline_version":"0.24.1","proximity_score":"20.00","proximity_band":"far","proximity_rationale":"Derived deterministically from 7 extracted project(s). Most-advanced status: undisclosed. Band: far. Modifiers: +5 depth (7 programs at undisclosed). Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":0,"social_links":null,"careers_page_url":"https://gallant.com/careers/","pipeline_page_url":"https://www.gallant.com/product-pipeline/","external_registry_ids":{"sec":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-14T07:52:01.844Z\",\"rationale\":\"sec returned 0 candidates for \\\"Gallant\\\".\",\"officers_matched\":[],\"candidate_count\":0}","opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-14T07:50:02.567Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"Gallant\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-06-03 01:09:12.242231+00","updated_at":"2026-09-23 00:21:15.45767+00","scores":{"ambition":6,"publicity":4,"media_reach":4,"reliability":5,"falsifiability":8,"claim_integrity":10,"collaborativity":5,"context_validity":8,"pipeline_quality":5,"explanatory_power":5.5,"results_alignment":7,"scandal_integrity":8,"publication_quality":6,"premise_plausibility":6.8,"implementation_fidelity":7,"independent_replication":3},"public_records_count":73,"publications_count":24,"projects_count":7,"funding_rounds_count":2,"clinical_trials_count":0,"publication_status":"published_disqualified","public_url":"https://eternalsearch.net/companies/zhU2cyCV","api_url":"https://eternalsearch.net/api/v1/companies/zhU2cyCV"},{"id":"13954d9d-e85c-47dc-b7d4-ca49e94ba543","public_id":"OCOTXe5f","name":"AKL Therapeutics","canonical_name":"AKL Therapeutics","aliases":["AKL Research & Development Limited","AKL"],"one_liner":"AKL Therapeutics develops APPA, an investigational oral therapy for osteoarthritis and other inflammatory diseases of ageing.","description":"AKL Therapeutics is a privately held pharmaceutical company developing treatments for inflammatory diseases with high unmet need. Its lead clinical asset is APPA, a patented investigational oral medicine for osteoarthritis and other diseases of ageing. The company says APPA combines two synthetically produced isomers and modulates NF-kB and Nrf2 activity rather than blocking immune response.","website":"https://akltherapeutics.com","canonical_website":"https://akltherapeutics.com/","logo_url":"https://akltherapeutics.com/wp-content/themes/aklrd/images/aklrd_logo_sm.png","headquarters":"Stevenage, United Kingdom","hq_country_code":"GB","founding_year":null,"primary_approach":"plant-derived metabolites, NF-kB/Nrf2 modulation, senotherapeutics","primary_field_slug":"modulating","field_slugs":["modulating","clearing"],"primary_idea_root_slug":"modulating","idea_root_slugs":["modulating","clearing"],"primary_modality_slug":"small_molecule","modality_slugs":["small_molecule"],"classification_rationale":"AKL Therapeutics is a therapeutics company developing APPA, an investigational oral medicine for osteoarthritis and other diseases of ageing. The strongest evidence supports classifying the company under modulating because APPA is described as modulating NF-kB and Nrf2 activity and as acting on the inflammatory cascade, which fits pathway-level pharmacologic modulation. There is also weaker secondary evidence for clearing from publication language describing senotherapeutic effects in senescent human chondrocytes. Its modality is best classified as small_molecule because APPA is described as an oral, patented, fixed-dose combination of synthetically produced compounds.","classification_confidence":91,"funding_stage":null,"total_funding_usd":null,"latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"operating","operating_status_reason":null,"operating_status_rationale":null,"operating_status_confidence":null,"business_model":"drug_developer","business_model_rationale":"The evidence consistently describes AKL Therapeutics / AKL Research & Development Limited as a pharmaceutical or biotech company advancing investigational therapeutic candidates, especially APPA for osteoarthritis and other inflammatory or ageing-related conditions. Multiple sources reference products under development, investigational use, and human clinical trials, which fits a drug developer rather than a platform, diagnostics, delivery technology, or services company.","business_model_confidence":96,"ip_market_structure":"The organization’s own patent position appears thin and only weakly relevant to any current operating corridor. One held asset, `CN300762432S`, is a Chinese design patent for a shower room model (`akl-3300`), and the evidence shows it terminated for non-payment with a termination date of March 18, 2012. It therefore does not create present exclusionary power. The other held asset, `GB2424833B`, covering an anti-inflammatory formulation comprising apocyanin and paeonol, was assigned to `AKL INFLAMMATORY Ltd` and is marked `Expired - Lifetime`, with anticipated expiration on April 8, 2025. That patent matters more substantively because it covers a composition, but the evidence indicates it no longer provides active blocking rights either. The main apparent field-corridor risk in the supplied record is `EP4727360A1`, a pending European patent application held by `Landlab Srl` and `Thesis BV`, directed to a composition for improved disease resistance in plants. On the evidence provided, these entities are the only visible third-party holders with potentially live blocking IP. That said, the subject matter is agricultural plant disease resistance, which sits in a different technical lane from the organization’s expired anti-inflammatory formulation patent and entirely different from the expired shower-room design patent. Based only on this record, the freedom-to-operate posture looks relatively open: the organization does not appear boxed in by a dense live patent estate, and the one live corridor reference is both pending and seemingly outside the organization’s demonstrated historical claim scope. Design-around also looks feasible. First, `EP4727360A1` is not yet granted, so claim scope is unsettled. Second, compositions are often designed around by changing active ingredients, ratios, use context, or target species/disease pathways, and nothing in the provided evidence suggests unusually foundational or platform-level claiming. By contrast, the organization’s own expired formulation patent suggests prior activity around apocyanin and paeonol rather than a locked proprietary moat today. On licensability versus strategic closure, the likely blocker looks more licensable than closed. The relevant third-party right is co-owned by commercial entities rather than, for example, a vertically integrated dominant incumbent with a broad granted family shown here. Because it is pending, recent, and apparently application-specific, it reads more like a potentially negotiable asset than a hard strategic wall. Overall, the corridor looks navigable, with limited evidence of active exclusionary pressure.","is_public":true,"disqualified":false,"disqualified_reason":null,"disqualified_at":null,"research_status":"ready","is_editors_choice":false,"overall_score":38.56,"overall_score_computed_at":"2026-07-13 17:33:00.146324+00","pipeline_version":"0.24.1","proximity_score":"70.00","proximity_band":"translational","proximity_rationale":"Derived deterministically from 2 extracted project(s). Most-advanced status: phase 2. Band: translational. Modifiers: +5 modality breadth (3 modalities at max band). Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":2,"social_links":{"github":null,"twitter":null,"youtube":null,"facebook":null,"instagram":null,"linkedin_company":"https://www.linkedin.com/company/akl-research-&-development-limited/"},"careers_page_url":null,"pipeline_page_url":"https://akltherapeutics.com/research-development/strategy/","external_registry_ids":{"opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-25T23:00:01.071Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"AKL Therapeutics\\\".\",\"officers_matched\":[],\"candidate_count\":0}","companies_house":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-25T23:00:01.029Z\",\"rationale\":\"companies_house returned 0 candidates for \\\"AKL Therapeutics\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-06-03 01:09:11.422844+00","updated_at":"2026-07-20 01:20:43.127444+00","scores":{"ambition":5.75,"publicity":4,"media_reach":3,"reliability":5,"falsifiability":8,"claim_integrity":10,"collaborativity":7,"context_validity":6,"pipeline_quality":5,"explanatory_power":5,"results_alignment":6,"scandal_integrity":8,"publication_quality":7,"premise_plausibility":7,"implementation_fidelity":8,"independent_replication":4},"public_records_count":160,"publications_count":11,"projects_count":2,"funding_rounds_count":0,"clinical_trials_count":0,"publication_status":"published","public_url":"https://eternalsearch.net/companies/OCOTXe5f","api_url":"https://eternalsearch.net/api/v1/companies/OCOTXe5f"},{"id":"4894a325-4c95-4e52-b286-f564ef026231","public_id":"Kk7G9GtP","name":"Yumanity Therapeutics","canonical_name":"Yumanity Therapeutics","aliases":["Yumanity"],"one_liner":"Yumanity Therapeutics developed brain drugs for neurodegenerative diseases using yeast-based research approaches.","description":"Yumanity Therapeutics was a Boston-based developer of brain drugs focused on neurodegenerative diseases. The company used yeast as an unorthodox tool to better understand disease biology and find potential treatments. In 2022, it announced plans to sell most research assets to Janssen and merge with Kineta, ending its run as an independent biotechnology company.","website":null,"canonical_website":"https://www.biopharmadive.com/news/yumanity-kineta-janssen-asset-sale-reverse-merger/624940/","logo_url":"https://ml.globenewswire.com/Resource/Download/7c3a4e1a-343d-47c0-bffa-a9fe76998a3a","headquarters":"Boston, Massachusetts, United States","hq_country_code":"US","founding_year":2014,"primary_approach":"yeast, neurodegeneration, brain drugs","primary_field_slug":"modulating","field_slugs":["discovery","modulating","training"],"primary_idea_root_slug":"modulating","idea_root_slugs":["discovering","modulating","training"],"primary_modality_slug":"small_molecule","modality_slugs":["small_molecule","immunotherapy","biologic"],"classification_rationale":"Yumanity Therapeutics was a clinical-stage biotech focused on discovering and developing disease-modifying therapies for neurodegenerative diseases. The strongest company-specific evidence points to a small-molecule Parkinson's program, YTX-7739, a brain-penetrant stearoyl-CoA desaturase inhibitor intended to reduce alpha-synuclein toxicity and abnormal lipid biology, which supports modulating as the primary idea root and small_molecule as the primary modality. Multiple sources also describe Yumanity's yeast-based and assay-driven platform for transforming neurodegenerative drug discovery, so discovering remains an important secondary root. Some candidate chunks reflect post-merger Kineta evidence rather than Yumanity-specific operations; those slugs are retained only because they appeared in the inputs, but they are not the primary classification.","classification_confidence":84,"funding_stage":"acquired","total_funding_usd":null,"latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"acquired","operating_status_reason":"acquired","operating_status_rationale":"Derived from funding_stage=acquired (site-analyzer acquisition/dissolution evidence); operating-status detector had not run.","operating_status_confidence":60,"business_model":"drug_developer","business_model_rationale":"The strongest evidence consistently describes Yumanity Therapeutics as a therapeutic company advancing its own drug candidates. Multiple sources call it a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies, describe YTX-7739 as its lead investigational therapy, and note Phase 1 clinical activity in Parkinson's disease. Although some evidence mentions assay systems or broadly applicable technology, that appears subordinate to its primary therapeutics pipeline rather than a standalone platform business.","business_model_confidence":95,"ip_market_structure":"On the supplied record, the only clearly identified patent owner is Yumanity Therapeutics, so the main IP that matters here is the organization’s own chemistry estate rather than a demonstrated third-party blocking wall. The strongest asset is the family published as US20200010462A1 and shown as granted in the U.S. as US11970486B2, with active status and an anticipated expiration of October 24, 2037. That looks like a core composition-and-use patent family and is the most important patent in the evidence because granted U.S. composition claims are usually the hardest barrier for competitors to avoid. The record also shows another company-held granted U.S. patent, US12268687B2, also titled “Compounds and uses thereof,” which suggests a second granted layer in the same general therapeutic area, although the excerpt is too truncated to assess exact scope. By contrast, the WO2021247916 PCT family appears weaker as a present barrier because it is marked ceased, with non-entry signals in Europe, so it does not read like a durable international blocking asset on this record. For freedom to operate, the posture is only cautiously positive. The organization appears to control at least one meaningful U.S. granted family around its own compounds, which is good for exclusivity, but ownership of one’s own patents does not itself prove FTO against others. Since no third-party corridor patents are actually included in the supplied evidence, there is no concrete basis here to say another company holds blocking IP. The correct reading is narrower: the evidence supports proprietary position, but it does not establish clean FTO beyond the organization’s own claimed space. Design-around feasibility looks moderate in the abstract. If the key granted claims are true composition-of-matter claims on specific scaffolds and substitution patterns, designing around usually requires moving to materially different chemotypes rather than making cosmetic analog changes. The ceased PCT family also suggests some narrowing of international leverage, which makes geographic design-around easier outside surviving national filings. As to licensability versus strategic closure, the likely blockers visible here do not look like an entrenched outside thicket; they look like in-house assets that would normally be licensable through partnering, acquisition, or field-restricted deals if the owner were commercially motivated. The evidence does not show a strategically closed third-party corridor.","is_public":true,"disqualified":true,"disqualified_reason":"Yumanity Therapeutics was a neurodegeneration biotech, specifically a brain-drug company working on Parkinson's disease and related protein-misfolding disorders. The evidence shows disease-focused CNS drug discovery using yeast and iPSC models, not a program to measure, slow, reverse, or otherwise target the biology of aging itself.","disqualified_at":"2026-07-02T06:37:54.742Z","research_status":"ready","is_editors_choice":false,"overall_score":38.44,"overall_score_computed_at":"2026-07-02 06:37:36.649093+00","pipeline_version":"0.24.1","proximity_score":"55.00","proximity_band":"translational","proximity_rationale":"Derived deterministically from 5 extracted project(s). Most-advanced status: phase 1. Band: translational. Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":0,"social_links":null,"careers_page_url":null,"pipeline_page_url":null,"external_registry_ids":{"sec":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-27T23:06:00.537Z\",\"rationale\":\"sec returned 0 candidates for \\\"Yumanity Therapeutics\\\".\",\"officers_matched\":[],\"candidate_count\":0}","opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-27T20:39:00.243Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"Yumanity Therapeutics\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-06-03 01:09:13.815251+00","updated_at":"2026-09-16 16:38:04.361959+00","scores":{"ambition":7.2,"publicity":5,"media_reach":4,"reliability":5,"falsifiability":8.8,"claim_integrity":9.23,"collaborativity":7,"context_validity":6,"pipeline_quality":3,"explanatory_power":7,"results_alignment":7,"scandal_integrity":5,"publication_quality":7,"premise_plausibility":7.8,"implementation_fidelity":7,"independent_replication":4},"public_records_count":124,"publications_count":11,"projects_count":5,"funding_rounds_count":5,"clinical_trials_count":0,"publication_status":"published_disqualified","public_url":"https://eternalsearch.net/companies/Kk7G9GtP","api_url":"https://eternalsearch.net/api/v1/companies/Kk7G9GtP"},{"id":"5bb243bc-69ab-4ab8-b42e-da41d38bac37","public_id":"atjcG8n9","name":"Regerna Therapeutics","canonical_name":"Regerna Therapeutics","aliases":["Regerna"],"one_liner":"Regerna develops RNA-binding protein therapeutics to restore and regenerate functional muscle in aging, injury, and muscular dystrophy.","description":"Regerna Therapeutics is developing regenerative therapeutics to restore functional muscle lost through injury, aging, and dystrophies. Its platform focuses on RNA-binding proteins that regulate RNA stability, splicing, and translation. The company identifies AUF1 as its lead therapeutic and master controller of muscle repair and regeneration, with programs including AUF1 LNP and AAV approaches and REG-A40 for Duchenne Muscular Dystrophy.","website":"https://regernatx.com","canonical_website":"https://regernatx.com/","logo_url":"https://static1.squarespace.com/static/691524cbd0ecec3c7ffce312/t/69161c4fa035e93a04865cf8/1762993355831/","headquarters":"New York City, New York, United States","hq_country_code":null,"founding_year":null,"primary_approach":"RNA-binding proteins, AUF1, muscle regeneration","primary_field_slug":"repairing","field_slugs":["repairing","delivery","modulating"],"primary_idea_root_slug":"repairing","idea_root_slugs":["repairing","delivering","modulating"],"primary_modality_slug":"gene_therapy","modality_slugs":["gene_therapy","rna_therapeutic","biologic"],"classification_rationale":"Regerna Therapeutics is a therapeutic biotech developing regenerative muscle medicines for aging-related decline, injury, and muscular dystrophies. The strongest evidence supports a repairing biology classification because the company repeatedly describes restoring or rebuilding functional muscle and advancing AUF1 programs that accelerate muscle regeneration. Its clearest modality is gene therapy, supported by explicit AUF1 AAV and gene-therapy pipeline references, while RNA-binding protein therapeutics and LNP programs also support secondary RNA-therapeutic, biologic, and delivery-related elements.","classification_confidence":85,"funding_stage":null,"total_funding_usd":null,"latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"operating","operating_status_reason":null,"operating_status_rationale":null,"operating_status_confidence":null,"business_model":"multi","business_model_rationale":"The strongest evidence supports both therapeutic pipeline development and a platform model. Regerna is explicitly described as developing regenerative therapeutics, which fits drug development, and the same source says its platform focuses on RNA-binding proteins that regulate RNA stability, splicing, and translation, which supports a platform component.","business_model_confidence":91,"ip_market_structure":"Based on the evidence provided, the main blocking IP appears to sit with New York University and Regenxbio, which are listed as applicants/assignees on the AUF1 muscular dystrophy family. The most important corridor patents are WO2023004331A1, covering AUF1 combination therapies for muscle degenerative disease, and WO2024020574A2 together with its national-phase counterpart IL318484A, covering AUF1 gene therapy for limb girdle muscular dystrophy. Those filings matter because they appear to claim the core therapeutic concept itself: AUF1 delivered by AAV, with promoter and sequence-engineering features such as codon optimization and CpG depletion, for muscular dystrophy indications. That is a fairly central position in the space, not a narrow peripheral improvement. The older US5733728A on heart failure looks much less relevant as a practical blocker to an AUF1 muscular dystrophy program based on the text supplied. On freedom to operate, the posture looks constrained if this organization’s program depends on AUF1 gene therapy for limb girdle muscular dystrophy or closely related muscle-degenerative uses. The corridor patents appear to cover both monotherapy and combination-therapy variants, which reduces obvious room to maneuver inside the same therapeutic thesis. The fact pattern suggests that operating without a license would carry material risk if the organization is pursuing AUF1-in-AAV for these indications. Design-around looks possible in principle but not easy if the organization wants to preserve the same biological mechanism and disease target. Changing promoter, capsid, dosing, or sequence optimization alone may not be enough if the blocking claims are anchored to AUF1 use in muscular dystrophy broadly. A more credible design-around would likely require moving outside the AUF1 construct, outside AAV delivery, outside the claimed disease scope, or into a meaningfully different mechanism or patient segment. That is a substantial strategic pivot rather than a light engineering workaround. These blockers look more licensable than strategically closed. The presence of institutional and commercial co-owners, multiple jurisdictions, and active patent-family prosecution is consistent with assets meant to support partnering and licensing. At the same time, because the patents seem close to the therapeutic core, access may be expensive and selective even if technically available.","is_public":true,"disqualified":false,"disqualified_reason":null,"disqualified_at":null,"research_status":"ready","is_editors_choice":false,"overall_score":38.39,"overall_score_computed_at":"2026-06-28 17:35:21.438306+00","pipeline_version":"0.24.1","proximity_score":"40.00","proximity_band":"early_mechanism","proximity_rationale":"Derived deterministically from 4 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Modifiers: +5 depth (4 programs at preclinical). Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":2,"social_links":null,"careers_page_url":null,"pipeline_page_url":null,"external_registry_ids":{"sec":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-25T06:27:00.250Z\",\"rationale\":\"sec returned 0 candidates for \\\"Regerna Therapeutics\\\".\",\"officers_matched\":[],\"candidate_count\":0}","opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-25T02:09:00.070Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"Regerna Therapeutics\\\".\",\"officers_matched\":[],\"candidate_count\":0}","companies_house":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-25T03:12:00.073Z\",\"rationale\":\"companies_house returned 0 candidates for \\\"Regerna Therapeutics\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-06-03 01:09:13.255696+00","updated_at":"2026-07-20 07:13:38.732918+00","scores":{"ambition":7.88,"publicity":4,"media_reach":2,"reliability":5,"falsifiability":8.5,"claim_integrity":1,"collaborativity":1,"context_validity":5,"pipeline_quality":3,"explanatory_power":6.19,"results_alignment":7,"scandal_integrity":8,"publication_quality":8,"premise_plausibility":7.44,"implementation_fidelity":7,"independent_replication":3},"public_records_count":65,"publications_count":5,"projects_count":4,"funding_rounds_count":0,"clinical_trials_count":0,"publication_status":"published","public_url":"https://eternalsearch.net/companies/atjcG8n9","api_url":"https://eternalsearch.net/api/v1/companies/atjcG8n9"},{"id":"8f968063-e636-4bbd-baf3-3d7f89d819b7","public_id":"Mht7lsDD","name":"Longevity Biotech","canonical_name":"Longevity Biotech","aliases":[],"one_liner":"Longevity Biotech develops precision approaches to address neurodegenerative diseases.","description":"Longevity Biotech is focused on changing the neuroscience paradigm for neurodegenerative diseases by developing products that reset dysregulated immune systems. Its initial focus is Parkinson's Disease, with expansion into related neurodegenerative diseases. The company uses a Precision Neuroscience Platform to profile immune biomarkers and a proprietary Hybridtide Platform for synthetic peptide-based therapeutics.","website":"https://longevitybiotech.com","canonical_website":"https://longevitybiotech.com/","logo_url":"https://image.pitchbook.com/LU0yc2AAhiOG7fzPAuWHV3n1aTu1758790159311_200x200","headquarters":"Philadelphia, Pennsylvania, United States","hq_country_code":"US","founding_year":null,"primary_approach":"immune rebalancing, Hybridtides, precision neuroscience","primary_field_slug":"modulating","field_slugs":["modulating","measurement"],"primary_idea_root_slug":"modulating","idea_root_slugs":["modulating","measuring"],"primary_modality_slug":"biologic","modality_slugs":["biologic"],"classification_rationale":"Longevity Biotech appears to be a therapeutic biotech company developing peptide-based candidates for neurodegenerative disease, especially Parkinson’s disease. The strongest evidence supports a primary modulating classification because the company describes products that reset dysregulated immune systems and develop specific modulators of validated pathways to restore immune balance and reduce neuroinflammation. Its modality is best classified as biologic because the core therapeutic platform is described as synthetic peptide-based therapeutics. The company also shows a secondary measuring capability through immune biomarker profiling, but that appears to support the therapeutic program rather than define the main offering.","classification_confidence":88,"funding_stage":null,"total_funding_usd":null,"latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"operating","operating_status_reason":null,"operating_status_rationale":null,"operating_status_confidence":null,"business_model":"multi","business_model_rationale":"The strongest evidence supports both drug development and platform technology. The company describes therapeutic development for neurodegenerative disease and also presents proprietary platform capabilities, including a Precision Neuroscience Platform and Hybridtide Platform.","business_model_confidence":92,"ip_market_structure":"On the evidence provided, the clearest IP position is that Longevity Biotech itself appears to control the core disclosed corridor rather than facing an identified outside blocker. The material patents are US9782454B2, “Highly active polypeptides and methods of making and using the same,” assigned to Longevity Biotech and shown as active with anticipated expiration on April 22, 2031; US10543255B2, which appears to cover peptides comprising non-natural amino acids and related methods; and EP2968469A4, the European counterpart, still listed as pending. Inventor overlap across Scott Shandler and Samuel H. Gellman reinforces that this is a coherent internal patent family around non-natural amino acid peptide engineering, production, and use. The freedom-to-operate posture therefore looks comparatively strong inside this specific corridor, because the only concrete rights in the record are the company’s own US grant, a second US grant, and a pending EP application in the same family. What is missing is equally important: no third-party field-corridor patents are actually included in the evidence excerpt, so there is no basis here to identify a named outside holder with blocking claims. That means the record supports “owned core position with no demonstrated blocker in the supplied set,” not a broad clean bill of health across the entire peptide therapeutics landscape. Design-around feasibility looks mixed. If the operative claims are broad around peptides containing non-natural amino acids plus methods of making and using them, designing around may be technically possible only by moving outside specific claimed sequence architectures, residue types, activity profiles, or manufacturing/use claims. But because the titles and metadata suggest platform-style coverage rather than a single narrow composition, a competitor may need a meaningful shift in scaffold or chemistry, not just minor substitutions. On licensability versus strategic closure, the evidence points more toward strategically held platform IP than an obviously open licensing estate. These patents are assigned directly to Longevity Biotech and cover enabling peptide technology, which usually functions as a core exclusionary asset. Without third-party blocker evidence, the main practical conclusion is that Longevity Biotech seems to own the most important demonstrated rights in this corridor, and any licensing pressure would more likely run from others needing access to Longevity’s estate than the reverse.","is_public":true,"disqualified":true,"disqualified_reason":"This is a Parkinson's disease biotech, not an aging-biology company. The evidence points to a peptide drug program, immune biomarker profiling, and neuroinflammation work in PD models and Phase I testing, but nothing here shows a program aimed at aging itself or a defined aging mechanism across age-related decline.","disqualified_at":"2026-07-02T18:22:22.182Z","research_status":"ready","is_editors_choice":false,"overall_score":38.31,"overall_score_computed_at":"2026-07-02 18:21:58.480761+00","pipeline_version":"0.24.1","proximity_score":"55.00","proximity_band":"translational","proximity_rationale":"Derived deterministically from 4 extracted project(s). Most-advanced status: phase 1. Band: translational. Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":1,"social_links":{"github":null,"twitter":null,"youtube":null,"facebook":null,"instagram":null,"linkedin_company":"https://www.linkedin.com/company/longevity-biotech/"},"careers_page_url":"https://www.longevitybiotech.com/careers/","pipeline_page_url":"https://www.longevitybiotech.com/pipeline/","external_registry_ids":{"sec":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-28T02:57:19.313Z\",\"rationale\":\"sec returned 0 candidates for \\\"Longevity Biotech\\\".\",\"officers_matched\":[],\"candidate_count\":0}","opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-28T02:57:19.317Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"Longevity Biotech\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-06-03 01:09:12.677837+00","updated_at":"2026-07-20 02:50:42.17659+00","scores":{"ambition":7.25,"publicity":3,"media_reach":1,"reliability":5,"falsifiability":8.5,"claim_integrity":10,"collaborativity":4,"context_validity":5,"pipeline_quality":5,"explanatory_power":6.75,"results_alignment":7,"scandal_integrity":8,"publication_quality":7,"premise_plausibility":7.25,"implementation_fidelity":8,"independent_replication":3},"public_records_count":99,"publications_count":3,"projects_count":4,"funding_rounds_count":0,"clinical_trials_count":1,"publication_status":"published_disqualified","public_url":"https://eternalsearch.net/companies/Mht7lsDD","api_url":"https://eternalsearch.net/api/v1/companies/Mht7lsDD"},{"id":"b7852d0f-7b87-4ac2-8ce2-c63ded675a0b","public_id":"bVtS6hwB","name":"MetHealthspan","canonical_name":"Columbia University Irving Medical Center","aliases":["CUIMC"],"one_liner":"Columbia University Irving Medical Center drives discovery, advances care, and educates leaders in medicine and health sciences.","description":"Columbia University Irving Medical Center is an academic medical center focused on research, patient care, and health sciences education. The site describes CUIMC as driving discovery, advancing care, and educating leaders. Its schools include the Vagelos College of Physicians and Surgeons, Mailman School of Public Health, School of Nursing, and College of Dental Medicine.","website":"https://cumc.columbia.edu","canonical_website":"https://cumc.columbia.edu/","logo_url":null,"headquarters":"630 West 168th Street New York, NY 10032 United States","hq_country_code":"US","founding_year":null,"primary_approach":"medical research, clinical care, education","primary_field_slug":"clinical_care","field_slugs":["clinical_care","education_media"],"primary_idea_root_slug":null,"idea_root_slugs":[],"primary_modality_slug":null,"modality_slugs":[],"classification_rationale":"Columbia University Irving Medical Center is an academic medical center and healthcare delivery organization centered on patient care, hospital and clinic services, clinical research, and health sciences education. The supplied evidence supports classifying it primarily as clinical care, with education also explicitly part of its mission; there is no evidence here for a specific aging-biology idea root, therapeutic modality, or longevity-product pipeline.","classification_confidence":91,"funding_stage":null,"total_funding_usd":"75000000","latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"operating","operating_status_reason":null,"operating_status_rationale":null,"operating_status_confidence":null,"business_model":"multi","business_model_rationale":"The evidence supports multiple primary functions rather than a single model. Columbia University Irving Medical Center is described as an academic medical center focused on \"research, patient care, and health sciences education,\" indicating a mix of nonprofit research and patient-facing service delivery.","business_model_confidence":91,"ip_market_structure":"On the evidence provided, the most important blocking IP appears to sit with Cardiovascular Systems, Inc. and Shockwave Medical, Inc. Cardiovascular Systems has both an older guidewire patent, US7666202B2, directed to orbital atherectomy guide wire design, and a much more important live asset, US11730509B2, directed to generating orbital motion in drive shafts for rotational medical devices. The older guidewire patent is already fee-lapsed and effectively at end of life, with adjusted expiration on June 26, 2026, so it is a near-term concern at most. By contrast, US11730509B2 is active through April 22, 2042 and appears to cover a core mechanical principle for orbital or rotational atherectomy-style systems. Shockwave’s US12426938B2, active through June 9, 2043, covers low-profile electrodes for a shock wave catheter and looks relevant if the organization’s product direction touches intravascular lithotripsy or shockwave energy delivery. The thrombectomy patent US8920402B2 is also in the corridor, but the excerpt is too incomplete to assess its precise blocking weight. Freedom to operate therefore looks narrow to mixed, depending on modality. If the organization is pursuing orbital atherectomy mechanics, the strongest blocker in this record is the active CSI orbital-motion patent, not the expiring guidewire patent. If it is pursuing shockwave catheter architecture, Shockwave’s electrode patent is the more serious obstacle. In other words, the corridor suggests meaningful third-party control over the core actuation or energy-delivery layers of several adjacent device categories. Design-around feasibility looks better for the expired or expiring guidewire concepts and worse for the live platform patents. A guidewire geometry claim can often be avoided by dimensional, structural, or interface changes, and that issue may soon disappear anyway. Designing around a patent aimed at generating orbital motion in a drive shaft is likely harder if orbital motion is central to product performance, because the claim appears closer to the operating principle. Likewise, low-profile electrode architecture in a shock wave catheter may be design-aroundable only by materially changing electrode layout, insulation, pulse routing, or catheter construction, which could impose performance tradeoffs. These blockers look more strategically closed than naturally licensable. CSI and Shockwave are operating strategic device companies holding patents on what appear to be core platform features, so a license is possible in theory but should not be assumed easy, cheap, or available on purely commercial terms.","is_public":true,"disqualified":true,"disqualified_reason":"This is not a longevity company. Columbia University Irving Medical Center is a broad academic medical center that does general biomedical research, clinical care, and medical education; the cited programs are mainstream cardiology, oncology, and translational-research infrastructure, not interventions aimed at the biology of aging.","disqualified_at":"2026-06-24T18:52:48.067Z","research_status":"ready","is_editors_choice":false,"overall_score":38.24,"overall_score_computed_at":"2026-06-24 18:52:09.026721+00","pipeline_version":"0.24.1","proximity_score":"92.00","proximity_band":"near_readout","proximity_rationale":"Derived deterministically from 10 extracted project(s). Most-advanced status: approved. Band: near_readout. Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":1,"social_links":null,"careers_page_url":"https://cumc.columbia.edu/careers","pipeline_page_url":null,"external_registry_ids":{"sec":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-22T14:18:12.423Z\",\"rationale\":\"sec returned 0 candidates for \\\"Columbia University Irving Medical Center\\\".\",\"officers_matched\":[],\"candidate_count\":0}","opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-22T12:03:01.051Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"Columbia University Irving Medical Center\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-05-21 22:31:23.16207+00","updated_at":"2026-07-20 08:33:38.11755+00","scores":{"ambition":5.15,"publicity":4,"media_reach":4,"reliability":8,"falsifiability":8.38,"claim_integrity":8.8,"collaborativity":7,"context_validity":6,"pipeline_quality":4,"explanatory_power":6,"results_alignment":6,"scandal_integrity":8,"publication_quality":8,"premise_plausibility":7.69,"implementation_fidelity":7,"independent_replication":5},"public_records_count":72,"publications_count":48,"projects_count":10,"funding_rounds_count":1,"clinical_trials_count":0,"publication_status":"published_disqualified","public_url":"https://eternalsearch.net/companies/bVtS6hwB","api_url":"https://eternalsearch.net/api/v1/companies/bVtS6hwB"},{"id":"7c0473f2-6203-4b61-af6f-b2994f3ffba1","public_id":"KoPT9feb","name":"Dialectic Therapeutics","canonical_name":"Dialectic Therapeutics","aliases":["Dialectic","Dialectic Therapeutics, Inc."],"one_liner":"Dialectic Therapeutics develops targeted anti-cancer drugs using APTaD protein degradation technology.","description":"Dialectic Therapeutics is a biotechnology company developing anti-cancer drugs for patients with few or no other options. Its lead candidate, DT2216, is an Antiapoptotic Protein Targeted Degradation compound that selectively degrades BCL-XL. DT2216 is in Phase 1/2 clinical trials for fibrolamellar carcinoma and platinum-resistant ovarian cancer.","website":"https://dtsciences.com","canonical_website":"https://dtsciences.com/","logo_url":"https://image.pitchbook.com/oVCVPVJBul9UfVbCIsaKBUWoFD01697112131922_200x200","headquarters":"Dallas, Texas, United States","hq_country_code":"US","founding_year":null,"primary_approach":"protein degradation, BCL-XL, targeted oncology","primary_field_slug":"modulating","field_slugs":["modulating","clearing"],"primary_idea_root_slug":"modulating","idea_root_slugs":["modulating","clearing"],"primary_modality_slug":"small_molecule","modality_slugs":["small_molecule"],"classification_rationale":"Dialectic Therapeutics is a clinical-stage oncology biotech developing targeted anti-cancer drugs built on its Antiapoptotic Protein Targeted Degradation (APTaD) platform, with lead candidate DT2216 described as a compound that selectively degrades BCL-XL in cancer cells. The evidence strongly supports classifying the company’s therapeutic modality as small molecule. Among the allowed idea roots, modulating is the best fit because the company is pharmacologically altering a disease-relevant protein survival pathway through targeted degradation rather than using editing, replacement, or reprogramming; a weaker, indirect clearing signal appears only through founder-associated senescent-cell elimination research rather than the company’s core program itself.","classification_confidence":82,"funding_stage":null,"total_funding_usd":"17400000","latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"operating","operating_status_reason":null,"operating_status_rationale":null,"operating_status_confidence":null,"business_model":"drug_developer","business_model_rationale":"The evidence consistently describes Dialectic Therapeutics as a biotechnology company developing its own anti-cancer drug candidates, especially DT2216, and advancing that candidate through IND clearance, Phase 1/2 clinical trials, first-patient dosing, and FDA designations. Although the company references its APTaD technology platform, the supplied evidence centers on therapeutic product development rather than primarily offering a platform to third parties.","business_model_confidence":94,"ip_market_structure":"On the evidence provided, the organization appears to have a narrow but real self-held formulation position and no clearly demonstrated third-party blocking corridor. The meaningful assets are the pending Dialectic Therapeutics filings around “Small molecule formulation,” specifically EP4243775A1 and CA3196536A1. Both point to the same core subject matter: small-molecule nanoemulsion formulation, with repeated emphasis on formulation components such as medium chain triglycerides and related excipients. Those filings suggest the organization is trying to protect a delivery/formulation approach rather than a broad composition-of-matter estate over the active molecule itself. The listed US20140243147A1 CVT patent appears facially unrelated to pharmaceutical formulation and should not be treated as part of the relevant corridor. The freedom-to-operate posture therefore looks mixed but not obviously boxed in by the evidence supplied. Positive point: there is no concrete third-party field patent here that claims the formulation space and creates a visible blocking wall. Negative point: the organization’s own assets are still shown as pending, so they do not yet establish an issued exclusionary moat on this record, and pending status also means claim scope is unsettled. In practice, that leaves the company with some defensive signaling and future optionality, but only a modest demonstrated FTO advantage from this evidence alone. Design-around feasibility looks reasonably high. Because the apparent protected concept is formulation-centric, competitors could likely explore alternate excipient systems, carrier oils, surfactant packages, emulsion architecture, particle-size regimes, or non-nanoemulsion dosage forms while still pursuing the same small molecule. Conversely, if third parties later emerge with nearby formulation claims, this is also the kind of space where technical redesign is often more feasible than in core molecule patents. On licensability versus strategic closure, nothing here points to a tightly closed thicket controlled by a dominant outside owner. If blocking rights do emerge, they are more likely to be licensable formulation assets than strategically unapproachable platform monopolies, because formulation patents are often narrower and commercially negotiable. The main caveat is evidentiary: this conclusion is constrained by the absence of actual third-party corridor patents in the material provided.","is_public":true,"disqualified":true,"disqualified_reason":"This is an oncology biotech, not a longevity company. Dialectic Therapeutics develops targeted anti-cancer drugs, specifically the BCL-XL degrader DT2216 in Phase 1/2 trials for fibrolamellar carcinoma and platinum-resistant ovarian cancer, and the evidence points to cancer cell apoptosis control rather than aging biology or interventions aimed at slowing, reversing, or measuring aging.","disqualified_at":"2026-07-03T01:18:21.453Z","research_status":"ready","is_editors_choice":false,"overall_score":38.17,"overall_score_computed_at":"2026-07-03 01:18:06.877804+00","pipeline_version":"0.24.1","proximity_score":"60.00","proximity_band":"translational","proximity_rationale":"Derived deterministically from 2 extracted project(s). Most-advanced status: phase 1. Band: translational. Modifiers: +5 modality breadth (2 modalities at max band). Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":7,"social_links":null,"careers_page_url":null,"pipeline_page_url":"https://dtsciences.com/","external_registry_ids":{"sec":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-26T18:07:37.633Z\",\"rationale\":\"sec returned 0 candidates for \\\"Dialectic Therapeutics\\\".\",\"officers_matched\":[],\"candidate_count\":0}","opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-26T16:03:15.946Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"Dialectic Therapeutics\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-06-03 01:09:12.049627+00","updated_at":"2026-09-23 00:34:41.984992+00","scores":{"ambition":7,"publicity":4,"media_reach":4,"reliability":7,"falsifiability":9,"claim_integrity":8.57,"collaborativity":5,"context_validity":7,"pipeline_quality":5,"explanatory_power":6.5,"results_alignment":7,"scandal_integrity":8,"publication_quality":7,"premise_plausibility":8,"implementation_fidelity":8,"independent_replication":3},"public_records_count":124,"publications_count":6,"projects_count":2,"funding_rounds_count":2,"clinical_trials_count":1,"publication_status":"published_disqualified","public_url":"https://eternalsearch.net/companies/KoPT9feb","api_url":"https://eternalsearch.net/api/v1/companies/KoPT9feb"},{"id":"09286eba-f827-4609-9941-3c483f0d18b0","public_id":"5PRzdGKz","name":"Mediwhale","canonical_name":"Mediwhale","aliases":["Mediwhale Inc."],"one_liner":"Mediwhale develops regulatory-approved retinal imaging AI for cardiovascular risk assessment and cardiometabolic disease prevention.","description":"Mediwhale leverages retinal imaging and AI to support early detection, personalized risk assessment, and preventive care for cardiometabolic disease. Its Dr.Noon CVD product is described as a retina-based AI risk prediction solution for future cardiovascular disease risk. The company says its AI products have regulatory approval and reimbursement in Korea and are available in hospitals in Dubai, the UK, and Italy.","website":"https://mediwhale.com","canonical_website":"https://mediwhale.com/","logo_url":"https://mediwhale.com/wp-content/uploads/2025/07/%EB%A1%9C%EA%B3%A0-1024x660.jpg","headquarters":"Seoul, South Korea","hq_country_code":"KR","founding_year":null,"primary_approach":"retinal imaging, AI, cardiovascular risk assessment","primary_field_slug":"diagnostics","field_slugs":["diagnostics","software_data"],"primary_idea_root_slug":null,"idea_root_slugs":[],"primary_modality_slug":null,"modality_slugs":[],"classification_rationale":"Mediwhale is a non-therapeutic digital health company focused on AI-based diagnostics from retinal imaging. Its products analyze retinal or fundus images to detect eye disease and estimate cardiometabolic or cardiovascular risk, positioning the company primarily in diagnostics and secondarily in software/data rather than in longevity therapeutics or intervention development.","classification_confidence":95,"funding_stage":"series_c_plus","total_funding_usd":null,"latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"operating","operating_status_reason":null,"operating_status_rationale":null,"operating_status_confidence":null,"business_model":"diagnostics","business_model_rationale":"The strongest evidence consistently describes Mediwhale as developing AI-based retinal imaging products used to assess cardiovascular risk and detect disease. Its offerings are framed as diagnostic solutions used in care settings rather than therapeutics, delivery technology, or a general-purpose software platform.","business_model_confidence":94,"ip_market_structure":"Based only on the supplied evidence, the organization appears to have a very early and still-pending proprietary position centered on WO2025230312A1, assigned to Mediwhale Inc. That application is framed as a “method and apparatus for supporting subject-customized prescription based on systemic disease risk,” with classifications pointing to medical informatics and patient-data processing rather than a narrow hardware claim set. In corridor terms, this suggests Mediwhale is trying to stake out the downstream clinical decision-support layer: using systemic disease risk outputs to support individualized prescribing or treatment recommendations. The more immediate blocking IP in the field appears to sit elsewhere. EP2890983B1, held by Queens University of Belfast and University of Maryland entities, is active and granted, and it specifically concerns detecting drusen and predicting age-related macular degeneration. That matters because it appears to claim disease-detection/prediction subject matter tied to retinal pathology, which could constrain anyone building ophthalmic risk models if their workflow depends on drusen-based AMD prediction. JP5672058B2 also looks relevant at the technical substrate level: it concerns spectral data analysis and in vivo substance detection, which suggests a possible instrumentation or signal-processing blocker if the organization’s product stack relies on spectral analysis rather than purely software-layer inference. The freedom-to-operate posture therefore looks mixed. Mediwhale has some offensive IP around personalized prescription support, but because its own filing is pending, recent, and apparently focused on a later-stage decision-support use case, it does not by itself neutralize earlier third-party rights around biomarker detection, retinal feature interpretation, or measurement pipelines. FTO is stronger if the organization operates mainly at the software recommendation layer using independently sourced risk inputs; it is weaker if the product itself detects drusen, predicts AMD from retinal findings, or depends on protected spectral-analysis methods. Design-around looks plausible. The cleanest path would be to avoid claimed detection modalities and feature sets, especially drusen-specific AMD prediction and spectral-analysis implementations, and instead rely on alternative imaging biomarkers, different model inputs, or noninfringing data-processing pipelines. By contrast, if the commercial value proposition requires those exact diagnostic primitives, design-around becomes materially harder. On licensability, EP2890983B1 looks more likely licensable than strategically closed because the assignees are academic institutions, which often license rather than vertically commercialize. JP5672058B2 is harder to read from the excerpt, but instrumentation-style patents are often enforceable and sometimes less flexible commercially if tied to a platform supplier. Overall, the likely blockers do not look impossible to ","is_public":true,"disqualified":true,"disqualified_reason":"Mediwhale is a retinal imaging AI company for cardiovascular and cardiometabolic risk prediction. That is a diagnostics and risk-assessment business, not an aging-biology company and not a developer of interventions that target the biology of aging.","disqualified_at":"2026-06-30T06:06:36.616Z","research_status":"ready","is_editors_choice":false,"overall_score":38.04,"overall_score_computed_at":"2026-06-30 06:06:00.835642+00","pipeline_version":"0.24.1","proximity_score":"92.00","proximity_band":"near_readout","proximity_rationale":"Derived deterministically from 4 extracted project(s). Most-advanced status: approved. Band: near_readout. Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":4,"social_links":null,"careers_page_url":null,"pipeline_page_url":null,"external_registry_ids":{"opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-25T19:45:00.178Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"Mediwhale\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-06-03 01:09:12.754782+00","updated_at":"2026-07-20 05:49:57.95405+00","scores":{"ambition":5.2,"publicity":5,"media_reach":5,"reliability":7,"falsifiability":8.6,"claim_integrity":8.82,"collaborativity":6,"context_validity":6,"pipeline_quality":6,"explanatory_power":6.4,"results_alignment":7,"scandal_integrity":5,"publication_quality":6,"premise_plausibility":7.6,"implementation_fidelity":8,"independent_replication":5},"public_records_count":162,"publications_count":22,"projects_count":4,"funding_rounds_count":1,"clinical_trials_count":0,"publication_status":"published_disqualified","public_url":"https://eternalsearch.net/companies/5PRzdGKz","api_url":"https://eternalsearch.net/api/v1/companies/5PRzdGKz"},{"id":"9836e102-46df-4a74-9ac2-bdc38efab64e","public_id":"RFCNkNu4","name":"Elixirgen Therapeutics","canonical_name":"Elixirgen Therapeutics","aliases":["Elixirgen Therapeutics, Inc."],"one_liner":"Develops therapies for rare diseases and aging-associated diseases using ZSCAN4 telomere technology and Bobcat mRNA.","description":"Elixirgen Therapeutics develops therapies for rare diseases and aging-associated diseases using ZSCAN4 and Bobcat mRNA technologies. Its ZSCAN4 program is in a Phase I/II clinical trial for Telomere Biology Disorders using autologous cell therapy. Its Bobcat mRNA platform is designed to deliver large payloads, including full-length dystrophin for Duchenne muscular dystrophy.","website":"https://elixirgentx.com","canonical_website":"https://elixirgentx.com/","logo_url":"https://image.pitchbook.com/gAHeBObxKzXCluiQiaQ8gEA58Ga1739418768359_200x200","headquarters":"Baltimore, Maryland, United States","hq_country_code":"US","founding_year":2017,"primary_approach":"ZSCAN4, telomere elongation, mRNA","primary_field_slug":"repairing","field_slugs":["repairing","delivery","replacement","modulating"],"primary_idea_root_slug":"repairing","idea_root_slugs":["repairing","delivering","replacing","modulating"],"primary_modality_slug":"cell_therapy","modality_slugs":["cell_therapy","gene_therapy","rna_therapeutic"],"classification_rationale":"Elixirgen Therapeutics is a therapeutic biotech developing rare-disease and aging-associated programs centered on a ZSCAN4 telomere-restoration platform and a Bobcat mRNA platform. Its clearest aging-relevant program is EXG-34217 for telomere biology disorders with bone marrow failure, using autologous CD34+ hematopoietic stem cells treated ex vivo with ZSCAN4 to elongate telomeres, which supports a primary repairing idea root and a primary cell-therapy modality, with additional gene-therapy characterization in company materials and press coverage. Separately, the company describes Bobcat mRNA as a platform for delivering large payloads, supporting RNA-therapeutic capability and a secondary delivering method root.","classification_confidence":86,"funding_stage":null,"total_funding_usd":null,"latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"operating","operating_status_reason":null,"operating_status_rationale":null,"operating_status_confidence":null,"business_model":"multi","business_model_rationale":"The strongest evidence supports both a drug developer model and a platform model. Elixirgen says it is advancing proprietary controllable self-replicating RNA technology and also developing therapies across multiple disease areas. Additional official and company-linked evidence shows a named lead candidate, EXG-34217, in a Phase 1/2 trial, indicating active therapeutic development alongside core platform technology.","business_model_confidence":91,"ip_market_structure":"On the face of this evidence, the organization appears to be Elixirgen or an Elixirgen affiliate, and its core owned IP is concentrated in two areas. First, US12098392B2, assigned to Elixirgen Scientific, covers compositions and methods for differentiating human pluripotent stem cells into desired cell types and runs active to November 12, 2038. That looks like the strongest estate for a cell-engineering or disease-modeling platform because it can protect both media/composition choices and workflow-level differentiation methods. Second, the ZSCAN4 family, evidenced here by US20160030514A1 and its granted counterpart US10335456B2, appears to cover use of ZSCAN4 for rejuvenating human cells. That is narrower but potentially important if the company’s value proposition relies on cell rejuvenation, telomere biology, or reprogramming-related effects. The blocking-IP picture is thinner than the prompt suggests because the supplied evidence does not clearly show a robust third-party corridor. The one obvious non-Elixirgen asset is PT3079715T, which names Targovax as original assignee and covers a peptide mixture. Based on title and subject matter, that looks more like an oncology/vaccine formulation right than a direct blocker to Elixirgen’s stem-cell differentiation or ZSCAN4 work, unless the product specifically depends on peptide-mixture immunotherapy. WO2025212951A1, relating to protein expression in synthetic mRNA, could signal a neighboring corridor if Elixirgen uses synthetic mRNA delivery to drive differentiation or rejuvenation, but the excerpt does not identify the assignee, claim scope, or status clearly enough to call it a definitive blocker. So the freedom-to-operate posture appears mixed but not boxed in. If Elixirgen stays close to its own differentiation protocols and ZSCAN4-based rejuvenation methods, it seems to have meaningful proprietary cover. The main FTO risk would arise at the implementation layer: synthetic mRNA expression systems, delivery constructs, or specific reagent compositions that may sit outside these owned claims. Design-around therefore looks feasible in principle, especially by changing delivery modality, factor combinations, or manufacturing workflow, but less feasible if a commercial product requires a very specific synthetic-mRNA expression method owned elsewhere. From this evidence alone, the likely blockers do not look strategically closed so much as incomplete or adjacent; the only clearly identified third-party patent appears licensable if ever relevant, but it does not read as the central obstacle.","is_public":true,"disqualified":false,"disqualified_reason":null,"disqualified_at":null,"research_status":"ready","is_editors_choice":false,"overall_score":37.85,"overall_score_computed_at":"2026-07-03 03:51:49.450404+00","pipeline_version":"0.24.1","proximity_score":"65.00","proximity_band":"translational","proximity_rationale":"Derived deterministically from 5 extracted project(s). Most-advanced status: phase 2. Band: translational. Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":3,"social_links":null,"careers_page_url":null,"pipeline_page_url":"https://elixirgentx.com/#science","external_registry_ids":{"sec":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-26T18:32:09.765Z\",\"rationale\":\"sec returned 0 candidates for \\\"Elixirgen Therapeutics\\\".\",\"officers_matched\":[],\"candidate_count\":0}","opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-26T15:31:46.985Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"Elixirgen Therapeutics\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-06-03 01:09:12.086004+00","updated_at":"2026-07-20 02:34:10.101977+00","scores":{"ambition":7.75,"publicity":4,"media_reach":4,"reliability":6,"falsifiability":8.25,"claim_integrity":10,"collaborativity":7,"context_validity":6,"pipeline_quality":7,"explanatory_power":4.75,"results_alignment":6,"scandal_integrity":8,"publication_quality":7,"premise_plausibility":7,"implementation_fidelity":8,"independent_replication":3},"public_records_count":113,"publications_count":5,"projects_count":5,"funding_rounds_count":0,"clinical_trials_count":2,"publication_status":"published","public_url":"https://eternalsearch.net/companies/RFCNkNu4","api_url":"https://eternalsearch.net/api/v1/companies/RFCNkNu4"},{"id":"4eea6a78-bc17-469c-a08c-44d0acc29a24","public_id":"jtPW2zlk","name":"HCW Biologics","canonical_name":"HCW Biologics","aliases":["HCW Biologics Inc.","HCWB"],"one_liner":"Clinical-stage biopharmaceutical company developing fusion immunotherapies for autoimmune diseases, cancer and senescence-associated dysplasia.","description":"HCW Biologics is a clinical-stage biopharmaceutical company developing first-in-class fusion immunotherapies for autoimmune diseases, cancer and senescence-associated dysplasia. Its approach is to rebalance or rejuvenate immune cells to remove disease cells or reduce senescent cells linked to chronic inflammation. The company uses proprietary TOBI and TRBC platforms to create multi-domain cytokine-based and immune-cell-targeting fusion molecules.","website":"https://hcwbiologics.com","canonical_website":"https://hcwbiologics.com/","logo_url":"https://www.marketbeat.com/logos/hcw-biologics-inc-logo.png?v=20210804085138","headquarters":"Miami, Florida, United States","hq_country_code":"US","founding_year":null,"primary_approach":"fusion immunotherapeutics, cytokine platforms, immune-cell rebalancing","primary_field_slug":"modulating","field_slugs":["modulating","clearing"],"primary_idea_root_slug":"modulating","idea_root_slugs":["modulating","clearing"],"primary_modality_slug":"immunotherapy","modality_slugs":["immunotherapy","biologic","cell_therapy"],"classification_rationale":"HCW Biologics is a clinical-stage biopharmaceutical company developing immune-focused therapeutics for cancer, autoimmune disease, inflammaging, and age-related disease. Across the evidence, its core approach is immunotherapy built from biologic fusion molecules, including multi-domain cytokine constructs, checkpoint-inhibitor formats, T-cell engagers, and some cell-therapy work. The aging-mechanism signal is primarily modulating because the company repeatedly frames its strategy around reducing chronic inflammation, rebalancing or rejuvenating immune cells, and expanding regulatory T cells; there is also secondary clearing evidence where its programs are described as reducing senescent cells.","classification_confidence":89,"funding_stage":"public","total_funding_usd":"60000000","latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"operating","operating_status_reason":null,"operating_status_rationale":null,"operating_status_confidence":null,"business_model":"drug_developer","business_model_rationale":"The strongest and most consistent evidence describes HCW Biologics as a clinical-stage biopharmaceutical company advancing its own therapeutic candidates through preclinical, IND-enabling, and human clinical development. Multiple sources reference named drug candidates and trials, including HCW9302, HCW9218, HCW11-006, and immune checkpoint inhibitor programs. Although HCW Biologics also describes TOBI and TRBC as proprietary platforms, the evidence frames them primarily as internal discovery and development technologies supporting the company's therapeutics pipeline rather than as a standalone platform business.","business_model_confidence":96,"ip_market_structure":"I’m pulling the repo guidance first so the analysis stays aligned with the project’s required workflow, then I’ll synthesize the patent corridor strictly from the evidence you provided. The home snapshot here is a subdirectory, so I’m locating the actual repo root and the canonical instruction files before finishing the analysis. I have the repo rules. I’m checking the latest session note now in case there’s any patent-analysis formatting or evidence-handling context that affects the final writeup. On the evidence provided, the organization appears to control a meaningful but uneven internal patent estate rather than face a clearly mapped third-party blockade. The strongest owned asset is `US11401324B2`, a granted patent on single-chain chimeric polypeptides, which likely matters most because grants generally give the cleanest exclusion leverage. Around that, `CA3181417A1` is a pending HCW Biologics application on anti-CD26 proteins, and `WO2023201310A1` is a PCT-family filing on multi-chain chimeric polypeptides for circadian clock gene disorders, although the record shown marks the WO application as ceased. `WO2019046313A1` covers IL-15-based fusions to IL-7 and IL-21, but the evidence shows it under Altor Bioscience and also as ceased at the WO level, so it helps as technical lineage evidence more than as a clearly current blocking right on this record. The freedom-to-operate posture therefore looks mixed but not obviously boxed in. For the organization’s own disclosed architectures, there is at least some self-owned coverage, especially around chimeric polypeptide formats and specific immune/cytokine constructs. But the corridor analysis is incomplete because no field-corridor patents held by others are actually included in the evidence block, even though the prompt anticipates them. That means there is no concrete basis here to identify an external blocker, a dominant competitor assignee, or a must-license estate. So the right conclusion is not “clear FTO,” but rather “no demonstrated third-party block on this record.” Design-around feasibility looks moderate. The portfolio appears modality-specific: anti-CD26 targeting, IL-15/IL-7/IL-21 fusion designs, and circadian-disorder multi-chain constructs. That usually leaves room to alter target, chain architecture, cytokine combination, valency, or therapeutic indication while staying near the same broad product thesis. Conversely, exact lead constructs that sit close to the granted single-chain claims could be harder to move without performance tradeoffs. As to whether blockers look licensable or strategically closed, the evidence does not show any actual third-party blocking patents, so there is no concrete licensor or closed fortress visible here. The corridor looks more like an internally staked platform with patchy prosecution status than a field already locked by named outside owners.","is_public":true,"disqualified":false,"disqualified_reason":null,"disqualified_at":null,"research_status":"ready","is_editors_choice":false,"overall_score":37.77,"overall_score_computed_at":"2026-06-30 08:27:25.455622+00","pipeline_version":"0.24.1","proximity_score":"65.00","proximity_band":"translational","proximity_rationale":"Derived deterministically from 15 extracted project(s). Most-advanced status: phase 1. Band: translational. Modifiers: +5 depth (3 programs at phase_1); +5 modality breadth (2 modalities at max band). Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":2,"social_links":null,"careers_page_url":"https://hcwbiologics.com/careers/","pipeline_page_url":"https://hcwbiologics.com/pipeline/","external_registry_ids":{"sec":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-14T03:33:12.289Z\",\"rationale\":\"sec returned 0 candidates for \\\"HCW Biologics\\\".\",\"officers_matched\":[],\"candidate_count\":0}","opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-14T03:24:14.571Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"HCW Biologics\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-06-03 01:09:12.346035+00","updated_at":"2026-09-23 00:41:43.679068+00","scores":{"ambition":7.56,"publicity":3,"media_reach":3,"reliability":6,"falsifiability":8.67,"claim_integrity":9.47,"collaborativity":7,"context_validity":5,"pipeline_quality":7,"explanatory_power":6.49,"results_alignment":7,"scandal_integrity":8,"publication_quality":7,"premise_plausibility":7.67,"implementation_fidelity":8,"independent_replication":3},"public_records_count":83,"publications_count":16,"projects_count":15,"funding_rounds_count":2,"clinical_trials_count":1,"publication_status":"published","public_url":"https://eternalsearch.net/companies/jtPW2zlk","api_url":"https://eternalsearch.net/api/v1/companies/jtPW2zlk"},{"id":"7880b8a4-781a-4d85-8127-b8648d0a80d1","public_id":"gnMmKjof","name":"Yap Therapeutics","canonical_name":"Medley Therapeutics","aliases":["YAP Therapeutics","Medley Therapeutics, Inc.","YAP Therapeutics, Inc."],"one_liner":"Medley Therapeutics develops regenerative genetic medicines and advanced biologics for chronic and life-threatening diseases.","description":"Medley Therapeutics, formerly known as YAP Therapeutics, describes a dual-platform approach using genetic medicine and advanced biologics. Its genetic medicine platform aims to activate innate regenerative pathways, including cardiac regeneration through Hippo/YAP signaling modulation. Its advanced biologics platform targets fibrosis and solid tumor cancers.","website":"https://medleytx.com","canonical_website":"https://medleytx.com/","logo_url":"https://mms.businesswire.com/media/20250108168669/en/2346892/5/yap_id_final_r1.2_outlined_transparent_no_tag_080723.jpg","headquarters":"United States","hq_country_code":"US","founding_year":null,"primary_approach":"AAV gene therapy, Hippo/YAP modulation, advanced biologics","primary_field_slug":"repairing","field_slugs":["repairing","modulating"],"primary_idea_root_slug":"repairing","idea_root_slugs":["repairing","modulating"],"primary_modality_slug":"gene_therapy","modality_slugs":["gene_therapy","biologic"],"classification_rationale":"Medley Therapeutics is a therapeutic biotech developing regenerative genetic medicines and advanced biologics, with the clearest evidence pointing to an AAV gene therapy program for heart regeneration. Its platform is described as activating innate regenerative pathways and promoting cardiac regeneration and cardiomyocyte renewal after myocardial infarction or heart failure through Hippo/YAP signaling modulation, which supports repairing as the primary idea root and modulating as a secondary mechanism. There is no evidence in the provided chunks for non-therapeutic offering fields.","classification_confidence":84,"funding_stage":null,"total_funding_usd":null,"latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"operating","operating_status_reason":null,"operating_status_rationale":null,"operating_status_confidence":null,"business_model":"drug_developer","business_model_rationale":"The strongest evidence indicates Medley Therapeutics is advancing therapeutic products rather than primarily selling tools or services. The company website describes a dual-platform approach in genetic medicine and advanced biologics, while external sources report product pipeline activity and clinical development, including dosing in a Phase 1 trial. Together this supports classifying it as a drug developer.","business_model_confidence":89,"ip_market_structure":"The organization appears to have a narrow but relevant proprietary position through its own pending application, `CA3259889A1`, filed by Medley Therapeutics with Baylor College of Medicine and Texas Medical Center, covering improved cardiac function via Hippo-signaling gene therapy. On the face of the evidence, that looks like an application directed to a specific therapeutic concept in cardiac gene therapy rather than a broad platform estate. Its status matters: it is still pending, so it does not yet provide issued-claim leverage and does not itself solve freedom-to-operate risk. The more important corridor issue is that the surrounding AAV gene-therapy landscape appears to be populated by third-party holders with granted or active rights. The clearest examples in the record are `AU2020208933A1/AU2020208933B2`, associated with Institut Pasteur, CNRS, and Inserm, covering AAV-mediated restoration of otoferlin, and `US10383922B2`, held by University of Pennsylvania and University of Florida interests, covering AAV-mediated RPGR retinal gene therapy and remaining active to an anticipated 2033 expiration. `WO2024197073A2` also signals additional recent AAV-mediated gene-therapy filings by others, though the excerpt is too thin to assess scope. These patents are disease-specific on their face, which cuts both ways: they are not obvious direct blockers to Hippo-pathway cardiac therapy unless their claims reach vector design, promoter architecture, dosing constructs, or broader AAV delivery mechanics that overlap the company’s implementation. So the freedom-to-operate posture looks mixed. Based only on this evidence, Medley appears to own differentiated cardiac-application IP, but not a visible foundational AAV platform estate. That usually means its core biology may be protectable while its productization path could still run through third-party vector, construct, or delivery claims. The immediate blockers shown here do not read like universal AAV patents; they look more indication-anchored, which suggests some room to operate if the company’s cardiac construct, payload, capsid, and administration choices are distinct. Design-around therefore looks plausible. If the third-party claims are tied tightly to otoferlin, RPGR, retinal use, or dual-vector auditory restoration, a cardiac Hippo-signaling program should have meaningful opportunities to differentiate by transgene, tissue targeting, promoter selection, vector configuration, and route of administration. As to licensability, the named holders are largely academic or research institutions, which often do license, but they can still be strategically selective, especially where assets are central to partnered programs. Overall, the corridor looks manageable but not clean: likely licensable in principle, yet potentially dependent on whether any unseen claim scope reaches general AAV implementation rather than disease-specific embodiments.","is_public":true,"disqualified":false,"disqualified_reason":null,"disqualified_at":null,"research_status":"ready","is_editors_choice":false,"overall_score":37.68,"overall_score_computed_at":"2026-06-28 08:11:06.122388+00","pipeline_version":"0.24.1","proximity_score":"35.00","proximity_band":"early_mechanism","proximity_rationale":"Derived deterministically from 4 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":3,"social_links":{"github":null,"twitter":"https://x.com/Medley_Tx","youtube":null,"facebook":null,"instagram":"https://www.instagram.com/medley_therapeutics/","linkedin_company":"https://www.linkedin.com/company/medleytx/"},"careers_page_url":null,"pipeline_page_url":"https://www.medleytx.com/technology","external_registry_ids":{"sec":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-23T20:48:38.046Z\",\"rationale\":\"sec returned 0 candidates for \\\"Medley Therapeutics\\\".\",\"officers_matched\":[],\"candidate_count\":0}","opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-23T16:47:38.393Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"Medley Therapeutics\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-06-03 01:09:13.802311+00","updated_at":"2026-07-20 07:33:31.480365+00","scores":{"ambition":7.7,"publicity":4,"media_reach":4,"reliability":6,"falsifiability":7.3,"claim_integrity":10,"collaborativity":6,"context_validity":6,"pipeline_quality":5,"explanatory_power":5.25,"results_alignment":7,"scandal_integrity":8,"publication_quality":7,"premise_plausibility":6.75,"implementation_fidelity":7,"independent_replication":3},"public_records_count":75,"publications_count":2,"projects_count":4,"funding_rounds_count":0,"clinical_trials_count":1,"publication_status":"published","public_url":"https://eternalsearch.net/companies/gnMmKjof","api_url":"https://eternalsearch.net/api/v1/companies/gnMmKjof"},{"id":"323c8111-b6c1-4cf8-92aa-69b6abf1b4f4","public_id":"rlfYlfgu","name":"Casma Therapeutics","canonical_name":"Casma Therapeutics","aliases":["Casma Therapeutics, Inc","Casma"],"one_liner":"Casma Therapeutics develops cellular degradation approaches based on autophagy for drug discovery and development.","description":"Casma Therapeutics is developing novel cellular degradation approaches based on the autophagy pathway. Its PHLYT platform initiates target-specific autophagic degradation of disease targets independent of size or complexity. Casma aims to reprogram autophagy to eliminate diseases that current drugs have failed to target, including oncology, inflammation, neurodegeneration, and metabolic disorders.","website":"https://casmatx.com","canonical_website":"https://casmatx.com/","logo_url":"https://images.crunchbase.com/image/upload/c_pad,h_256,w_256,f_auto,q_auto:eco,dpr_1/tr0q1ptzedtzkvgwuyqe?ik-sanitizeSvg=true","headquarters":"Boston, Massachusetts, United States","hq_country_code":"US","founding_year":null,"primary_approach":"autophagy, targeted degradation, PHLYT","primary_field_slug":"clearing","field_slugs":["clearing","modulating"],"primary_idea_root_slug":"clearing","idea_root_slugs":["clearing","modulating"],"primary_modality_slug":"small_molecule","modality_slugs":["small_molecule"],"classification_rationale":"Casma Therapeutics is a therapeutic biotech focused on autophagy and lysosomal biology, with a platform aimed at target-specific autophagic degradation and a lead TRPML1 agonist program for lysosomal dysfunction. The strongest classification is clearing because the company repeatedly describes its science in terms of autophagy-driven degradation and clearance of cellular waste. There is also secondary evidence for modulating because its lead program pharmacologically activates TRPML1, but the company’s core thesis is more directly about autophagy-enabled cellular clearance. The evidenced therapeutic modality is small_molecule, supported by references to TRPML1 agonist programs and an oral lead candidate, CSM-101.","classification_confidence":89,"funding_stage":"series_c_plus","total_funding_usd":"104500000","latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"operating","operating_status_reason":null,"operating_status_rationale":null,"operating_status_confidence":null,"business_model":"multi","business_model_rationale":"The merged evidence supports both drug development and platform characteristics. Casma is repeatedly described as developing medicines and advancing a named therapeutic candidate, including \"Casma’s lead program, CSM-101\" and plans for IND-enabling work, which supports drug_developer. Separate company materials also explicitly describe a \"PHLYT platform\" and \"Platform & pipeline,\" which supports a platform model. Together, the best fit is multi.","business_model_confidence":92,"ip_market_structure":"On the evidence provided, the organization appears to have built a fairly coherent TRPML-centered patent position around three layers: small-molecule modulators, biomarker readouts, and pathway-level activation methods. The most important held assets are the two “TRPML modulators” families, WO2021127337A1 and WO2022032073A2, both assigned to Casma Therapeutics and both framed broadly around small-molecule modulation of TRPML targets for autophagy-related disease use. Those likely matter most because composition-of-matter style claims, if they survive nationally, are usually the hardest for competitors to work around. WO2022015810A2 adds a separate biomarker layer for TRPML1 activation, but that asset is co-filed with University of Washington and Washington University in St. Louis, so control may be shared rather than exclusively internal. WO2022031469A1 suggests a further position around TFEB activation and lysosomal biogenesis, expanding beyond a single assay or chemotype into adjacent mechanism-of-action territory. The freedom-to-operate picture is only partially knowable from this record because no third-party field-corridor patents are actually included in the evidence set. Based strictly on what is here, there is no identified external blocker that can be mapped against the organization’s programs. What can be said is that the organization has attempted to fence its own corridor broadly enough that a later entrant working on TRPML agonists or related lysosomal-autophagy chemistry could face pressure from Casma’s filings. But that is not the same as proving Casma itself has clean FTO, because upstream third-party patents on TRPML targets, screening methods, disease applications, or overlapping chemotypes may still exist outside this record. Design-around looks moderately feasible at the platform level but potentially harder at the lead-compound level. A competitor could try non-overlapping chemotypes, different TRPML isoform selectivity, non-small-molecule modalities, or adjacent lysosomal/autophagy mechanisms that avoid the claimed biomarker or TFEB methods. If Casma’s claims end up broad and well-supported, however, direct design-arounds inside TRPML small molecules may be constrained. As to licensability versus strategic closure, the co-owned biomarker patent looks more naturally licensable because university participation often correlates with licensing pathways. The core small-molecule TRPML modulator families look more strategically closed: they appear central to the company’s therapeutic thesis and therefore more likely to be defended as exclusionary program IP than broadly licensed out.","is_public":true,"disqualified":false,"disqualified_reason":null,"disqualified_at":null,"research_status":"ready","is_editors_choice":false,"overall_score":37.47,"overall_score_computed_at":"2026-06-29 17:35:06.483905+00","pipeline_version":"0.24.1","proximity_score":"15.00","proximity_band":"far","proximity_rationale":"Derived deterministically from 4 extracted project(s). Most-advanced status: undisclosed. Band: far. Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":4,"social_links":null,"careers_page_url":null,"pipeline_page_url":"https://www.casmatx.com/platform-pipeline/","external_registry_ids":{"sec":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-25T14:26:00.334Z\",\"rationale\":\"sec returned 0 candidates for \\\"Casma Therapeutics\\\".\",\"officers_matched\":[],\"candidate_count\":0}","opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-25T14:26:00.338Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"Casma Therapeutics\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-06-03 01:09:11.806737+00","updated_at":"2026-09-23 00:45:35.755124+00","scores":{"ambition":7,"publicity":5,"media_reach":4,"reliability":6,"falsifiability":8.5,"claim_integrity":10,"collaborativity":7,"context_validity":5,"pipeline_quality":6,"explanatory_power":6.5,"results_alignment":6,"scandal_integrity":8,"publication_quality":7,"premise_plausibility":7.5,"implementation_fidelity":7,"independent_replication":4},"public_records_count":128,"publications_count":4,"projects_count":4,"funding_rounds_count":2,"clinical_trials_count":0,"publication_status":"published","public_url":"https://eternalsearch.net/companies/rlfYlfgu","api_url":"https://eternalsearch.net/api/v1/companies/rlfYlfgu"},{"id":"da5e563a-bebe-4a57-813c-6bb5fbcc49df","public_id":"jq3FdjKS","name":"X-Therma","canonical_name":"X-Therma","aliases":["X-Therma, Inc.","X-Therma GmbH"],"one_liner":"X-Therma develops biopreservation platforms for organs, engineered tissues, and cell and gene therapies.","description":"X-Therma pioneers a biopreservation platform intended to transform living medicines into on-demand treatments. Its products include DMSO-free cryopreservation media and subzero preservation and transport systems for organs, tissues, cells, and biologics. The company says its XT-ViVo and TimeSeal solution stores kidneys for up to 5 days at high subzero temperatures for transplantation.","website":"https://x-therma.com","canonical_website":"https://x-therma.com/","logo_url":"https://image.pitchbook.com/JWxO8sLxYCxvhWArmLql2diXz6P1687763125465_200x200","headquarters":"Hercules, California, United States","hq_country_code":"US","founding_year":null,"primary_approach":"biopreservation, cryopreservation, antifreeze molecules","primary_field_slug":"research_tools","field_slugs":["research_tools","biobanking"],"primary_idea_root_slug":null,"idea_root_slugs":[],"primary_modality_slug":null,"modality_slugs":[],"classification_rationale":"X-Therma is a biopreservation and organ-preservation platform company focused on cryopreservation media and subzero preservation, storage, and transport systems for organs, tissues, cells, biologics, and living medicines. The evidence supports classifying it primarily as research tools and services infrastructure for regenerative medicine and cell/gene therapy workflows, with a secondary biobanking and storage signal because its products are explicitly positioned around preservation and cold-chain enablement rather than development of an aging therapeutic or intervention modality.","classification_confidence":88,"funding_stage":null,"total_funding_usd":"35400000","latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"operating","operating_status_reason":null,"operating_status_rationale":null,"operating_status_confidence":null,"business_model":"platform","business_model_rationale":"X-Therma is explicitly described as \"a biotechnology company developing a breakthrough platform for regenerative medicine and organ preservation\" and as a \"biopreservation platform\" company. The evidence centers on enabling preservation media and organ transport/preservation systems rather than a therapeutic drug pipeline, which best fits the platform business model.","business_model_confidence":95,"ip_market_structure":"Based only on the provided evidence, the organization appears to own the core patent position rather than face a clearly evidenced third-party blocking wall. The key held assets are US10694739B2, covering compositions and methods for reducing ice crystal formation, and the later peptoid-family filings US11608414B2/US20200239632A1 and EP3609906B1/EP3609906A4, which extend protection into novel peptoid polymers and methods of use in both the US and Europe. Those patents matter because they look like the technical center of gravity for the company’s platform: peptoid-based ice-control or cryopreservation-related compositions, with continuations or family extensions suggesting an effort to widen claim coverage over time. The packaging design registration EM151360910002S is peripheral and does not materially affect the core technical corridor. On freedom to operate, the evidence supports a relatively strong internal posture but does not establish a full clean FTO against the field, because no third-party corridor patents are actually provided here. On this record, there is no named outside patent holder that clearly blocks commercialization. That means the immediate IP story is ownership-led rather than encumbrance-led. Still, the breadth of the company’s own peptoid and anti-ice claims implies that anyone operating close to the same chemistry or use case could run into this organization’s rights, while the reverse question, whether the organization infringes others, cannot be answered definitively from this evidence alone. Design-around looks feasible in principle but probably not trivial. If a competitor can move away from the claimed peptoid structures, specific monomer choices, salts, or method-of-use combinations, there may be room to avoid the strongest claims. But because the family spans both composition and use, and because continuation activity is visible, simple substitution may not be enough if the product still relies on substantially similar peptoid-mediated ice-crystal suppression. As for licensability versus strategic closure, the evidence points more toward a strategically built proprietary estate than an obviously open licensing posture. Multiple jurisdictions, active status, long remaining terms, and continuation behavior usually signal a company intending to defend a platform. Nothing here shows refusal to license, but nothing suggests an open corridor either; if these patents are important to another party, they are more likely negotiation leverage than dormant paper.","is_public":true,"disqualified":true,"disqualified_reason":"This is not a longevity company. X-Therma builds preservation and transport systems for donor organs, tissues, and cell therapies, including kidney storage for transplantation and DMSO-free cryomedia, but the company is not developing interventions that target aging biology or engineering replacement organs for patients.","disqualified_at":"2026-07-01T01:10:12.015Z","research_status":"ready","is_editors_choice":false,"overall_score":37.45,"overall_score_computed_at":"2026-07-01 01:09:18.191454+00","pipeline_version":"0.24.1","proximity_score":"18.00","proximity_band":"far","proximity_rationale":"Derived deterministically from 3 extracted project(s). Most-advanced status: exploratory. Band: far. Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":4,"social_links":null,"careers_page_url":null,"pipeline_page_url":null,"external_registry_ids":{"sec":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-25T21:22:00.444Z\",\"rationale\":\"sec returned 0 candidates for \\\"X-Therma\\\".\",\"officers_matched\":[],\"candidate_count\":0}","opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-25T19:35:06.027Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"X-Therma\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-06-03 01:09:13.793265+00","updated_at":"2026-09-23 00:47:30.133494+00","scores":{"ambition":6.67,"publicity":5,"media_reach":4,"reliability":6,"falsifiability":9,"claim_integrity":7.5,"collaborativity":5,"context_validity":7,"pipeline_quality":5,"explanatory_power":6.33,"results_alignment":8,"scandal_integrity":8,"publication_quality":7,"premise_plausibility":7.67,"implementation_fidelity":8,"independent_replication":4},"public_records_count":118,"publications_count":2,"projects_count":3,"funding_rounds_count":2,"clinical_trials_count":0,"publication_status":"published_disqualified","public_url":"https://eternalsearch.net/companies/jq3FdjKS","api_url":"https://eternalsearch.net/api/v1/companies/jq3FdjKS"},{"id":"b57674f5-6d3e-4a10-b68f-af4acf8e909a","public_id":"oPRkkkwp","name":"Elevian","canonical_name":"Elevian","aliases":["Elevian, Inc."],"one_liner":"Elevian develops regenerative medicines, led by recombinant rGDF11 protein for post-stroke recovery.","description":"Elevian is developing medicines that promote regeneration and recovery, with a lead recombinant protein program for stroke treatment in the days following the event. Its rGDF11 program is described as promoting neovascularization, stimulating neurogenesis, and reducing inflammation in preclinical models of ischemic and hemorrhagic stroke. The company also describes broader preclinical work in aging-related cardiovascular, neurological, metabolic, pulmonary, renal, inflammatory, and skeletal muscle dysfunction.","website":"https://www.elevian.com/","canonical_website":"https://www.elevian.com/","logo_url":"https://static1.squarespace.com/static/5b7168984eddec1ee06cba31/t/5b992c6af950b779d552bd0b/1689173675226/","headquarters":"127 Western Avenue, Allston, MA, 02134, United States","hq_country_code":"US","founding_year":null,"primary_approach":"rGDF11, GDF11 pathway modulation, regenerative medicine","primary_field_slug":"replacement","field_slugs":["replacement","modulating","repairing"],"primary_idea_root_slug":"replacing","idea_root_slugs":["replacing","modulating","repairing"],"primary_modality_slug":"biologic","modality_slugs":["biologic"],"classification_rationale":"Elevian develops regenerative medicines based on recombinant GDF11 (rGDF11), a circulating factor associated with young-blood regenerative effects. Its lead biologic program aims to support stroke recovery by restoring regenerative capacity, including healthier vascularization, neurogenesis, and reduced inflammation; this aligns primarily with replacing via circulating-factor restoration, with signaling modulation and regenerative repair as secondary mechanisms.","classification_confidence":95,"funding_stage":null,"total_funding_usd":"60500000","latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"operating","operating_status_reason":null,"operating_status_rationale":null,"operating_status_confidence":null,"business_model":"drug_developer","business_model_rationale":"Elevian is consistently described as developing medicines and therapeutic candidates rather than primarily offering a platform, diagnostics, delivery technology, or services. Official and press sources describe a lead recombinant protein program for stroke recovery, broader age-related disease programs, IND planning, manufacturing scale-up, and Phase 1 clinical trial preparation, which fits a drug developer model.","business_model_confidence":97,"ip_market_structure":"Elevian appears to control the central disclosed stroke-treatment family: WO2021236824A1 and its pending EP counterpart EP4154001A4. The family claims methods and compositions using GDF11 molecules to treat stroke, with a May 2020 priority date; the PCT application is listed as ceased, but the evidence identifies national-stage activity including a pending European application. US11725033B2, titled “GDF11 variants and uses thereof,” also appears material to Elevian’s broader GDF11 platform, though the supplied excerpt does not establish its precise claim scope. The principal third-party concern in the supplied evidence is the Harvard/Brigham and Women’s neurogenesis-and-angiogenesis application, US20160220640A1. It describes increasing GDF11, including administration of GDF11 polypeptide or encoding nucleic acid, but is expressly listed as abandoned. On this record it is not an enforceable U.S. blocker, although its disclosed subject matter signals prior-art pressure against broad GDF11-for-regeneration claims. Elevian’s freedom-to-operate posture therefore looks comparatively favorable for a stroke-specific GDF11 program: it has a directly aligned, pending family and no clearly live third-party blocking patent identified in the evidence. That conclusion is necessarily narrow—patent status and claim scope would need jurisdiction-specific confirmation before a commercial FTO opinion. Design-around options appear plausible where a product avoids claimed GDF11 molecule definitions, dosing/regimen limitations, delivery routes, or stroke-treatment indications—for example, distinct engineered variants, alternative regenerative factors, or non-stroke indications. However, variant-based development may encounter Elevian’s own GDF11-variant patent estate. The apparent third-party blocker is not presently a licensing issue because the cited Harvard/Brigham application is abandoned. Elevian’s own pending family is strategically important, but the evidence does not reveal any licensing posture or whether it is open versus closed.","is_public":false,"disqualified":false,"disqualified_reason":null,"disqualified_at":null,"research_status":"ready","is_editors_choice":false,"overall_score":37.36,"overall_score_computed_at":"2026-09-22 23:42:47.132486+00","pipeline_version":"0.26.0","proximity_score":"35.00","proximity_band":"early_mechanism","proximity_rationale":"Derived deterministically from 2 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":5,"social_links":null,"careers_page_url":"https://www.elevian.com/careers","pipeline_page_url":null,"external_registry_ids":{"sec":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-02T23:15:02.070Z\",\"rationale\":\"sec returned 0 candidates for \\\"Elevian\\\".\",\"officers_matched\":[],\"candidate_count\":0}","opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-02T23:15:02.077Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"Elevian\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-05-05 14:59:22.574384+00","updated_at":"2026-09-23 00:48:41.569791+00","scores":{"ambition":7.38,"publicity":3,"media_reach":5,"reliability":6,"falsifiability":8,"claim_integrity":10,"collaborativity":5,"context_validity":4,"pipeline_quality":3,"explanatory_power":5.71,"results_alignment":7,"scandal_integrity":8,"publication_quality":7,"premise_plausibility":6.76,"implementation_fidelity":8,"independent_replication":4},"public_records_count":80,"publications_count":1,"projects_count":2,"funding_rounds_count":3,"clinical_trials_count":0,"publication_status":"evaluated_not_published","public_url":null,"api_url":"https://eternalsearch.net/api/v1/companies/oPRkkkwp"},{"id":"ffa8b5e4-6a65-46c3-8f04-574f960acadd","public_id":"5ef1ULJl","name":"Elastrin Therapeutics","canonical_name":"Elastrin Therapeutics","aliases":["Elastrin Therapeutics Inc.","Elastrin Therapeutics Ltd."],"one_liner":"Elastrin Therapeutics develops targeted therapies to reverse arterial calcification and address cardiovascular and age-related conditions.","description":"Elastrin Therapeutics is focused on reversing arterial hardening caused by calcification, a driver of heart attacks, stroke, peripheral artery disease, and limb loss. Its platform delivers therapy directly to sites of calcification without invasive surgery or lifelong drugs. The company states that the same targeting platform can address multiple cardiovascular and age-related conditions.","website":"https://elastrin.com","canonical_website":"https://elastrin.com/","logo_url":"https://static.wixstatic.com/media/d8f26c_34e6aa45018942c8b773e835f3292078~mv2.png/v1/fit/w_2500,h_1330,al_c/d8f26c_34e6aa45018942c8b773e835f3292078~mv2.png","headquarters":"Greenville, South Carolina, United States","hq_country_code":"US","founding_year":null,"primary_approach":"targeted calcification reversal, elastin targeting, bioengineering","primary_field_slug":"clearing","field_slugs":["clearing","delivery","repairing"],"primary_idea_root_slug":"clearing","idea_root_slugs":["clearing","delivering","repairing"],"primary_modality_slug":"nanoparticle_therapeutic","modality_slugs":["nanoparticle_therapeutic","small_molecule","biologic"],"classification_rationale":"Elastrin Therapeutics is a therapeutic biotech company developing targeted treatments for arterial calcification and related vascular tissue damage by directing EDTA-loaded nanoparticles to degraded elastin in calcified arteries. The strongest classification is clearing because the company explicitly emphasizes removing harmful calcification and calcium deposits that stiffen arteries, with delivering also relevant because the platform is built around localized targeting to calcification sites, and some secondary repairing signal from language about restoring damaged arteries and tissue. The best-supported modality is nanoparticle_therapeutic, with weaker secondary evidence for small-molecule cargo and an antibody-based biologic targeting component.","classification_confidence":89,"funding_stage":null,"total_funding_usd":"10000000","latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"operating","operating_status_reason":null,"operating_status_rationale":null,"operating_status_confidence":null,"business_model":"multi","business_model_rationale":"The evidence supports both a drug developer and platform company. BioSpace describes Elastrin Therapeutics Inc. as \"leveraging a platform to develop therapeutics,\" and the company website says it \"develops targeted therapies to reverse arterial calcification and address cardiovascular and age-related conditions.\"","business_model_confidence":91,"ip_market_structure":"On the evidence provided, the meaningful corridor IP is held by third parties rather than this organization. The clearest active blocker is Central South University’s Chinese patent family around stable, durable antioxidant nanodots for type 2 diabetes, published as CN116333302A and granted as CN116333302B, with a March 31, 2023 priority date and active status in China. That matters if the organization’s product concept depends on selenium or similar antioxidant nanodot formulations for diabetes use, because the claim theme appears to combine both composition and therapeutic application. A second corridor reference is Emory University’s CA2544235C on pyrophosphate-containing dialysates and related systems. That patent reached grant in Canada, but the provided record says it is expired for fee reasons as of October 27, 2024, so it looks more like prior art shaping the field than a current Canadian exclusion right. The Medtronic vascular application, US20100280595A1, concerns localized administration of calcium-chelating agents but is expressly listed as abandoned, so it is not a live U.S. blocker, though again it may signal prior-art boundaries around local anti-calcification delivery devices. The Russian patent RU2468368C1 suggests another third-party position around manganese-complex detection of atherosclerosis markers, but the excerpt is too thin to assess scope or status confidently. The freedom-to-operate posture therefore looks mixed but not broadly shut down on this record. In China, FTO appears meaningfully constrained if the organization is pursuing antioxidant nanodot therapeutics in diabetes, because that is the one clearly active, recent, and on-point asset. Outside that lane, the live blocking picture is thinner: one cited patent is expired, one abandoned, and one insufficiently described. Just as important, no held patents of the organization itself are included here, so there is no visible defensive estate or cross-licensing leverage in this evidence set. Design-around feasibility appears moderate to good. The most obvious route is to avoid the specific claimed chemistry and use-case combinations suggested by the Chinese patent: different particle composition, different stability mechanism, different indication, or a non-nanodot antioxidant architecture. Around the dialysate and calcium-chelation references, design-around pressure is lower because the Canadian right is expired and the U.S. application was abandoned. As for licensability, Central South University is the only holder that looks like a realistic present licensing counterparty. A university-owned therapeutic platform patent is often licensable in principle, though possibly territory-limited and application-specific. Medtronic’s abandoned filing does not present a licensing need, and Emory’s expired Canadian patent no longer looks strategically closed. On this evidence, the corridor is narrower than crowded, with one notable active Chinese choke point rather than a dense","is_public":true,"disqualified":false,"disqualified_reason":null,"disqualified_at":null,"research_status":"ready","is_editors_choice":false,"overall_score":37.17,"overall_score_computed_at":"2026-07-01 03:37:42.113475+00","pipeline_version":"0.24.1","proximity_score":"40.00","proximity_band":"early_mechanism","proximity_rationale":"Derived deterministically from 2 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Modifiers: +5 depth (2 programs at preclinical). Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":1,"social_links":null,"careers_page_url":null,"pipeline_page_url":null,"external_registry_ids":{"sec":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-26T05:06:10.755Z\",\"rationale\":\"sec returned 0 candidates for \\\"Elastrin Therapeutics\\\".\",\"officers_matched\":[],\"candidate_count\":0}","opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-26T05:06:10.759Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"Elastrin Therapeutics\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-06-03 01:09:12.075399+00","updated_at":"2026-09-23 00:51:13.779729+00","scores":{"ambition":7.75,"publicity":4,"media_reach":4,"reliability":7,"falsifiability":8.5,"claim_integrity":10,"collaborativity":4,"context_validity":5,"pipeline_quality":4,"explanatory_power":6.75,"results_alignment":8,"scandal_integrity":8,"publication_quality":6,"premise_plausibility":7.75,"implementation_fidelity":8,"independent_replication":2},"public_records_count":71,"publications_count":1,"projects_count":2,"funding_rounds_count":1,"clinical_trials_count":0,"publication_status":"published","public_url":"https://eternalsearch.net/companies/5ef1ULJl","api_url":"https://eternalsearch.net/api/v1/companies/5ef1ULJl"},{"id":"aabded02-fa41-4e15-861c-e261d519068a","public_id":"pfAIHlo2","name":"Deep Longevity","canonical_name":"Deep Longevity","aliases":["Deep Longevity Limited"],"one_liner":"Deep Longevity provides AI-powered aging clocks and SaaS platforms for biological age prediction and personalized health insights.","description":"Deep Longevity provides personalized health insights designed to drive preventive care and early interventions. Its commercially available aging clocks include Blood Age, Mind Age, Biometric Age, and Epigenetic Age. The company provides SaaS platforms, including SenoClock and SenoClock Gold, for biological age predictions and health summary reports using blood, DNA, microbiome, and psychological survey inputs.","website":"https://deeplongevity.com","canonical_website":"https://deeplongevity.com/","logo_url":"https://image.pitchbook.com/r2uuaXO74DdBg1dw29uz13aotmk1709083525447_200x200","headquarters":"Hong Kong","hq_country_code":"HK","founding_year":null,"primary_approach":"AI aging clocks, biological age prediction, multi-omics","primary_field_slug":"measurement","field_slugs":["measurement","diagnostics","software_data"],"primary_idea_root_slug":"measuring","idea_root_slugs":["measuring"],"primary_modality_slug":null,"modality_slugs":[],"classification_rationale":"Deep Longevity is a non-therapeutic longevity company focused on biological-age measurement, aging clocks, and digital delivery infrastructure. The evidence consistently describes commercial aging-clock products and biological age reports, including Blood Age, Mind Age, Epigenetic Age, and related tests, alongside an Aging Cloud Platform, API, and SaaS capabilities. That supports classifying the company under the measuring idea root, with diagnostics/testing as the primary offering and software/data as a secondary offering.","classification_confidence":95,"funding_stage":"acquired","total_funding_usd":null,"latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"acquired","operating_status_reason":"acquired","operating_status_rationale":"Derived from funding_stage=acquired (site-analyzer acquisition/dissolution evidence); operating-status detector had not run.","operating_status_confidence":60,"business_model":"multi","business_model_rationale":"The merged evidence supports multiple core commercial models. Deep Longevity describes a \"Longevity Cloud Platform,\" \"Longevity as a Service (LaaS),\" and \"API SaaS Platforms,\" which fits platform/data-software. It also sells aging clocks, biological age reports, and tests available from survey or blood inputs, which supports a diagnostics-style offering. Because both software/platform infrastructure and productized biological-age assessment tools are central to the business, `multi` is the best fit.","business_model_confidence":89,"ip_market_structure":"The organization appears to be Deep Longevity, and the strongest in-hand asset in this record is its own microbiome-aging patent family: US20200075127A1, granted as US11373732B2, titled “Aging markers of human microbiome and microbiomic aging clock.” On the face of the evidence, that gives it an issued position around using microbiota-derived markers to predict age or biological aging, with active status and a long tail to expiration. That is meaningful, but it is also technically narrow: it supports a microbiome-clock corridor rather than a broad monopoly over all aging clocks. The main blocking IP in the surrounding field appears to sit with other biomarker modalities. TruDiagnostic and Cornell University look relevant through WO2025043209A1, covering retroelement- and LINE-1 methylation-based age estimation. InSilico Medicine IP Ltd matters through US20220005552A1, directed to methylation data signatures and methods for determining a methylation aging clock. The partial EP3970150A1 record points to a separate proteomics corridor for “deep proteome markers of human biological aging.” Taken together, the evidence suggests the field is partitioning by data type: microbiome for Deep Longevity, methylation/epigenetic approaches for TruDiagnostic/Cornell and InSilico, and proteomic approaches elsewhere. That gives Deep Longevity a mixed freedom-to-operate posture. If it stays anchored to microbiome-derived aging prediction, its own granted patent strengthens its position. If it expands into methylation clocks, retroelement/LINE-1 methylation states, or proteomic age markers, the corridor becomes more crowded and potentially restrictive, even though at least some of the cited third-party rights are still pending rather than issued. Pending status reduces immediate enforcement certainty but still creates prosecution and commercialization risk. Design-around looks fairly feasible because the evidence itself implies multiple separable biomarker stacks. A microbiome-first product can likely avoid the tightest epigenetic and proteomic claims if feature selection, assay inputs, and model architecture are kept distinct. The harder case is a multimodal longevity platform combining microbiome with methylation or proteomics, where overlap risk rises quickly. On licensability, TruDiagnostic/Cornell and InSilico look more likely licensable than structurally closed, because these are identifiable commercial or academic-rights holders rather than purely defensive assignees. But the fact that multiple filings target aging-clock methods suggests strategic value is high, so licenses, if available, would likely be negotiated from a position of field control rather than openness.","is_public":true,"disqualified":false,"disqualified_reason":null,"disqualified_at":null,"research_status":"ready","is_editors_choice":false,"overall_score":37.14,"overall_score_computed_at":"2026-07-01 02:54:38.798828+00","pipeline_version":"0.24.1","proximity_score":"35.00","proximity_band":"early_mechanism","proximity_rationale":"Derived deterministically from 12 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":3,"social_links":{"github":null,"twitter":"https://x.com/Deep_Longevity","youtube":null,"facebook":"https://www.facebook.com/DeepLongevity","instagram":"https://www.instagram.com/deep_longevity/","linkedin_company":"https://www.linkedin.com/company/deep-longevity/"},"careers_page_url":null,"pipeline_page_url":null,"external_registry_ids":{"opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-26T16:55:02.417Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"Deep Longevity\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-06-03 01:09:12.039265+00","updated_at":"2026-09-23 00:53:16.253545+00","scores":{"ambition":6.17,"publicity":4,"media_reach":4,"reliability":5,"falsifiability":7.67,"claim_integrity":8.89,"collaborativity":8,"context_validity":6,"pipeline_quality":4,"explanatory_power":5.5,"results_alignment":7,"scandal_integrity":8,"publication_quality":7,"premise_plausibility":7,"implementation_fidelity":8,"independent_replication":4},"public_records_count":114,"publications_count":39,"projects_count":12,"funding_rounds_count":1,"clinical_trials_count":0,"publication_status":"published","public_url":"https://eternalsearch.net/companies/pfAIHlo2","api_url":"https://eternalsearch.net/api/v1/companies/pfAIHlo2"},{"id":"6a440895-79a5-4784-98ca-80cdb4994ac7","public_id":"I3WFr2i3","name":"Cyclarity Therapeutics","canonical_name":"Cyclarity Therapeutics","aliases":["Underdog Pharmaceuticals","Cyclarity Pharmaceuticals"],"one_liner":"Cyclarity develops drugs to prevent age-related conditions by removing arterial plaque and clearing non-degradable cholesterol from arterial wall cells.","description":"Cyclarity Therapeutics is a US startup developing UDP-003, an engineered cyclodextrin small-molecule candidate aimed at removing 7-ketocholesterol (7KC), a toxic oxidized cholesterol species implicated in atherosclerotic plaque biology. The strongest support is that the program has entered Phase 1 human testing and the company has reported early human PK/PD and safety signals consistent with 7KC excretion, but evidence for plaque regression or clinical benefit remains unproven and is still mostly company-linked or early-stage.","website":"https://cyclaritytx.com/","canonical_website":"https://cyclaritytx.com/","logo_url":"https://cyclaritytx.com/wp-content/uploads/2022/06/Cyclarity-Logo-1.1-o.png","headquarters":null,"hq_country_code":"US","founding_year":null,"primary_approach":"cyclodextrins, cholesterol clearance, plaque removal","primary_field_slug":"clearing","field_slugs":["clearing","discovery"],"primary_idea_root_slug":"clearing","idea_root_slugs":["clearing","discovering"],"primary_modality_slug":"small_molecule","modality_slugs":["small_molecule"],"classification_rationale":"Cyclarity Therapeutics is a clinical-stage therapeutic company developing cyclodextrin-based drug candidates, including UDP-003, to treat age-related cardiovascular disease by clearing toxic oxidized cholesterol and other non-degradable sterols from arterial-wall cells, thereby targeting plaque biology and atherosclerosis at the damage-clearance level. The core classification is clearing via a small-molecule modality, with secondary support for discovering because the company has also described an AI-driven modified cyclodextrin design platform for sterol-binding drug discovery.","classification_confidence":96,"funding_stage":"seed","total_funding_usd":"34400000","latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"operating","operating_status_reason":null,"operating_status_rationale":null,"operating_status_confidence":null,"business_model":"drug_developer","business_model_rationale":"The strongest evidence consistently describes the company as developing therapeutic drug candidates: it is a \"clinical stage biopharmaceutical company\" engineering therapies, it \"develops easy-to-use drugs,\" and it is advancing UDP-003 into Phase 1 human testing. That is most consistent with a drug developer rather than a platform, diagnostics, services, delivery technology, or software company.","business_model_confidence":96,"ip_market_structure":"On the evidence provided, the only clearly identified patent holder in this corridor is the organization itself, through a chain from SENS Research Foundation to Underdog Pharmaceuticals and now Cyclarity Therapeutics. The key asset is `US11279774B2`, an issued U.S. patent on cyclodextrin dimers, compositions, and uses, with an anticipated expiration of January 3, 2040 and current status shown as active. That appears to be the core enforceable U.S. right. The family also includes `WO2020142716A1` as the PCT filing, plus regional counterparts such as `CA3184962A1` in Canada and `EP3906263A4` in Europe. `CA3184962A1` is still pending, so it may broaden or solidify protection if granted. The PCT itself is marked ceased, but that does not undermine the significance of the national and regional follow-ons. Because no third-party “field-corridor” patents are actually included in the supplied evidence, there is no concrete basis here to identify blocking IP held by others. That matters for freedom to operate: this evidence supports a strong proprietary position for Cyclarity around cyclodextrin dimer chemistry and uses tied to cholesterol or 7-ketocholesterol, but it does not prove clean FTO against third-party estates. In other words, the organization appears to own an important slice of the space, but the record here does not show whether someone else owns adjacent composition, formulation, delivery, or disease-use claims that could still constrain commercialization. Design-around looks feasible in principle but not obviously easy if a competitor wants to stay in the same mechanistic lane. The claims appear centered on cyclodextrin dimers, linkers, compositions, and their use, so alternatives might include non-dimer constructs, different scavenger scaffolds, non-cyclodextrin chemistries, or materially different delivery/formulation approaches. A closer-in design-around that still relies on cyclodextrin dimer architectures for 7-ketocholesterol removal would likely face meaningful infringement risk. As to licensability versus strategic closure, the company-held estate looks like core platform IP rather than peripheral filings, so it is more likely to be strategically retained than casually licensed. But that conclusion only applies to Cyclarity’s own patents. The supplied record contains no third-party blocker patents, so there is no evidence here to judge whether outside blockers, if they exist, are likely licensable or effectively closed.","is_public":true,"disqualified":false,"disqualified_reason":null,"disqualified_at":null,"research_status":"ready","is_editors_choice":false,"overall_score":37.1,"overall_score_computed_at":"2026-06-24 20:31:19.562478+00","pipeline_version":"0.24.1","proximity_score":"55.00","proximity_band":"translational","proximity_rationale":"Derived deterministically from 7 extracted project(s). Most-advanced status: phase 1. Band: translational. Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":3,"social_links":null,"careers_page_url":"https://cyclaritytx.com/contact-us#career","pipeline_page_url":"https://cyclaritytx.com/our-science/","external_registry_ids":{"sec":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-22T12:57:00.230Z\",\"rationale\":\"sec returned 0 candidates for \\\"Cyclarity Therapeutics\\\".\",\"officers_matched\":[],\"candidate_count\":0}","opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-22T11:12:00.908Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"Cyclarity Therapeutics\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-05-23 13:45:00.761619+00","updated_at":"2026-09-23 00:55:21.824614+00","scores":{"ambition":7.8,"publicity":4,"media_reach":4,"reliability":7,"falsifiability":8.43,"claim_integrity":10,"collaborativity":6,"context_validity":5,"fact_check_score":1.82,"pipeline_quality":6,"explanatory_power":6.13,"results_alignment":7,"scandal_integrity":8,"publication_quality":6,"premise_plausibility":7.6,"implementation_fidelity":8,"independent_replication":3},"public_records_count":82,"publications_count":9,"projects_count":7,"funding_rounds_count":6,"clinical_trials_count":1,"publication_status":"published","public_url":"https://eternalsearch.net/companies/I3WFr2i3","api_url":"https://eternalsearch.net/api/v1/companies/I3WFr2i3"},{"id":"48ea9cab-ac6d-4344-b95b-27a079639b76","public_id":"fbjiPG8M","name":"Muna Therapeutics","canonical_name":"Muna Therapeutics","aliases":["Muna","Muna Therapeutics ApS"],"one_liner":"Muna Therapeutics develops therapies to slow or stop neurodegenerative diseases including Alzheimer’s and Parkinson’s.","description":"Muna Therapeutics discovers and develops therapies intended to slow or stop neurodegenerative diseases including Alzheimer’s and Parkinson’s. The company focuses on preserving cognition and other brain functions, enhancing resilience to disease pathology, and resolving neuroinflammation. Its all-in-human MiND-MAP discovery and validation approach uses single-cell spatial multi-omics, bioinformatics, structural biology, computational chemistry, and cell-based screening.","website":"https://munatherapeutics.com","canonical_website":"https://munatherapeutics.com/","logo_url":"https://images.crunchbase.com/image/upload/c_pad,f_auto,q_auto:eco,dpr_1/mzmvzttu3o1pxaiawndy?ik-sanitizeSvg=true","headquarters":"Copenhagen, Denmark","hq_country_code":"DK","founding_year":null,"primary_approach":"small molecules, microglia, resilience","primary_field_slug":"modulating","field_slugs":["modulating","discovery"],"primary_idea_root_slug":"modulating","idea_root_slugs":["modulating","discovering"],"primary_modality_slug":"small_molecule","modality_slugs":["small_molecule"],"classification_rationale":"Muna Therapeutics is a therapeutic biotech focused on neurodegenerative disease, with disclosed programs including MNA-001, an oral small-molecule TREM2 agonist, and Kv1.3 blockers aimed at modulating microglial biology, neuroinflammation, and resilience in diseases such as Alzheimer’s, Frontotemporal Dementia, and Parkinson’s. Its primary fit is modulating because the company’s lead programs act through signaling and immune-pathway targets rather than replacement, editing, or reprogramming. The company also has a strong discovering component through its MiND-MAP platform, which uses single-cell spatial multi-omics, bioinformatics, structural biology, computational chemistry, and screening to identify and validate human-relevant targets and treatments.","classification_confidence":93,"funding_stage":null,"total_funding_usd":"74000000","latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"operating","operating_status_reason":null,"operating_status_rationale":null,"operating_status_confidence":null,"business_model":"drug_developer","business_model_rationale":"The strongest evidence consistently describes Muna Therapeutics as a company that discovers and develops therapies for neurodegenerative diseases, and later-stage evidence shows it is advancing a named candidate, MNA-001, in a Phase 1 trial. Although Muna also references its MiND-MAP platform and platform-enabled partnerships, the weight of evidence supports a primary business model of therapeutic product development rather than a standalone platform business.","business_model_confidence":96,"ip_market_structure":"The core IP visible here appears to sit with Muna Therapeutics, and the key patents are its TREM2 modulator family: WO2024008722A2 as the PCT publication, plus national-stage filings such as IL317435A, with corresponding country status entries in Europe, Japan, Korea, China, Australia, Canada, Morocco, Mexico, and Israel. The evidence points to a single family with priority back to July 4, 2022 and a fairly broad geographic filing strategy. That is the main corridor-defining asset. By contrast, BR102019007976A2 appears unrelated on its face: it concerns charcoal processing, names a different inventor and original assignee, and does not look relevant to a TREM2 therapeutic program. On this evidence alone, it should not be treated as a meaningful blocker in the organization’s field corridor. Freedom to operate therefore looks strongest where the organization is itself Muna or controls rights under this family, because the only clearly relevant patent estate in the record is its own. If the organization is not Muna, then the posture is much tighter: Muna’s family likely occupies at least part of the small-molecule TREM2 modulator space, especially given the chemistry classifications and repeated references to compounds, salts, and pyrimidine-related subject matter. The fact pattern suggests potential composition-of-matter coverage rather than a narrow process claim set, which is the kind of protection most likely to constrain competing drug candidates. Design-around may be feasible, but not obviously easy. If the claims are centered on specific chemotypes or substitution patterns, a competitor could try to move to a distinct scaffold, a different TREM2 modality, or biologics rather than small molecules. But if the family claims a broad genus around TREM2 modulation, design-around becomes materially harder and more chemistry-intensive. The evidence does not give claim text, so the corridor should be viewed as real but with uncertain width. As to licensing posture, these patents look more likely licensable than structurally closed, because they sit in a conventional biotech therapeutic family with multi-jurisdictional prosecution behavior consistent with value preservation and partnering optionality. That said, if TREM2 is central to Muna’s strategy, the practical posture may still be strategically closed for direct competitors even if a license is theoretically possible.","is_public":true,"disqualified":false,"disqualified_reason":null,"disqualified_at":null,"research_status":"ready","is_editors_choice":false,"overall_score":36.67,"overall_score_computed_at":"2026-07-05 04:47:11.316984+00","pipeline_version":"0.24.1","proximity_score":"55.00","proximity_band":"translational","proximity_rationale":"Derived deterministically from 4 extracted project(s). Most-advanced status: phase 1. Band: translational. Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":5,"social_links":{"github":null,"twitter":null,"youtube":null,"facebook":null,"instagram":null,"linkedin_company":"https://www.linkedin.com/company/muna-therapeutics/"},"careers_page_url":"https://munatherapeutics.com/careers/","pipeline_page_url":"https://munatherapeutics.com/our-science/","external_registry_ids":{"opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-27T18:57:31.476Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"Muna Therapeutics\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-06-03 01:09:12.844561+00","updated_at":"2026-09-23 00:56:53.143659+00","scores":{"ambition":8.25,"publicity":5,"media_reach":4,"reliability":6,"falsifiability":8,"claim_integrity":9.63,"collaborativity":8,"context_validity":7,"pipeline_quality":6,"explanatory_power":5.75,"results_alignment":6,"scandal_integrity":8,"publication_quality":6,"premise_plausibility":7,"implementation_fidelity":8,"independent_replication":3},"public_records_count":153,"publications_count":33,"projects_count":4,"funding_rounds_count":2,"clinical_trials_count":0,"publication_status":"published","public_url":"https://eternalsearch.net/companies/fbjiPG8M","api_url":"https://eternalsearch.net/api/v1/companies/fbjiPG8M"},{"id":"9bd17e29-7ab0-43cb-864a-ab49020a9b7a","public_id":"Fbrqw7y8","name":"Age Labs","canonical_name":"Age Labs","aliases":["Age Labs AS"],"one_liner":"Age Labs develops and commercializes diagnostic biomarker tests for early detection of age-related diseases.","description":"Age Labs is a Norwegian life science company that discovers, develops and commercializes diagnostic tests for early detection of age-related diseases. Its biomarker work uses advanced machine learning on epigenetic datasets from biobanks. The company lists a pipeline that includes rheumatoid arthritis early detection, biological age prediction, COVID-19 severity prediction, and other diagnostics and drug response biomarkers.","website":"https://agelabs.com","canonical_website":"https://agelabs.com/","logo_url":"https://cdn.prod.website-files.com/5ef7c2022152abfdbfa45bcb/5ef7c2022152ab2d78a45bdd__Age%20Labs%20PNG.png","headquarters":"Oslo, Norway","hq_country_code":"NO","founding_year":null,"primary_approach":"epigenetic biomarkers, machine learning, diagnostics","primary_field_slug":"measurement","field_slugs":["measurement","diagnostics","software_data","research_tools"],"primary_idea_root_slug":"measuring","idea_root_slugs":["measuring","operating-trials"],"primary_modality_slug":null,"modality_slugs":[],"classification_rationale":"Age Labs is a non-therapeutic molecular diagnostics company focused on biomarker-based testing and biological age measurement, using epigenetics, DNA methylation, biobank datasets, and machine learning to discover, develop, and commercialize diagnostic tests for age-related disease and related risk prediction. The strongest fit is measuring, with a secondary operating-trials capability because the company explicitly positions its blood tests and epigenetic readouts for clinical-trial patient selection, surrogate endpoints, and earlier assessment of drug effects. Its business offering is primarily diagnostics, with some supporting software/data and research-tool characteristics from its machine-learning and biobank analysis work.","classification_confidence":96,"funding_stage":null,"total_funding_usd":null,"latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"operating","operating_status_reason":null,"operating_status_rationale":null,"operating_status_confidence":null,"business_model":"diagnostics","business_model_rationale":"Across the strongest evidence, Age Labs is repeatedly described as a Norwegian molecular diagnostics company that discovers, develops, and commercializes biomarkers, diagnostic tests, and blood-test-based tools for early detection of age-related diseases and for use in clinical trials. While some evidence also shows collaboration, sample analysis, and machine-learning-enabled biomarker work, those appear to support the core diagnostics business rather than establish a primary platform, services, or drug developer model.","business_model_confidence":93,"ip_market_structure":"On the evidence provided, the most meaningful blocking IP appears to sit with established academic or institutional holders rather than with this organization itself. The strongest identified blocker is KAUST’s granted US11542559B2, published as US20210079482A1, covering methylation-based biomarkers in breast cancer screening, diagnosis, or prognosis; because it is active and runs to an anticipated 2039 expiration, it is the clearest live exclusion risk in any breast-cancer-focused methylation assay corridor. A second relevant cluster is the Horvath/Levine/Ferrucci “phenotypic age and DNA methylation based biomarkers” filing, associated with NIH and UC San Diego. That application is marked abandoned, so it is weaker as a direct exclusion right, but it still signals a dense aging-clock and methylation-biomarker landscape around life expectancy and morbidity uses. The older US20100151468A1 application on epigenetic biomarkers for cancer detection and relapse monitoring is also abandoned, which reduces present blocking force, though it shows prior-art pressure around global DNA methylation index methods. WO2022272120A1 on epigenetic clocks also looks relevant at the field level, but the provided excerpt is too thin to assess claim scope or status precisely. The organization’s freedom-to-operate posture therefore looks mixed but not shut down. If its product touches broad epigenetic clocking, methylation-derived age inference, or disease-specific methylation panels, it is entering a corridor already populated by well-known academic-origin filings. But the direct blocking risk appears narrower where the evidence is abandoned or only evidentiary of crowding rather than enforceable exclusivity. On this record, the main live risk is disease-area and claim-specific, especially breast-cancer methylation signatures. Design-around seems feasible if the organization avoids patented marker sets, avoids disease-specific claimed panels, and frames its method around different loci, different model construction, or non-identical clinical use claims. That is easier in general aging or research-use contexts than in tightly defined cancer screening workflows. The likely blockers also look more licensable than strategically closed: NIH, UC, and KAUST are typical institutional patent holders that often license, although exclusive field licenses to commercial partners could still narrow access. Overall, this looks like a navigable but crowded IP corridor, with careful claim mapping and assay design likely more important than assuming broad freedom.","is_public":true,"disqualified":true,"disqualified_reason":"Age Labs is a diagnostics company. It develops biomarker tests and prediction models for rheumatoid arthritis, COVID-19 severity, drug response, and a biological age predictor, but the core business is disease diagnostics, not interventions on aging biology and not a platform built primarily to measure aging itself.","disqualified_at":"2026-07-01T17:07:34.825Z","research_status":"ready","is_editors_choice":false,"overall_score":36.61,"overall_score_computed_at":"2026-07-01 17:07:10.122667+00","pipeline_version":"0.24.1","proximity_score":"23.00","proximity_band":"far","proximity_rationale":"Derived deterministically from 4 extracted project(s). Most-advanced status: exploratory. Band: far. Modifiers: +5 depth (3 programs at exploratory). Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":2,"social_links":{"github":"https://github.com/agelabs","twitter":null,"youtube":null,"facebook":"https://www.facebook.com/AgeLabsCom/","instagram":null,"linkedin_company":"https://www.linkedin.com/company/agelabs/"},"careers_page_url":null,"pipeline_page_url":"https://agelabs.com/biomarkers","external_registry_ids":{"opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-26T05:53:06.222Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"Age Labs\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-06-03 01:09:11.378693+00","updated_at":"2026-09-23 00:59:07.388942+00","scores":{"ambition":5.75,"publicity":4,"media_reach":4,"reliability":5,"falsifiability":8.5,"claim_integrity":10,"collaborativity":8,"context_validity":6,"pipeline_quality":4,"explanatory_power":6.25,"results_alignment":6,"scandal_integrity":8,"publication_quality":7,"premise_plausibility":7.5,"implementation_fidelity":7,"independent_replication":3},"public_records_count":131,"publications_count":12,"projects_count":4,"funding_rounds_count":2,"clinical_trials_count":0,"publication_status":"published_disqualified","public_url":"https://eternalsearch.net/companies/Fbrqw7y8","api_url":"https://eternalsearch.net/api/v1/companies/Fbrqw7y8"},{"id":"c2c07af4-eee0-4b46-b15c-e863a99cdff1","public_id":"a1SWeVKs","name":"Viscient Bio","canonical_name":"Viscient Biosciences","aliases":["Viscient"],"one_liner":"Viscient Biosciences uses 3D human tissue models and multi-omics analysis to discover and develop drugs.","description":"Viscient Biosciences is a San Diego-based biotechnology company working at the intersection of human 3D tissue technology and multi-omics analysis. The company uses three-dimensional disease models made from human cells to discover disease drivers and develop drugs. Its initial discovery and development work is in non-alcoholic steatohepatitis, and the site says it has advanced one drug to the preclinical level while preparing it for Phase 1 studies.","website":"https://viscientbiosciences.com","canonical_website":"https://viscientbiosciences.com/","logo_url":"https://images.crunchbase.com/image/upload/c_pad,h_170,w_170,f_auto,b_white,q_auto:eco,dpr_4/a2xb5pbapurwwr1ar2qb","headquarters":"San Diego, California, United States","hq_country_code":"US","founding_year":null,"primary_approach":"3D tissue models, multi-omics, drug discovery","primary_field_slug":"discovery","field_slugs":["discovery","research_tools"],"primary_idea_root_slug":"discovering","idea_root_slugs":["discovering"],"primary_modality_slug":"small_molecule","modality_slugs":["small_molecule"],"classification_rationale":"Viscient Biosciences is a therapeutics biotech centered on discovery infrastructure: it uses proprietary 3D human tissue/bioprinted disease models plus transcriptomics, multi-omics, sequencing, and bioinformatics to discover and develop drug candidates, especially in liver disease such as NASH/MASH. The evidence also grounds at least one small-molecule program, while some sources describe its platform capabilities in a way that fits research tools and services.","classification_confidence":85,"funding_stage":null,"total_funding_usd":"1000000","latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"operating","operating_status_reason":null,"operating_status_rationale":null,"operating_status_confidence":null,"business_model":"multi","business_model_rationale":"The strongest evidence supports both a platform and a drug developer model. Viscient says it works at the intersection of human 3D tissue technology and multi-omics analysis, indicating an enabling discovery platform, and it also explicitly says it uses these models to discover disease drivers and develop drugs, with lead therapeutic programs for MASH/NASH and other liver diseases.","business_model_confidence":91,"ip_market_structure":"The organization appears to be building its own IP position around tryptanthrin chemistry, not around platform analytics. Its relevant in-house assets are a single patent family, filed off the April 26, 2022 priority date, covering “tryptanthrin derivatives and their uses,” with visible members in Europe ([EP4514804A4](pending)), Canada ([CA3250182A1](pending)), and Argentina ([AR129148A1](published application)). Those filings matter because they suggest the company’s claimed moat is composition-of-matter and therapeutic use of specific trypanthrin-derived compounds. The practical limit is that these are still applications rather than issued patents in the evidence shown, so they support a prospective exclusivity story more than a fully hardened enforcement position. On the blocking side, the only corridor patent in the record is [WO2024039873A1], “Multi-omic sample analysis methods.” Based on the title alone, that looks like a methods/platform patent in sample analysis rather than a chemistry patent directed to tryptanthrin derivatives themselves. The evidence excerpt does not identify the assignee, so the holder of the potential blocking IP cannot be named from the provided record. Still, this is the third-party patent that matters because it is the only visible non-company filing positioned as corridor IP. That yields a mixed but fairly workable freedom-to-operate posture. For the company’s core small-molecule program, the evidence does not show a third-party composition blocker directly reading on the same chemical space, which is favorable. The main visible risk is narrower and operational: if the organization’s R&D or companion workflows depend on protected multi-omic analysis methods, then freedom to operate could tighten around discovery, biomarker stratification, or translational profiling rather than the drug candidate itself. Design-around looks reasonably feasible. Analytical-method patents are often easier to route around than composition claims: the company could use alternative assay stacks, different computational workflows, external providers, or generate equivalent biological insight through non-claimed experimental designs. That makes the corridor look more navigable than closed. Absent evidence of a competitor holding overlapping tryptanthrin compound claims, the likely blockers here look more licensable than strategically exclusionary, with the caveat that the unknown owner and actual claim scope of WO2024039873A1 would determine how much negotiation pressure exists in practice.","is_public":true,"disqualified":true,"disqualified_reason":"Viscient Biosciences is a disease-focused biotech, not a longevity company. The evidence points to NASH and fatty liver drug discovery using 3D human tissue models and multi-omics, with no stated program targeting aging biology, lifespan, or a defined mechanism of aging.","disqualified_at":"2026-07-04T22:17:55.472Z","research_status":"ready","is_editors_choice":false,"overall_score":36.22,"overall_score_computed_at":"2026-07-04 22:17:47.406317+00","pipeline_version":"0.24.1","proximity_score":"35.00","proximity_band":"early_mechanism","proximity_rationale":"Derived deterministically from 5 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":3,"social_links":null,"careers_page_url":"https://www.viscientbiosciences.com/careers","pipeline_page_url":null,"external_registry_ids":{"sec":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-27T21:30:00.895Z\",\"rationale\":\"sec returned 0 candidates for \\\"Viscient Biosciences\\\".\",\"officers_matched\":[],\"candidate_count\":0}","opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-27T19:21:00.257Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"Viscient Biosciences\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-06-03 01:09:13.7669+00","updated_at":"2026-09-23 01:00:30.659414+00","scores":{"ambition":6.25,"publicity":4,"media_reach":3,"reliability":5,"falsifiability":8.5,"claim_integrity":10,"collaborativity":8,"context_validity":7,"pipeline_quality":5,"explanatory_power":6.5,"results_alignment":6,"scandal_integrity":5,"publication_quality":6,"premise_plausibility":7.5,"implementation_fidelity":7,"independent_replication":3},"public_records_count":112,"publications_count":6,"projects_count":5,"funding_rounds_count":1,"clinical_trials_count":0,"publication_status":"published_disqualified","public_url":"https://eternalsearch.net/companies/a1SWeVKs","api_url":"https://eternalsearch.net/api/v1/companies/a1SWeVKs"},{"id":"84308280-1e69-4621-873e-938b7cfaa88a","public_id":"EV9iCdDK","name":"Rejuvenate BioMed","canonical_name":"Rejuvenate Biomed","aliases":["Rejuvenate Biomed NV"],"one_liner":"AI-enabled clinical-stage biotech developing combination therapeutics to delay the onset of multiple age-related diseases.","description":"Rejuvenate Biomed is a Belgian clinical-stage biomedical company founded in 2017 by Ann Belien, PhD. The company develops proprietary combination drugs for age-related diseases using CombinAge, an AI-enabled in silico platform, and CelegAge, an in vitro and in vivo C. elegans and cell-culture platform. Its lead candidate RJx-01 is a proprietary oral combination drug for sarcopenia and is under evaluation in a fully enrolled Phase 2 trial in COPD-induced sarcopenia.","website":"https://rejuvenatebiomed.com","canonical_website":"https://rejuvenatebiomed.com/","logo_url":"https://www.rejuvenatebiomed.com/bundles/rejuvenateapp/img/logo_v2.webp?v1","headquarters":"Belgium","hq_country_code":"US","founding_year":2017,"primary_approach":"AI drug discovery, combination therapeutics, healthspan platforms","primary_field_slug":"discovery","field_slugs":["discovery","modulating"],"primary_idea_root_slug":"discovering","idea_root_slugs":["discovering","modulating"],"primary_modality_slug":"small_molecule","modality_slugs":["small_molecule"],"classification_rationale":"Rejuvenate Biomed is a clinical-stage biotech developing therapeutics for age-related diseases, centered on an AI-enabled discovery platform for combination and repurposed drugs and a lead oral candidate, RJx-01, for sarcopenia. The strongest classification is discovering because the company explicitly describes AI-driven drug-repurposing and in silico discovery capabilities, while modulating is also supported because its therapeutic approach is pharmacologic combination treatment rather than editing, replacement, or reprogramming. Its identified therapeutic modality is small molecule, based on the oral combination drug program RJx-01.","classification_confidence":89,"funding_stage":"series_b","total_funding_usd":null,"latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"operating","operating_status_reason":null,"operating_status_rationale":null,"operating_status_confidence":null,"business_model":"drug_developer","business_model_rationale":"The strongest evidence consistently describes Rejuvenate Biomed as a clinical-stage company developing proprietary therapeutic candidates, including RJx-01 in Phase 2 clinical testing, and as developing proprietary combination drugs for age-related diseases. Its AI and biological platforms appear to support internal discovery and development rather than being presented as the primary standalone business.","business_model_confidence":93,"ip_market_structure":"The organization appears to have a meaningful but still relatively narrow proprietary position built around age-related or degenerative-disease combinations and formulation work. Its own evidence shows Rejuvenate Biomed NV as assignee on `WO2020002715A1`, covering a pharmaceutical combination for age-related and/or degenerative diseases, and on the related Japanese family member `JP2024161512A` / `JP7832631B2`, which is shown as granted and active with anticipated expiry in 2039. That Japanese grant matters most because it is the clearest issued right in the record. The newer `IL320373A` on metformin minitablets suggests a second layer of protection focused on dosage form or administration rather than broad therapeutic concept. The main apparent blocking corridor in the supplied record is `EP2925314A1` / `EP2925314B1`, a granted European patent on combination therapeutics and methods for treatment of neurodegenerative and other diseases, held by another party. Based on title and snippet alone, this looks relevant because it occupies adjacent combination-therapy territory in neurodegeneration, which overlaps the company’s age-related/degenerative disease positioning. That does not prove direct claim collision, but it does suggest nontrivial freedom-to-operate risk in Europe if Rejuvenate’s lead products rely on overlapping drug pairings, indications, or treatment methods. Overall, the freedom-to-operate posture looks mixed: stronger where the company can rely on its own specific formulation IP, especially the metformin minitablet concept and the granted Japanese family, but weaker if commercialization depends on broad combination-therapy claims in neurodegeneration that may already be covered by third-party European rights. The evidence does not show a dense thicket of blockers, just one potentially important corridor patent, so the risk is real but not clearly fatal. Design-around feasibility appears moderate. If the blocker is method- or combination-specific, there may be room to differentiate through composition details, dosing architecture, formulation format, patient population, or non-overlapping disease framing. The minitablet filing especially suggests an attempt to build that kind of workaround space. On licensability, the third-party patent looks more likely licensable than strategically closed, because it is a conventional granted therapeutic-combination asset rather than platform-control IP, but that remains uncertain from the evidence alone.","is_public":true,"disqualified":false,"disqualified_reason":null,"disqualified_at":null,"research_status":"ready","is_editors_choice":false,"overall_score":35.99,"overall_score_computed_at":"2026-06-29 03:50:19.334092+00","pipeline_version":"0.24.1","proximity_score":"65.00","proximity_band":"translational","proximity_rationale":"Derived deterministically from 3 extracted project(s). Most-advanced status: phase 2. Band: translational. Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":3,"social_links":null,"careers_page_url":null,"pipeline_page_url":"https://www.rejuvenatebiomed.com/en/science","external_registry_ids":{"sec":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-25T07:00:00.875Z\",\"rationale\":\"sec returned 0 candidates for \\\"Rejuvenate Biomed\\\".\",\"officers_matched\":[],\"candidate_count\":0}","opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-25T01:36:00.297Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"Rejuvenate Biomed\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-06-03 01:09:13.273845+00","updated_at":"2026-09-23 01:03:49.667988+00","scores":{"ambition":7,"publicity":5,"media_reach":4,"reliability":7,"falsifiability":8.33,"claim_integrity":7.5,"collaborativity":8,"context_validity":6,"pipeline_quality":6,"explanatory_power":6.33,"results_alignment":8,"scandal_integrity":8,"publication_quality":7,"premise_plausibility":7.33,"implementation_fidelity":8,"independent_replication":4},"public_records_count":128,"publications_count":6,"projects_count":3,"funding_rounds_count":6,"clinical_trials_count":0,"publication_status":"published","public_url":"https://eternalsearch.net/companies/EV9iCdDK","api_url":"https://eternalsearch.net/api/v1/companies/EV9iCdDK"},{"id":"cb0e367f-da44-4142-aa6b-93ed7b6e54fa","public_id":"dcjdGeO9","name":"AIRAmed","canonical_name":"AIRAmed","aliases":["AIRAmed GmbH"],"one_liner":"AIRAmed makes MR brain image data measurable using AI-based volumetry for neurodegenerative disease assessment.","description":"AIRAmed develops AIRAscore software solutions that analyze MR brain data using artificial intelligence. The software measures volumes of dedicated brain areas and compares results with reference populations to support early and differential diagnosis of neurodegenerative diseases. The company says its products are based on clinical practice and current research findings from experts at the University Hospital of Tübingen.","website":"https://patient.airamed.de","canonical_website":"https://patient.airamed.de/","logo_url":"https://patient.airamed.de/assets/images/c/airamed_hero_unternehmen-38926009.jpg","headquarters":"Tübingen, Germany","hq_country_code":"DE","founding_year":null,"primary_approach":"AI brain volumetry, MRI analysis, radiology","primary_field_slug":"software_data","field_slugs":["software_data","diagnostics"],"primary_idea_root_slug":null,"idea_root_slugs":[],"primary_modality_slug":null,"modality_slugs":[],"classification_rationale":"AIRAmed is best supported as a software and medical imaging company rather than a therapeutics developer. The evidence consistently describes AIRAscore as AI-based MRI brain volumetry software that analyzes MR brain data, quantifies regional brain volumes, and compares results with reference populations to support early and differential diagnosis of neurodegenerative diseases. The supplied materials emphasize AI in radiology, medical image processing, and software development, with no evidence of a biological intervention, therapeutic modality, or longevity-mechanism program.","classification_confidence":95,"funding_stage":null,"total_funding_usd":null,"latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"operating","operating_status_reason":null,"operating_status_rationale":null,"operating_status_confidence":null,"business_model":"diagnostics","business_model_rationale":"The strongest evidence says AIRAmed develops AI software that analyzes MR brain data and supports early and differential diagnosis of neurodegenerative diseases. Although it is software-driven, the primary use described is diagnostic support, so diagnostics is the best fit among the allowed business model values.","business_model_confidence":90,"ip_market_structure":"On the evidence provided, the most plausible blocking-IP holders are Human Longevity Inc., Altos Labs Inc., Nanjing University of Science and Technology, and an unknown assignee behind US12311194B2. The patents that appear to matter most are WO2020033566A1 and WO2025160504A1, because both sit in AI-driven biomedical imaging workflows rather than narrow wet-lab mechanics. WO2020033566A1, assigned to Human Longevity, covers neural-network-based volumetric segmentation and parcellated surface representations for medical imaging, with examples around brain-region quantification using V-Net/U-Net style architectures. That is the closest corridor patent for organizations doing ML segmentation in neuroimaging or adjacent biomedical image analysis. But the evidence also says its legal status is “ceased,” which materially weakens it as a present blocker. WO2025160504A1, assigned to Altos Labs, is more current and still pending; it targets multi-model prediction of stained cellular structures, which is narrower but potentially important if the organization relies on virtual staining, label prediction, or multimodel image-to-image inference in cell biology. The freedom-to-operate posture therefore looks mixed but not heavily boxed in. On this record, the older zebrafish segmentation patent CN102063723B is expired for fee-related reasons and appears confined to automatic division of zebrafish diencephalon/midbrain images under a high-throughput imaging system, so it does not look like a durable blocker. Human Longevity’s application is technologically relevant but legally weakened by cessation. The main live risk is Altos Labs’ pending application, though pending status means claim scope is not yet fixed and enforceability is not yet mature. US12311194B2 could matter, but the evidence is too truncated to assess its owner, scope, or practical overlap. Design-around feasibility looks reasonably good. General image segmentation can be steered away from the specific brain parcellation and V-Net/U-Net framing in the Human Longevity filing, and stained-structure prediction can likely be redesigned by avoiding multimodel label-prediction workflows, limiting outputs, or using different training/input modalities. The likely blockers also look more licensable than strategically closed, with one expired, one ceased, and one still pending. Altos Labs is the exception: if its application matures with broad claims, it could become a more strategic corridor around AI-native cellular imaging.","is_public":true,"disqualified":true,"disqualified_reason":"AIRAmed is a medical imaging software company. It uses AI to measure MRI brain volumes for earlier and more accurate assessment of neurodegenerative disease, which is diagnostics and radiology support, not a program that targets the biology of aging or develops a longevity intervention.","disqualified_at":"2026-07-01T13:38:25.333Z","research_status":"ready","is_editors_choice":false,"overall_score":35.91,"overall_score_computed_at":"2026-07-01 13:37:33.880886+00","pipeline_version":"0.24.1","proximity_score":"15.00","proximity_band":"far","proximity_rationale":"Derived deterministically from 1 extracted project(s). Most-advanced status: undisclosed. Band: far. Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":1,"social_links":null,"careers_page_url":null,"pipeline_page_url":null,"external_registry_ids":{"opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-26T11:39:00.071Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"AIRAmed\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-06-03 01:09:11.413194+00","updated_at":"2026-07-20 03:32:07.446444+00","scores":{"ambition":5,"publicity":4,"media_reach":4,"reliability":6,"falsifiability":8,"claim_integrity":10,"collaborativity":4,"context_validity":5,"pipeline_quality":4,"explanatory_power":6,"results_alignment":7,"scandal_integrity":8,"publication_quality":6,"premise_plausibility":8,"implementation_fidelity":8,"independent_replication":3},"public_records_count":93,"publications_count":1,"projects_count":1,"funding_rounds_count":0,"clinical_trials_count":0,"publication_status":"published_disqualified","public_url":"https://eternalsearch.net/companies/dcjdGeO9","api_url":"https://eternalsearch.net/api/v1/companies/dcjdGeO9"},{"id":"702c8580-5cd9-475c-84a9-50216c7146f6","public_id":"QdGoFjn9","name":"L-Nutra","canonical_name":"L-Nutra","aliases":["L-Nutra Inc.","Prolon","L-Nutra Health"],"one_liner":"L-Nutra develops plant-based nutrition technology, including fasting mimicking diet programs, to support healthspan, longevity, and metabolic health.","description":"L-Nutra is pioneering nutrition technology that uses plant-based solutions to support health and longevity. Its science focuses on activating cellular reprogramming and rejuvenation through Fasting Mimicking Diet technology. The company offers L-Nutra Health for metabolic health conditions such as obesity and diabetes, and Prolon, a 5-day Fasting Mimicking Diet program rooted in preclinical research.","website":"https://l-nutra.com","canonical_website":"https://l-nutra.com/","logo_url":"https://l-nutra.com/wp-content/themes/lnutra/assets/img/logo.png","headquarters":"Culver City, California, United States","hq_country_code":"US","founding_year":null,"primary_approach":"fasting mimicking diet, plant-based nutrition, cellular rejuvenation","primary_field_slug":"consumer_products","field_slugs":["consumer_products"],"primary_idea_root_slug":null,"idea_root_slugs":[],"primary_modality_slug":null,"modality_slugs":[],"classification_rationale":"L-Nutra is a nutrition-technology company that commercializes consumer-facing plant-based fasting-mimicking dietary programs, notably the five-day ProLon program, as well as medical-nutrition offerings for healthspan and chronic-condition support. The supplied evidence supports a food and nutrition-products business, not a specific therapeutic drug or biotechnology modality.","classification_confidence":99,"funding_stage":null,"total_funding_usd":null,"latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"operating","operating_status_reason":null,"operating_status_rationale":null,"operating_status_confidence":null,"business_model":"consumer_product","business_model_rationale":"The strongest and most consistent evidence describes L-Nutra as a commercial company that develops, manufactures, markets, and sells nutrition-based medical food and fasting-mimicking diet programs. Multiple sources frame ProLon as L-Nutra's flagship branded product and describe direct commercialization of science-based nutrition offerings. Although one source mentions \"therapeutics,\" the evidence overall supports a primary consumer-product model more clearly than drug development, platform, diagnostics, or services.","business_model_confidence":91,"ip_market_structure":"The evidence identifies L‑Nutra as the relevant IP holder, not a third-party blocker. Its apparent portfolio includes WO2018138090A1, jointly associated with L‑Nutra and the University of Genoa/DIMES, covering dietary compositions for prevention or treatment of endometrial hyperplasia; WO2022012845A1, another dietary-composition publication; and US20250194656A1, a pending L‑Nutra application directed to longevity-oriented consumable products, their use, and manufacture for strength and function. WO2018138090A1 appears twice in the evidence and should be treated as one family, not two independent assets. No field-corridor patents held by others were provided. Accordingly, the supplied record does not establish any third-party blocking patent, its owner, or whether it is available for license. It also cannot support a conclusion that L‑Nutra has broad freedom to operate across longevity nutrition generally; it supports only the narrower observation that the identified company-held claims may provide some defensive or exclusionary coverage in their disclosed disease-specific diet and consumable-product areas. The immediate FTO posture is therefore mixed but not demonstrably constrained by an identified external actor. The older WO publication is marked “ceased,” which weakens reliance on the PCT publication itself as an enforceable blocker, although the evidence references national-family activity, including EP3573481B1. The pending US application does not yet provide issued US patent rights. Claim-level review of live national counterparts would be necessary before making product-clearance decisions. Design-around feasibility appears potentially meaningful because the disclosures concern specific dietary compositions, therapeutic/preventive uses, and manufacturing or consumption methods. A product that changes formulation, nutrient ranges, intended-use claims, dosing regimen, delivery format, or manufacturing process may reduce overlap, but this cannot be confirmed without the actual claims. On this evidence, any potential constraints look more like conventional licensing or claim-avoidance questions than strategically closed third-party bottlenecks; however, licensability cannot be determined from the record provided.","is_public":true,"disqualified":false,"disqualified_reason":null,"disqualified_at":null,"research_status":"ready","is_editors_choice":false,"overall_score":35.73,"overall_score_computed_at":"2026-09-22 23:55:04.824111+00","pipeline_version":"0.26.0","proximity_score":"92.00","proximity_band":"near_readout","proximity_rationale":"Derived deterministically from 6 extracted project(s). Most-advanced status: approved. Band: near_readout. Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":2,"social_links":null,"careers_page_url":null,"pipeline_page_url":null,"external_registry_ids":{"sec":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-26T05:01:00.270Z\",\"rationale\":\"sec returned 0 candidates for \\\"L-Nutra\\\".\",\"officers_matched\":[],\"candidate_count\":0}","opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-26T03:18:18.236Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"L-Nutra\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-06-03 01:09:12.605631+00","updated_at":"2026-09-22 23:55:04.829329+00","scores":{"ambition":5,"publicity":3,"media_reach":3,"reliability":7,"falsifiability":8.5,"claim_integrity":10,"collaborativity":7,"context_validity":5,"pipeline_quality":5,"explanatory_power":5.33,"results_alignment":7,"scandal_integrity":8,"publication_quality":6,"premise_plausibility":7,"implementation_fidelity":8,"independent_replication":3},"public_records_count":190,"publications_count":5,"projects_count":6,"funding_rounds_count":0,"clinical_trials_count":5,"publication_status":"published","public_url":"https://eternalsearch.net/companies/QdGoFjn9","api_url":"https://eternalsearch.net/api/v1/companies/QdGoFjn9"},{"id":"3f3f6365-1eb2-4c76-a2a2-0b13a4ef7c36","public_id":"OBIeGCCV","name":"Trivium Vet","canonical_name":"TriviumVet","aliases":["Trivium Vet","TriviumVet Designated Activity Company"],"one_liner":"TriviumVet develops animal health therapeutics for serious diseases in cats and dogs.","description":"TriviumVet is an animal health company developing therapeutic solutions for unmet needs in pet diseases. Its programs address cardiology, gastroenterology, chronic kidney disease, age-related decline, and pain management in cats and dogs. The company lists Felycin-CA1 as a conditionally approved treatment for ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy.","website":"https://triviumvet.com","canonical_website":"https://triviumvet.com/","logo_url":"https://image.pitchbook.com/0x9hiVLqYkkHWRJPKFhljkFPgul1706542799392_200x200","headquarters":"Ireland","hq_country_code":"IE","founding_year":null,"primary_approach":"veterinary therapeutics, mTOR inhibition, sirolimus","primary_field_slug":"modulating","field_slugs":["modulating","measurement"],"primary_idea_root_slug":"modulating","idea_root_slugs":["modulating","translating"],"primary_modality_slug":"small_molecule","modality_slugs":["small_molecule"],"classification_rationale":"TriviumVet is a veterinary therapeutics company developing drug products for companion animals, with evidence spanning approved and investigational programs such as sirolimus delayed-release tablets, rapamycin formulations, omeprazole, and other clinical-stage products. The strongest aging-relevant signal is pharmacologic pathway modulation through rapamycin/sirolimus, which supports the primary idea root of modulating, while its stated practice of leveraging human therapeutics for companion animal healthcare also supports a secondary translating classification. Its therapeutic modality is best classified as small_molecule, and the supplied evidence does not support assigning a non-therapeutic offering field.","classification_confidence":89,"funding_stage":"acquired","total_funding_usd":null,"latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"acquired","operating_status_reason":"acquired","operating_status_rationale":"Derived from funding_stage=acquired (site-analyzer acquisition/dissolution evidence); operating-status detector had not run.","operating_status_confidence":60,"business_model":"drug_developer","business_model_rationale":"The strongest and most consistent evidence shows TriviumVet primarily develops veterinary therapeutic products, including named drug candidates, clinical studies, regulatory approval activity, and patented veterinary formulations. Although one company page also mentions diagnostics, the preponderance of evidence centers on therapeutic product development such as Felycin-CA1, Liavium-CA1, FDA approval work, and patented rapamycin-based veterinary formulations. That supports classifying the company primarily as a drug developer rather than a broader multi-model business.","business_model_confidence":90,"ip_market_structure":"The organization appears to be Triviumvet, and its own patent position is centered on veterinary uses and formulations of rapamycin plus a newer neuropathic-pain program. The core in-house asset is the rapamycin family: WO2021124264A1 and EP4076399A1 both cover veterinary formulations comprising rapamycin and methods of using them to treat animal diseases, with the disclosure explicitly pointing to uses such as improving cardiac health. The evidence also shows a related U.S. family member, US12599590B2, which suggests Triviumvet has at least one granted right in that family, not just pending applications. A second company-held family, WO2024068242A1, is directed to veterinary compositions for neuropathic pain and appears to be built around pregabalin-containing oral animal dosage forms. The most visible third-party corridor patent in the evidence is WO2011135580A2, “Pharmaceutical compositions of sirolimus.” Because sirolimus is rapamycin, this looks like the main blocking-IP reference for Triviumvet’s rapamycin program. On the evidence provided, that third-party patent matters more than the neuropathic-pain family, because Triviumvet’s own rapamycin claims are downstream veterinary-use and formulation claims, while the corridor patent title suggests broader composition coverage around sirolimus itself. That creates a classic FTO split: Triviumvet may own valuable veterinary-specific improvements, but still risk needing clearance if a broader sirolimus composition patent reads onto the product formulation they commercialize. So the freedom-to-operate posture looks mixed rather than clean. Triviumvet appears to have a credible offensive position in animal-specific indications, dosing formats, and use claims, but the rapamycin program likely sits in a corridor shaped by earlier sirolimus composition IP held by others. Design-around may be feasible if the blocking claims are formulation-specific rather than compound-wide: changing excipients, dosage form, release profile, route, animal-specific administration format, or claim scope tied to specific disease use could preserve product value while avoiding a narrow composition estate. If, however, the third-party claims are broad around stabilized or bioavailable sirolimus compositions, design-around becomes harder and the practical route shifts toward licensing. Based on the evidence alone, the likely blocker looks more licensable than strategically closed, because it appears to be a general pharmaceutical sirolimus composition asset rather than a veterinary-exclusive platform aimed directly at Triviumvet’s niche. But Triviumvet’s FTO for rapamycin still likely depends on the exact formulation chosen, not just on owning animal-use patents.","is_public":true,"disqualified":false,"disqualified_reason":null,"disqualified_at":null,"research_status":"ready","is_editors_choice":false,"overall_score":35.49,"overall_score_computed_at":"2026-07-02 05:22:21.122266+00","pipeline_version":"0.24.1","proximity_score":"92.00","proximity_band":"near_readout","proximity_rationale":"Derived deterministically from 10 extracted project(s). Most-advanced status: approved. Band: near_readout. Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":0,"social_links":null,"careers_page_url":null,"pipeline_page_url":"https://triviumvet.com/","external_registry_ids":{"opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-27T13:27:02.240Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"TriviumVet\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-06-03 01:09:13.698385+00","updated_at":"2026-09-23 01:06:58.621887+00","scores":{"ambition":6,"publicity":4,"media_reach":4,"reliability":5,"falsifiability":8.67,"claim_integrity":9,"collaborativity":6,"context_validity":6,"pipeline_quality":5,"explanatory_power":6.33,"results_alignment":6,"scandal_integrity":8,"publication_quality":7,"premise_plausibility":7.67,"implementation_fidelity":7,"independent_replication":4},"public_records_count":127,"publications_count":6,"projects_count":10,"funding_rounds_count":2,"clinical_trials_count":0,"publication_status":"published","public_url":"https://eternalsearch.net/companies/OBIeGCCV","api_url":"https://eternalsearch.net/api/v1/companies/OBIeGCCV"},{"id":"b077aad1-479e-44cc-9063-600ee62e3920","public_id":"N1uJcAe6","name":"Intervene Immune","canonical_name":"Intervene Immune","aliases":["Intervene Immune, Inc."],"one_liner":"Intervene Immune develops treatments for thymus regeneration and human longevity.","description":"Intervene Immune presents itself as a company translating aging biology into treatments that rejuvenate the immune system and enhance human longevity. Its site centers on the TRIIM and TRIIM-X studies, which it says demonstrated thymus regeneration and epigenetic age reversal in humans. The company also offers or plans immune monitoring services and lists a clinical development pipeline spanning somatropin, GH biobetters, immune tolerance biologics, and small-molecule target discovery.","website":"https://interveneimmune.com","canonical_website":"https://interveneimmune.com/","logo_url":"https://image.pitchbook.com/Y51v7iJ8MewEQzWxkJtpdVMpA1k1701086650220_200x200","headquarters":"1124 West Carson Street, MRL Building, 3rd Floor, Torrance, CA 90502","hq_country_code":"US","founding_year":null,"primary_approach":"thymus regeneration, immune monitoring, epigenetic clocks","primary_field_slug":"repairing","field_slugs":["repairing","modulating","measurement","discovery"],"primary_idea_root_slug":"repairing","idea_root_slugs":["repairing","modulating","measuring","discovering"],"primary_modality_slug":"biologic","modality_slugs":["biologic","small_molecule","cell_therapy"],"classification_rationale":"Intervene Immune is primarily a therapeutic company focused on thymus regeneration and reversal of immunosenescence, which fits best under repairing because the company repeatedly frames its work as regenerative restoration of immune function in aging humans. The evidence also supports modulating through its TRIIM/TRIIM-X regimen and oral candidate activity, while the pipeline indicates biologics and some cell-therapy-related programs, alongside immune monitoring and target-discovery work in functional genomics and epigenetic pathways.","classification_confidence":78,"funding_stage":null,"total_funding_usd":null,"latest_valuation_usd":null,"latest_valuation_basis":null,"latest_valuation_as_of":null,"employee_count":null,"employee_count_source":null,"employee_count_as_of":null,"stock_ticker":null,"stock_exchange":null,"company_status":"active","operating_status":"operating","operating_status_reason":null,"operating_status_rationale":null,"operating_status_confidence":null,"business_model":"drug_developer","business_model_rationale":"The strongest evidence describes Intervene Immune as a therapeutics company: it \"develops treatments for thymus regeneration and human longevity\" and presents clinical programs and a pipeline oriented around human treatment development rather than a standalone platform or services business.","business_model_confidence":90,"ip_market_structure":"On the evidence provided, the relevant blocking IP appears to sit primarily with Intervene Immune and, to a lesser extent, with Smart Immune; two older thymus-regeneration filings from academic institutions look less constraining. The most important patent is Intervene Immune’s US20200254066A1, now granted as US11730795B2 and listed as active through 2039. Its title and description indicate a fairly direct claim set around human aging reversal using a combination regimen that includes growth hormone or related secretagogues, DHEA, and metformin, which makes it the clearest corridor patent if this organization is pursuing pharmacologic thymic or age-reversal interventions built around that cocktail. Smart Immune’s WO2024175738A1 also matters because it targets “method for thymus regeneration,” but the evidence shows the PCT publication itself as “ceased,” even though related national-phase filings exist; that suggests the family may still create regional friction, but it looks less mature and less certain than Intervene’s position. Freedom to operate therefore looks constrained in any program that closely tracks thymus-regeneration or age-reversal therapy using known endocrine/metabolic combinations, especially if it echoes the Intervene formulation logic. By contrast, the older US20160120945A1 on thymic regeneration is marked abandoned, which weakens it as a present blocker. The partial CA2966372A1 entry on BMP4-based thymic regeneration suggests another thematic corridor around regenerative signaling pathways, but the evidence here is too thin to treat it as a confirmed live obstacle. Design-around feasibility looks moderate rather than poor. The evidence implies several distinct technical lanes: Intervene is centered on a specific drug combination and dosing concept, Smart Immune appears more cell/progenitor-based, and the older academic work includes GDF11/BMP4-style regeneration concepts. That usually means a party may be able to avoid the strongest blocker by changing modality, mechanism, or regimen composition rather than trying to practice the same therapeutic recipe. The harder design-around case is any product whose value proposition depends specifically on the GH/DHEA/metformin-style age-reversal protocol. As to licensing posture, Intervene’s granted, active patent looks like the most likely licensable blocker because it is held by a commercial entity with a defined therapeutic program. Smart Immune’s family also looks commercially owned and therefore potentially licensable, but possibly more strategically closed if it underpins a core platform. The abandoned academic filing looks unlikely to require a license. Overall, the corridor is real but not airtight: the main risk is a targeted blockade around specific thymus/aging-reversal regimens, not a total lock on all thymus-regeneration approaches.","is_public":true,"disqualified":false,"disqualified_reason":null,"disqualified_at":null,"research_status":"ready","is_editors_choice":false,"overall_score":35.43,"overall_score_computed_at":"2026-06-24 19:08:54.863172+00","pipeline_version":"0.24.1","proximity_score":"23.00","proximity_band":"far","proximity_rationale":"Derived deterministically from 3 extracted project(s). Most-advanced status: exploratory. Band: far. Modifiers: +5 depth (3 programs at exploratory). Aging-relevance not LLM-reviewed in this pass.","rated_projects_count":0,"top_project_overall":null,"people_count":0,"social_links":null,"careers_page_url":null,"pipeline_page_url":"https://interveneimmune.com/pipeline/","external_registry_ids":{"sec":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-22T14:15:00.608Z\",\"rationale\":\"sec returned 0 candidates for \\\"Intervene Immune\\\".\",\"officers_matched\":[],\"candidate_count\":0}","opencorporates":"{\"id\":null,\"source\":\"unresolved\",\"resolved_at\":\"2026-06-22T14:15:00.611Z\",\"rationale\":\"opencorporates returned 0 candidates for \\\"Intervene Immune\\\".\",\"officers_matched\":[],\"candidate_count\":0}"},"created_at":"2026-05-21 22:31:23.16207+00","updated_at":"2026-07-20 08:32:19.958014+00","scores":{"ambition":7.98,"publicity":2,"media_reach":0,"reliability":6,"falsifiability":8.02,"claim_integrity":10,"collaborativity":5,"context_validity":6,"pipeline_quality":4,"explanatory_power":5.6,"results_alignment":7,"scandal_integrity":8,"publication_quality":6,"premise_plausibility":6.92,"implementation_fidelity":8,"independent_replication":2},"public_records_count":56,"publications_count":4,"projects_count":3,"funding_rounds_count":0,"clinical_trials_count":1,"publication_status":"published","public_url":"https://eternalsearch.net/companies/N1uJcAe6","api_url":"https://eternalsearch.net/api/v1/companies/N1uJcAe6"}],"pagination":{"limit":50,"offset":0,"total":689,"has_more":true},"access_level":"public","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/","attribution":"Eternal Search (eternalsearch.net), powered by Open Longevity","scope":"Applies to data produced by Eternal Search (scores, rationale, extracted structures, summaries, graph). Third-party texts keep their own rights; see text_policy on each record."},"generated_at":"2026-09-27T04:38:59.382Z","family":"companies"}